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Abstract
The adenosine Ai receptor (AiAR) and the sphingosine-1-phosphate (SSP/SIP) 
receptor, endothelial differentiation gene 1 (EDGl) are members of the large superfamily 
of cell surface G-protein-coupled receptors (GPCRs). AiAR activation by the purine, 
adenosine results in a number of cardio- and neuroprotective effects and has been 
implicated in the process of ischaemic preconditioning. S IP-mediated activation of the 
EDGl receptor also elicits a range of biological effects and has recently been shown to be 
heavily involved in the process of new blood vessel foimation called angiogenesis. 
Following a sustained agonist exposure, many GPCRs are desensitised such that their 
responses plateau and then diminish. The relative ability or inability of a GPCR to 
undergo agonist-mediated receptor phosphorylation and subsequent internalisation away 
from the cell surface is an important measure of a GPCR’s ability to become desensitised. 
This study has characterised the phosphorylation and internalisation of the human A]AR 
and the human EDGl receptor.
Whole cell receptor phosphorylation assays demonstrated that AiARs stably 
expressed in CHO cells were not phosphorylated in response to the agonist, R-PIA. In 
contrast, the A3AR, which is similar in terms of structure, G-protein coupling specificity 
and biological effects was rapidly phosphorylated following R-PIA exposure. 
Additionally, cell surface biotinylation assays showed that, whereas the A3AR was 
internalised rapidly following R-PIA exposure (ti/2= 10 min), the agonist-dependent loss of 
AiAR from the cell surface was much slower (ti/2= 90 min) and less complete. Using 
confocal analysis, it was shown that the mutation of Cys309, a site of palmitoylation within 
the C-terminal, had no visible effect on the cell surface expression of AiARs tagged with 
green fluorescent protein (GFP) following a 1 hour agonist exposure. In contrast, parallel 
studies within the lab demonstrated that mutation of Cys302 and Cys305 within the C- 
terminal of the A3AR resulted in a marked increase in basal receptor phosphorylation and 
an increased rate of internalisation.
Whole cell phosphorylation studies on hamster lung CCL-39 fibroblasts stably 
expressing human EDGl receptors showed that EDGl is phosphorylated in response to 
agonist (SIP) and also PMA, a phorbol ester that activates PKC subtypes. However, 
lysophosphatidic acid (LPA), a bioactive lipid similar in structure and biological effects to 
EDGl, had no effect on EDGl phosphorylation. Phosphoamino acid analysis showed that 
SIP and PMA stimulate the accumulation of phosphoserine and phosphothreonine but not
XIX
phosphotyrosine. Preincubation with the PKC inhibitor, GF109203X abolished EDGl 
phosphorylation in the presence of PMA but failed to block S IP-mediated EDGl 
phosphorylation, suggesting that these processes are mechanistically distinct. 
Additionally, the removal of 12 amino acids from the C-terminal tail of EDGl significantly 
reduced SIP- but not PMA-stimulated phosphorylation, providing further evidence of two 
distinct mechanisms of receptor phosphorylation. However, incubation of SIP and PMA 
together did not result in a significant increase in EDGl phosphorylation when compared 
to that achieved by SIP treatment alone. Therefore, although PMA- and SIP-mediated 
EDGl phosphorylation were distinct, each pathway utilised overlapping phosphorylation 
sites within EDGl. In vitro assays implicated a role for GRK2 in SIP-induced EDGl 
phosphorylation observed in intact cells. Also, the region between the last 12 and the last 
32 amino acids of the EDGl C-terminal was shown to be responsible for the in vitro S IP- 
dependent phosphorylation of EDGl in the presence of GRK2.
Phosphorylation of EDGl by SIP and PMA were related to the loss of cell surface 
EDGl. Two separate mechanisms of EDGl internalisation were observed: an SIP- 
dependent loss of cell surface EDGl receptor and a less complete yet still significant 
agonist-independent, PMA-mediated loss of cell surface EDGl which is abolished in the 
presence of GF109203X. Removal of the last 12 amino acids completely abolished S IP- 
mediated EDGl internalisation. Interestingly, this region is not required for the in vitro 
phosphorylation of EDGl by GRK2 in the presence of SIP, suggesting that another kinase 
may be involved in agonist-dependent EDGl internalisation. Internalisation of EDGl due 
to a 30 min SIP exposure was also shown to be irreversible following a 2 hour agonist 
removal. In contrast, whole cell receptor phosphorylation studies demonstrated that EDGl 
phosphorylation is reversible. Immunoblot analysis of total EDGl receptor expression 
following a 24 hour agonist treatment also demonstrated that EDGl is not significantly 
downregulated. Therefore, EDGl is phosphorylated following agonist exposure. The 
receptor is then internalised where it is dephosphorylated but is neither returned to the cell 
surface nor degraded. Alternatively, EDGl receptor recycling may be slow and hence 
requires a period of agonist removal longer than 2  hours.
XX
Chapter 1 
Introduction
Adenosine was first shown to act as an extracellular signalling molecule by Drury 
and Szent-Gyorgyi in 1929. This study demonstrated that extracellular application of the 
purines, adenosine and adenosine 5’-monophosphate (AMP), extracted from heart muscle, 
resulted in various biological effects such as heart block, arterial dilatation, lowering of 
blood pressure and inhibition of intestinal contraction. Adenosine is now fully established 
as a ubiquitous physiological regulator and neuromodulator that exerts its actions in a 
number of tissues, such as the brain, heait, kidney, vasculature and adipocytes via a 
specific sub-family of G-protein-coupled receptors (GPCRs) expressed on the plasma 
membrane (Olah and Stiles, 1995; Linden, 2001; Ralevic and Bumstock, 2000).
In contrast to adenosine, the concept of the bioactive phospholipid, sphingosine-1- 
phosphate (SSP/SIP), as both an extracellular signalling molecule as well as an 
intracellular second messenger has only been recognised within the last decade (Cuvellier 
et al., 1996; Lee et al., 1998b; Spiegel and Milstein, 2000a). Zhang et al in 1991 were one 
of the first groups to demonstrate the importance of SIP in cell growth regulation. A 
number of studies have since shown that SIP is a potent mitogen in a number of diverse 
cell types and elicits various biological effects such as the mobilisation of intracellular 
calcium, regulation of c y to skeletal organisation and cell growth, differentiation, survival 
and motility (Im et al., 1997; An et al., 1999; Hong et al., 1999; Pyne and Pyne, 2000a, 
2000b). As with adenosine signalling, SIP acts as an extracellular mediator by binding to 
a distinct sub-family of plasma membrane GPCRs.
1.1 Adenosine Structure. Synthesis And Metabolism
Adenosine is a ribonucleoside consisting of a D-ribose sugar and the nitrogenous 
base, adenine (Figure 1.1) and is a constitutive metabolite of all cells, involved in key 
pathways such as purinergic nucleic acid base synthesis, amino acid metabolism and the 
modulation of cellular metabolic status (Stone, 1985). The most common stimulus for 
adenosine formation is ischaemia, whereby inadequate blood flow results in tissue hypoxia 
(Berne, 1963; Belardinelli and Shyrock, 1992; Schrader, 1990). This has been 
demonstrated in cardiac myocytes, which rely almost entirely upon aerobic metabolism to 
generate the adenosine 5’ triphosphate (ATP) required for contractile activity (Mullane and 
Bullough, 1995) (Figure 1.2). Although changes in ATP should be the initial sensor of 
metabolic imbalance, ATP production is so tightly coupled to oxidative phosphorylation 
that only pronounced metabolic changes result in changes in intracellular ATP 
concentration. However, the intracellular ATP concentration is in the millimolar range 
whereas the intracellular concentration of AMP is in the low nanomolar range. Therefore,
AMP acts as a control signal to adapt primary metabolism to metabolic imbalance (Cunha, 
2001; Fell and Sauro, 1985). Because AMP cannot cross the plasma membrane, It is not 
suited to rapidly signalling stressful situations, such as ischaemia, to neighbouring cells 
(Cunha, 2001). Hence, a substrate cycle between AMP and adenosine through the 
opposing effects of 5’nucleotidase and adenosine kinase regulates the formation of 
intracellular adenosine upon changes in intracellular AMP concentration (Cunha, 2001; 
Dunwiddie and Masino, 2001). Intracellular adenosine may also be formed by the action of 
S-adenosylhomocysteine (SAH) hydroxylase (Dunwiddie and Massino, 2001). 
Additionally, substantial amounts of adenosine may be formed from the breakdown of 
adenine nucleotides that are present in the granules of autonomic nerves, platelets and mast 
cells (Linden, 2001). Adenine nucleotides are rapidly converted to adenosine by a family 
of ecto-ATP/ADPases including CD39 (NTPDase 1) and ecto-5’ nucleotidases including 
CD73 (Cunha, 2001; Dunwiddie and Massino, 2001; Linden, 2001; Mullane and Bullough,
1995). Extracellular adenosine then acts upon G-protein-coupled cell surface adenosine 
receptors (ARs) to produce specific biological effects. Excess adenosine can be degraded 
to inosine and finally uric acid via adenosine deaminase (Cunha, 2001; Mullane and 
Bullough, 1995). Non-concentrative bi-directional adenosine (or nucleoside) transporters 
equilibrate changes in the intracellular and extracellular adenosine concentrations (Cunha, 
2001; Mullane and Bullough, 1995).
1.2 Sphingosine-l-Phosphate Synthesis. Structure And Metabolism
The structure of SIP consists of one long hydrocarbon chain on a three carbon 
backbone containing a phosphate group and is a phosphorylated derivative of sphingosine, 
an integral sphingolipid component present in the membranes of most mammalian cells 
(Spiegel, 2000b) (Figure 1.3). SIP may be biosynthesised by cells either de novo through 
pathways of intermediate lipid metabolism or via stimulus-coupled liberation of the 
respective precursor glycerophospholipids and sphingolipids and subsequent enzymatic 
conversions (Goetzl and An, 1998, Pyne and Pyne, 2000a; Pyne and Pyne, 2000b; Vesper, 
1999. De novo synthesis of SIP begins with the condensation of a fatty acid-CoA and 
serine to foiTn 3-ketosphinganine, which is reduced and converted to a dihydroceramide in 
the endoplasmic reticulum (ER) (Goetzl and An, 1998). This is then sequentially 
converted to ceramide, sphingosine and finally SIP (Goetzl and An, 1998; Vesper, 1999). 
However, the contribution from stored sphingomyelin turnover constitutes the main source 
of free and secreted SIP (Goetzl and An, 1998).
Sphingolipid metabolism is a dynamic process resulting in the formation of a 
number of bioaetive metabolites including ceramide, sphingosine and SIP (Pyne and Pyne, 
2000a; Pyne and Pyne, 2000b) (Figure 1.4). Sphingomyelin degradation occurs in the 
membranes of lysosomes and endosomes and in the plasma membrane in response to 
growth factors, pro-inflammatory cytokines and arachidonic acid and also following 
cellular stress (Pyne and Pyne, 2000a; Pyne and Pyne, 2000b; Spiegel, 1999; Spiegel and 
Milstien, 2000b). Following sphingomyelinase activation, sphingomyelin is hydrolysed to 
ceramide, thought to be involved in cell growth arrest, differentiation and apoptosis 
(Hannun, 1996; Kolesnick et a l, 1998). Ceramide is then converted to sphingosine in the 
presence of ceramidase. Sphingosine has been shown to inhibit protein kinase C (PKC) 
and induce apoptosis (Spiegel and Milstien, 2000a; Spiegel and Milstien, 2000b). Finally, 
sphingosine can be phosphorylated by sphingosine kinase to produce SIP, implicated in 
cell growth and the inhibition of ceramide-mediated apoptosis (Spiegel, 1999; Spiegel and 
Milstien, 2000a; Spiegel and Milstien, 2000b). Metabolism of SIP is catalysed by both a 
pyridoxal phosphorylation-dependent lyase located in the ER, which degrades SIP to 
phosphoethanolamine and palmitaldehyde, and by a phosphatase which converts SIP back 
to sphingosine (Goetzl and An, 1998). Therefore, the dynamic balance between the 
concentration of all the bioactive sphingolipid metabolites helps determine cell fate. This 
is commonly known as the “sphingolipid rheostat” model (Spiegel, 1999; Pyne and Pyne, 
2000b) (Figure 1.4).
Following the intracellular production of SIP, SIP can be released into the 
extracellulai” space where it is present in an albumin-bound form (HIa et a l, 2001; Igarishi 
and Yatomi, 1998,). The main extracellular source of SIP within the blood is derived from 
platelets activated either via stress stimuli, phorbol esters or thrombin (Igarishi and 
Yatomi, 1998). Extracellular SIP can also be derived from other cell types such as mast 
cells and monocytes (Spiegel and Merrill, 1996; Hannun et a l, 2001). The accumulation 
of generated SIP within platelets can be attributed to the unique lack of the major SIP 
hydrolysing enzyme, S IP lyase in platelets (Pyne and Pyne, 2000a). However, the precise 
mechanisms regarding SIP release remain poorly understood. A recent study has also 
suggested that as well as newly released SIP, the extracellular SIP content could also be 
derived from by the extracellular metabolism of sphingomyelin since the biosynthetic 
enzymes, namely sphingomyelinase, ceramidase and sphingosine kinase have been shown 
to be secreted by cells (Hla et a l, 2001; Romiti et a l, 2000; Tabas, 1999). A recent study 
also demonstrated that the cystic fibrosis transmembrane regulator (CFTR), a member of
the ATP binding cassette family of proteins, is involved in the uptake of extracellular SIP 
and other related phosphorylated lipids (Boujaoude et ah, 2001). This uptake would 
therefore influence the balance between extracellular and intracellular SIP concentrations 
and hence, affect the ability of S IP to modulate biological activity via its interactions with 
cell surface GPCRs.
1.3 G-Protein-Coupled Receptors
The GPCR superfamily includes more than 1000 genes encoding receptors 
(Marinissen and Gutkind, 2001). This represents the largest family of transmembrane 
receptors responsible for the transduction of a diverse array of extracellular signals, 
including light, Ca^ "*", odorants, amino acids, nucleotides, peptides, fatty acid derivatives 
and various polypeptide ligands (Howard et ah, 2001; Ulrik, 2000).
GPCRs generally exist in equilibrium between an inactive (R) and active (R*) 
conformation (Milligan and Bond, 1997; Strange, 2000). Preferential agonist ligand 
binding to the R* state promotes an isomérisation step that stabilises the receptor in a 
relaxed state and shifts the equilibrium toward the active R* conformation, leading to the 
activation of intracellular heterotrimeric G proteins. The receptors can then mediate a 
variety of intracellular responses to regulate cellular function. There is a degree of 
variability amongst GPCRs concerning the equilibrium between the R and R* 
conformations. In the basal state of most GPCRs, the majority of receptors are in the 
inactive (R) state (Milligan and Bond, 1997). Therefore, true antagonist ligands with no 
preference for the R or R"^  receptor conformation are difficult to differentiate from inverse 
agonists, where only a small proportion of R* GPCRs can be preferentially converted to an 
R state by an inverse agonist. On the other hand, a substantial fraction of R* state 
receptors are found with other GPCRs, such as the histamine H2 receptor, and therefore 
display higher levels of basal effector activity (Milligan and Bond, 1997; Smit et ah,
1996). Hence, it is easier to separate full inverse agonists of the H2 receptor (cimetidine, 
ranitidine) and antagonists (burinamide) (Smit et a l, 1996). A select group of GPCRs, 
including the Kaposi’s sarcoma-associated herpesvirus, exhibit full constitutive activity 
and may not require or possess an endogenous ligand (Rosenkilde et al., 2001; Arvanitakis 
et aL, 1997).
GPCRs can be classified into three major subfamilies, based on their relationship to 
rhodopsin (class I), the calcitonin receptor (class II) and metabotropic receptors (class III) 
(Ulloa-Aguirre et aL, 1999; Ulrik, 2000). The subfamily of rhodopsin-like receptors (class 
I) is by far the largest and the most studied. The structure of class I GPCRs is defined by
seven transmembrane (TM) helices linked by three extracellular and three intracellular 
loops (Howard et aL, 2001; Ulloa-Aguirre et aL, 1999; Ulrik, 2000) (Figure 1.5). The 
extracellular N-terminus sequence contains N-linked glycosylation sites, thought to be 
involved in the trafficking of many GPCRs to the cell surface and implicated in the 
stabilisation of protein conformation, protection of proteins from proteases and modulation 
of protein function (Davidson et aL, 1996; Davidson et aL, 1995; Davis et aL, 1995; 
George et aL, 1986; Ulloa-Aguine et aL 1999). The intracellular C-terminus usually 
contains phosphorylation and palmitoylation sites that are intimately involved in regulating 
receptor trafficking and signal transduction (Ferguson, 2001; Ulloa-Aguirre et aL, 1999). 
TMs I, IV and VII contain only one hydrophilic residue and are therefore more 
hydrophobic than TMs II, III, V, and VI, which contain several ionic and/or neutral 
residues (Ulloa-Aguirre, 1999). The overall homology among all the class I GPCRs is low 
and restricted to a number of highly conserved key residues. These include a single 
conserved cysteine residue in the first two extracellular loops, which is responsible for 
protein stability, and a GPCR signature triplet sequence (typically DRY) found 
downstream from TM3, which is involved in G-protein interaction (Howard et aL, 2001; 
Ulloa-Aguine, 1999). From this point on, the term GPCR will refer to class I GPCRs.
1.4 G-Proteins
G-proteins are comprised of three subunits, termed a, P, and y (Downes and 
Gautam, 1999; Willard and Crouch, 2000). a  subunits contain two domains; a domain 
involved in binding and hydrolysing guanosine 5’ triphosphate (GTP) that is structurally 
identical to the large superfamily of GTPases, and a unique helical domain that buries the 
GTP in the core of the protein (Hamm, 1998). The p subunit consists of a seven- 
membered p-propeller structure based on its seven WD-40 repeats. The y subunit interacts 
with p through an N-terminal coiled coil and then all along the base of P, forming a 
functional unit under physiological conditions that is not dissociable except upon 
dénaturation (Hamm, 1998).
The binding of agonist to a GPCR changes the conformation of the receptor which 
promotes the exchange of guanosine 5’ diphosphate (GDP) for GTP on the G protein a- 
subunit. This allows the dissociation of a  from Py subunits (Downes and Gautam, 1999, 
Ham, 1998). The free a  and py subunits are then able to interact with effector molecules to 
evoke cellular responses. The intrinsic GTPase activity of the a  subunit hydrolyses GTP 
to GDP, allowing reassociation of the a  and Py subunits. The inactive G protein is
subsequently reformed and signalling is terminated (Downes and Gautam, 1999, Ham, 
1998) (Figure 1.6). The family of G proteins have been subdivided into four categories 
based upon the a-subunit composition: Gotj, which was originally shown to result in 
adenylate cyclase inhibition; Gets, which stimulates adenylate cyclase; Gcxq, which 
activates phospholipase C; and Gotu/n, implicated in the activation of small G-proteins, 
such as Rac and Rho (Downes and Gautam, 1999; Offermans, 2001; Radhika and 
Dhanasekaran, 2001; Ulloa-Aguin*e et aL, 1999). A comprehensive list of the Got family 
is shown in Table 1. The Py subunits also play a significant role in signal transduction by 
regulating the activity of several effectors such as the adenylyl cyclase types I, II, and IV, 
isofoi-ms 1-3 of phospholipase CP (PLCP) and phospholipase A2 (PLA2), as well as the 
activity of the muscarinic-gated channels (Hamm, 1998; Radhika and Dhanasekaran, 
2001; Ulloa-AguiiTe et aL, 1999)
G-proteins are also sensitive to a number of covalent modifications. Most G a 
subunits undergo N-myristoylation and/or palmitoylation (Chen and Manning, 2001; 
Willard and Crouch, 2000). In addition, Gy subunits are subject to prénylation (Chen and 
Manning, 2001). Each of these lipid modifications has been implicated in membrane 
targeting and to the interactions of these subunits with each other and other proteins (Chen 
and Manning, 2001; Hamm, 1998). Some G a subunits and a Gy subunit undergo 
phosphorylation, important in signal amplitude and duration (Chen and Manning, 2001). 
Also, a valuable experimental tool is the selective susceptibility to endotoxins of certain 
G a subunit members. For example, Gag subunits are adenosine 5’ diphosphate (ADP)- 
ribosylated in the presence of cholera toxin, resulting in protein activation due to inhibition 
of its GTPase activity (Chen and Manning, 2001; Hamm, 1998; Willard and Crouch,
2000). Similarly, Goci proteins undergo ADP-ribosylation in the presence of pertussis toxin 
(PTx) (Chen and Manning, 2001; Hamm, 1998; Willard and Crouch, 2000). This occurs at 
a cysteine residue close to the C-terminus and is thought to uncouple the G-protein from its 
receptor (Willard and Crouch, 2000).
1.5 Small G-Proteins
As mentioned above, activation of Gi2/i3-coupled receptors can result in the 
activation of small G-proteins. Small GTP-binding proteins are monomeric G-proteins 
with a molecular weight of 20-40kDa (Takai et aL, 2001). The superfamily of small G- 
proteins consists of more than 1 0 0  members found in eukaryote systems ranging from 
yeast to human and is made of at least 5 families: - Ras, Rab, Sarl/Arf and Ran (Bourne et
aL, 1990; Hall, 1990; Takai et aL, 2001). The Ras family consists of 6  members and 
regulates gene expression (Takai et aL, 2001). Rho/Rac/Cdc42 regulate cytoskeletal 
reorganisation and gene expression (Evers et aL, 2000; Fukata et aL, 2001; Sah et aL, 
2000; Takai et aL, 2001). Rab and Sarl/Aif regulate intracellular vesical trafficking 
(Ferguson, 2001; Takai et aL, 2001) and Ran regulates nucleocytoplasmic transport during 
Gi, S and G% phase (Take! et aL, 2001).
All small G-proteins have consensus amino acid sequences responsible for specific 
interaction with the GDP and GTP, for GTPase activity for the hydrolysis of bound GTP to 
GDP and P; and a region for interacting with downstream effectors (Bourne et aL, 1991; 
Takai et aL, 1992, Takai et aL, 2001). Ras, Rho/Rac/Cdc42 and Rab have sequences at 
their CO OH terminus that undergo posttranslational modifications with lipid. These 
include famesyl, geranylgeranyl, palmitoyl and methyl moieties and proteolysis (Casey 
and Seabra, 1996; Glomset and Farnsworth, 1994; Takai et aL, 1992; Takai et aL, 2001). 
The small G-proteins exist in two interconvertible forms: - GDP-bound inactive and GTP- 
bound active (Benard et aL, 1999; Takai et aL, 2001). Following stimulation from an 
upstream signal, GDP dissociates from the GDP-bound form followed by the binding of 
GTP. A conformational change of the downstream effector-binding region leads to 
interaction with downstream effectors, thereby altering their function. The GTP-bound 
form is then converted back to the inactive GDP-bound form via the intrinsic GTPase 
activity of the small G-protein, resulting in the release of the bound downstream effectors 
(Benard et aL, 1999; Takai et aL, 2001).
The rate-limiting step of GDP/GTP exchange is the dissociation of GDP from the 
GDP-bound form (Benard et aL, 1999; Takai et aL, 2001). Regulators called guanine 
nucleotide exchange proteins (GEPs), which are, in turn, regulated by an upstream signal, 
can increase the dissociation rate. GEPs interact with the GDP-bound form and release 
bound GDP to form a binary complex of small G-protein and GEP. GTP then replaces 
GEP, resulting in the formation of the active GTP-bound form (Benard et aL, 1999; Takai 
et aL, 2001). Most GEPs, such as son of sevenless (Sos), a Ras GEP and Rab3GEP are 
specific for each member or subfamily of small G-proteins (Boguski and McCormick, 
1993; Buday and Downward, 1993; Wada et aL, 1997). However, some GEPs, such as 
Dbl, a GEP active on Rho/Rac/Cdc42 proteins, exhibit wider substrate specificity (Hart et 
aL, 1991; Yaku et aL, 1994). GDP/GTP exchange reactions of Rho/Rac/Cdc42 and Rab 
are also regulated by the GDP dissociation inhibitors (GDIs), Rho GDI and Rab GDI 
respectively (Araki et aL, 1990; Fukui et aL, 1997; Ueda et aL, 1990). These molecules
inhibit the basal and GEP-stimulated dissociation of GDP from the GDP-bound form and 
keep the small G-protein in the inactive GDP-bound form. Rho GDI and RabGDI exhibit a 
wider substrate specificity than GEPs and GTPase-activating proteins (GAPs) and are 
active on all Rho/Rac/Cdc42 and Rabs respectively (Takai et aL, 2001). Hence, 
Rho/Rac/Cdc42 and Rab activation are susceptible to positive and negative regulators. 
The GTPase activity of each small G-protein is variable but relatively slow and is 
stimulated by GTPase-activating proteins (GAPs). Most GAPs, such as Ras GAP and 
Rab3 GAP, are highly specific for each member or subfamily of small G-protein (Boguski 
and McCormick, 1993; Fukui et aL, 1997). However, some GAPs, such as p i90, a GAP 
active on Rho/Rac/Cdc42 proteins have wider substrate specificity (Settleman et aL, 1992) 
(Figure 1.7).
1.6 Adenosine Receptors
Many of the extracellular effects of adenosine are mediated via a GPCR subfamily 
of cell surface adenosine receptors. At present, four subtypes have been recognised; the 
AiAR, A2aAR, A2bAR and A3AR, with each subtype isolated from a number of species 
(Palmer and Stiles, 1995; Ralevic and Bumstock, 1998; Tucker and Linden; 1993) (Table 
2). An overall amino acid identity of 87% exists between the various AiARs. A similar 
high degree of homology is observed between the different A2aAR subtypes (92% between 
the human and dog receptors). The identity between the human and rat A2bAR is around 
8 6 % whereas the A3AR exhibits a relatively low level of identity (72% between each 
species), reflected in the distinct pharmacological characteristics of each type of A3AR. 
There is also a distinct lack of amino acid sequence homology between the different AR 
subtypes. For example, the homology between the rat Ai and rat A3 receptors is only 45% 
whereas the human A3 receptor only shows approximately 50%, 43% and 40% homology 
with the human Ai, A2A and A2B receptors, respectively. This is indicative of the fact that 
each subtype represents a distinct receptor (Palmer and Stiles, 1995; Ralevick and 
Bumstock, 1998).
The protein structure of each adenosine receptors is typical of most GPCRs. Each 
member consists of seven a-helical transmembrane domains of hydrophobic amino acids 
composed of 20-27 amino acids. The amino-terminus of the receptor is positioned toward 
the extracellular space whereas the C-temiinus is orientated intracellularly. The 
transmembrane domains are connected by three extracellular and three intracellular loops 
of unequal size and the subsequent orientation of the transmembrane domains forms a
pocket for ligand binding. Consensus sites for N-linked glycosylation exist upon the 
extracellular regions of ARs although the precise location of the appropriate sites varies 
amongst AR subtypes. The “DRY” sequence present in the second intracellular loop of 
almost all GPCRs is present in all the AR subtypes and is implicated in the mediation of G- 
protein activation (Olah and Stiles, 2000; Ralevick and Bumstock, 1998).
A conserved cysteine residue representing a potential site of palmitoylation exists 
in the carboxyl-terminal tail of all AR subtypes, with the exception of the A2aAR. The A2 
and A3 receptors also have an abundance of serine and threonine residues distal to this site 
of palmitoylation. In contrast, the AiAR has only one such site although other sites are 
located in the third intracellular loop. Phosphorylation of this region has been shown to be 
crucial in the regulation of the processes of desensitisation and intemalisation of many 
GPCRs (Ferguson, 2001). The role of the C-terminal tail in GPCR regulation will be 
discussed extensively elsewhere.
1.7 Adenosine Receptor Subtypes
1.7.1. Ai Receptors
AiARs are ubiquitously expressed in most species, and are highly expressed in the 
central nervous system (CNS), with the greatest expression in brain observed in cortex, 
cerebellum, hippocampus and thalamus (Dixon etal., 1996; Ralevick and Bumstock, 1998; 
Reppert et aL, 1991; Tucker and Linden, 1993). Ai receptor mRNA is also widely 
distributed in peripheral tissues, having been localised in vas deferens, testis, white adipose 
tissue, stomach, spleen, pituitary, adrenal, heart, aorta, liver, eye and bladder (Dixon et a l, 
1996; Ralevick and Bumstock, 1998; Reppert et aL, 1991; Tucker and Linden, 1993). 
Low levels of expression are also found in lung, kidney and small intestine (Dixon et al., 
1996; Ralevick and Bumstock, 1998; Reppert et al., 1991). AiARs mediate a variety of 
signalling responses primarily through its coupling to different G proteins within the Gi/o 
family (Bevan et al., 1991; Linden, 2001; Olah and Stiles; 1995; Ralevick and Bumstock, 
1998; Waldhoer et aL, 1999) (Table 3). Traditionally, the AiAR has been associated with 
the inhibition of adenylate cyclase, resulting in a decrease in the second messenger cAMP. 
This then modulates the activity of cAMP-dependent protein kinase (PKA) (Londos et aL, 
1980; Van Calker et al., 1978; Ralevic and Bumstock, 1998; Linden, 2001). In addition, 
the inhibition of adenylate cyclase via AiARs can attenuate the effect of other receptors, 
such as the P2 adrenergic receptor (P2AR), that result in an increase in adenylate cyclase 
activity (McIntyre Jr. et at., 1994; Perlini et aL, 1998; Snyder et aL, 1998; Song and
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Belardinelli, 1996). AiAR activation has also been shown, in different cell types, to 
increase, decrease or have no effect on inositol phosphate accumulation, a measure of PLC 
activity (Dickenson and Hill, 1998; Linden, 2001; Selbie and Hill, 1998; Tomura et al.,
1997). This is because G/Go derived Py subunits are involved in the AiAR-mediated 
potentiation of Gq-coupled receptor stimulated PLC responses elicited, for example, by 
bradykinin, ATP and also via activation of A^sARs (Dickenson and Hill, 1998; Linden, 
2001; Selbie and Hill, 1998; Tomura et al., 1997). PLC activation increases inositol 
phospholipid hydrolysis, leading to the formation of inositol-1,4,5- trisphosphate (IP3) and 
diacylglycerol (DAG), and calcium mobilisation via interactions with specific receptors 
located on the endoplasmic reticulum. Elevation of cytosolic Ca^ "*" by IP3 stimulates a 
variety of signalling pathways, including PKC, phospholipase A% (PLA2), Ca^^-dependent 
K"*" channels and nitric oxide synthase (NOS) (Linden, 2001; Ralevic and Bumstock,
1998).
AiAR stimulation can also activate ATP-sensitive K^ channels ( K a t p  channels) that 
are regulated by metabolic demand and become closed when intracellular ATP levels are 
high (Baxter and Yellon, 1999; Bryon and Marshall, 1999; Heurtaux et al., 1995). K a t p  
channels mediate a reduction in action potential duration, vasodilatation and an increase in 
blood flow (Baxter and Yellon, 1999; Bryon and Marshall, 1999; Heurtaux et al., 1995). 
Subsequently, activation of these receptors has been shown to be involved in protective 
mechanisms against ischaemia, specifically ischaemic preconditioning. This is defined as 
a protective, acute adaptation to brief periods of ischaemia (Cam et al., 1997; Feminandy et 
al., 1998; Heurteaux, 1995; Rubino and Yellon, 2000; Sumeray and Yellon, 1997). The 
coupling of AiARs with K a t p  channels occurs through the G-protein in a membrane- 
delimited manner, although coupling via cytosolic factors is possible since AiARs, K a t p  
channels and PKC are intrinsically linked with ischaemic preconditioning (Carr et al., 
1997; Feminandy et al., 1998; Heurteaux, 1995; Rubino and Yellon, 2000; Sumeray and 
Yellon, 1997).
It has been discovered that activation of a protein tyrosine kinase by ligands of 
GPCRs might be mediated by Py subunits of G-proteins. This represents a novel system 
whereby signal transduction via GPCRs can be linked to MAP kinase activation. Mitogen- 
activated protein (MAP) kinase activation requires the interaction of SH2-containing 
proteins with phospho-tyrosine residues present in receptors with tyrosine kinase activity 
or in receptors associated with src-related tyrosine kinases. Recently, it has been
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discovered that AiARs may undergo tyrosine phosphorylation and that the physiological 
role of this may be related to signalling via SH2-containing proteins.
1.7.2. À7A Receptors
A2aARs are highly expressed in intermediate spiney neurons of the striatum 
(Linden, 2001; Ongini and Fredholm, 1996). Expression of A2aARs is also found in 
neutrophils, monocytes, macrophages, mast cells, platelets and vascular smooth muscle 
and endothelium (Linden, 2001; Ralevic and Bumstock, 1998). A2aAR activation 
commonly results in adenylate cyclase activation via coupling with the Gs G protein 
(Linden, 2001; Palmer and Stiles, 1995; Ralevic and Bumstock, 1998) (Table 3). 
However, receptors in the striatum may interact predominantly with Goif as Goif is more 
abundant in the striatum than Gs (Herve et a l, 1993). In striatal nerve terminals, A2A ARs 
mediate dual signalling via P- and N-type Ca^  ^ channels linked to Gg/ adenylate 
cyclase/PKA and cholera toxin-insensitive G protein/PKC respectively (Gubitz et a l,
1996) (Table 3). Functionally, the activation of A2aARs opposes the action of D2 
dopamine receptors in spiney neurons and antagonists of A2aARs are being investigated 
for possible use in Parkinson’s disease (Aoyama et al., 2000; Dunwiddie and Masino, 
2001; Linden, 2001). In addition, A2aAR activation of produces profound anti­
inflammatory responses (Sullivan and Linden, 1998) and also results in vasodilatation of 
coronary arteries and other blood vessels (Akatsuka et al., 1994).
1.7.3. A?R Receptors
Functional studies have found A2bARs in airway smooth muscle, fibroblasts, glial 
cells, the gastrointestinal tract and the vasculature (Ralevic and Bumstock, 1998). In 
addition, A2bARs have been shown to activate human mast cells, implying a possible role 
in allergic and inflammatory disorders, such as asthma (Meade et at., 2001). The A2bAR 
receptor signals through Gs to activate adenylate cyclase (Linden, 2001; Ralevic and 
Bumstock, 1998). Recent studies have also indicated that A2bARs can couple to Gq/Gn to 
produce a PLC and IPs-dependent increase in [Ca^’*']i and MAPK activation (Feoktistov and 
Biaggioni, 1995, Meade et al., 2001). Ca^  ^ mobilisation is not limited to cells that 
overexpress A2B receptors because the endogenous A2B receptors of human embryonic 
kidney-293 (HEK-293) cells produce a robust A2B-mediated Ca^ '*' mobilisation (Gao et al.,
1999). The PKA inhibitor, H89, blocks forskolin but not NEC A-stimulated MAPK 
activation in HEK cells, suggesting that the Gq pathway contributes to MAPK activation 
through a pathway including MEK and Ras (Gao et al., 1999). A2B receptors on vascular
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endothelial cells may contribute to a nitric oxide (NO)-dependent component of 
vasodilation mediated by Ca^^-dependent NOS activation (Linden, 2001) (Table 3).
1.7.4. A3 Receptors
The A3AR is widely distributed, with the highest levels of human A3AR mRNA 
found in lung and liver and lower levels in aorta and brain (Olah and Stiles, 1995; Ralevik 
and Bumstock, 1998). The A3AR is also found on mast cells where it facilitates the release 
of allergic mediators including histamine, suggesting a role in inflammation (Meade et a l, 
2001; Ralevik and Bumstock, 1998). Additionally, A3AR activation has been shown to be 
involved in ischaemic preconditioning (Carr et ah, 1997; Liang and Jacobson, 1998; 
Thourani et al,, 1999). As with the A%AR, the A3AR signals primarily through a Gi G 
protein to inhibit adenylate cyclase activity (Zhou et at., 1992). In rat basophilic leukemia 
cells (RBL-2H3, a cultured mast cell line) and in rat brain, the A3AR stimulates PLC and 
elevates IP3 levels and intracellular Ca^ "^  (Ralevic and Bumstock, 1998). A3AR activation 
can also result in protein kinase B (PKB) phosphorylation, mediating the protection of 
RBL-2H3 mast cells from apoptosis. (Table 3).
1.8 Physiological Effects Of AiAR
As described previously, the AiAR is distributed in a wide variety of mammalian 
tissues. Therefore, AiAR activation mediates a diverse set of biological effects. However, 
the main roles of the A%AR are as a cardioprotective and neuroprotective agent, with 
evidence also implicating a role in asthma.
1.8.1. Cardioprotective Effects
Several studies have demonstrated that, under conditions of ischaemia, adenosine is 
released to act as a cardioprotective agent (Auchampach and Boli, 1999; Fraser et a l, 
1999; Lasley and Smart, 2001; Marwick, 1997, McIntyre et a l, 1994). Many of the 
adenosine-induced cardioprotective effects have been attributed to activation of the AiAR. 
Decreased heart rate was attributed to the activation of Ai ARs located on the sinoatrial and 
atrioventricular nodes, resulting in bradycardia and heart block respectively (Olsson and 
Pearson, 1990). This aspect of A]AR signalling is used clinically to terminate 
supraventricular tachycardias.
Adenosine has been shown to be an important mediator of the endogenous defence 
against ischaemia-induced injury in the heart. A well-established myocardial action of 
adenosine is the reduction of harmful metabolic and contractile responses induced by (3 - 
adrenergic stimulation of cAMP signalling during periods of ischaemia (Auchampach and
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Bolli, 1999; McIntyre Jr. et a l, 1994; Perlini et a l, 1998; Song and Belardinelli, 1996). In 
recent years, AiAR, as well as A3AR, stimulation has been shown to mediate ischaemic 
preconditioning, defined as a protective, acute adaptation to brief periods of ischaemia 
(Carr et ah, 1997; Feminandy et al., 1998; Heurteaux, 1995; Liang and Jacobson, 1998; 
Rubino and Yellon, 2000; Sumeray and Yellon, 1997; Thourani et al., 1999) (Figure 8 ). 
This is where a brief period of sublethal ischaemia, consisting of either a single five minute 
period or a cycle of two or more 5 minute periods, is then followed by reflow, rendering 
the heart resistant to infarction from a subsequent, more sustained period of ischaemia 
(Rubino and Yellon, 2000; Sumeray and Yellon, 1997). As a result, there is a reduction in 
arrhythmias and cardiac cell death from the prolonged, potentially injurious period of 
ischaemia. The phenomenon is biphasic. The first phase is termed classical 
preconditioning and occurs within a few minutes of the initial preconditioning ischaemia. 
If the period of time between preconditioning ischaemia is extended beyond 120 minutes, 
no protection is observed. Delayed preconditioning, also referred to as the second window 
of protection, is where the preconditioning effect is observed 24 hours after the initial 
period of ischaemia and is thought to be associated with the induction of cytoprotective 
proteins, such as heat shock protein and endogenous anti-oxidants (Rubino and Yellon, 
2000; Sumeray and Yellon, 1997).
A;AR activation has a significant role in both forms of ischaemic preconditioning, 
alongside other mediators such as NO, free radicals and bradykinin. As outlined 
previously, AiAR-linked effector mechanisms include the stimulation of potassium 
conductance, inhibition of calcium conductance, activation of PKC, activation of MAP 
kinase and the activation of ATP-dependent potassium channels. All of these processes 
have been strongly implicated in ischaemic preconditioning (CaiT et al., 1997; Feminandy 
et al., 1998; Heurteaux, 1995; Liang and Jacobson, 1998; Rubino and Yellon, 2000; 
Sumeray and Yellon, 1997; Thourani et al., 1999). For example, there is evidence that the 
binding of agonist to Ai ARs leads to translocation of PKC subtypes to the nucleus and that 
this results in alterations in gene regulatory processes. This results in the altered 
expression of cytoprotective proteins important in mediating delayed preconditioning. 
Studies with isolated human atrial trabeculae have provided evidence that K ^tp  channels 
are involved in mediating human ischaemic preconditioning via activation of PKC. Recent 
research has also shown that ischaemia activates p38 MAP kinase but not the extracellular- 
regulated protein kinase (ERK) cascade. p38 was also shown to be activated after 
exposure to adenosine. In addition, the late phase of preconditioning in response to AiAR
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receptor activation in the rabbit heart appears to be mediated in part by the induction of 
manganese superoxide dismutase (Figure 1.8).
1.8.2. Neuroprotective Effects
AiARs play an important role in signalling within the CNS. For example, A%AR 
activation results in sleep induction, antinociception and the mediation of ethanol-induced 
motor incoordination (Dunwiddie and Masino, 2001; Nikodijevic et al., 1991; Porkka- 
Heiskanen et al., 1999; Ralevic and Bumstock, 1998). It is also well established that 
endogenous adenosine released by hypoxia, ischaemia, electrical activity or 
hypoglycaemia acts as a neuroprotective agent via stimulation of AiARs located pre and 
postsynaptically on cell bodies and on axons (Dunwiddie and Masino, 2001; Mitchell et 
al., 1995; Ralevic and Bumstock, 1998). In contrast, exposure to AiAR antagonists under 
these conditions exacerbates neuronal damage (Arvin et al., 1989; Mitchell et al., 1995). 
AiAR-mediated neuroprotection occurs via a number of mechanisms, including the 
inhibition of neurotransmission by decreasing the release of excitatory transmitters such as 
glutamate, hyperpolarizing neuronal membranes, reducing excitability and firing rate, 
directly inhibiting Ca^’*' channels and altering axonal transmission (Dunwiddie and Masino, 
2001; Ralevic and Bumstock, 1998; Santos et al., 2000. These actions reduce 
excitotoxicity by limiting Ca^ "^  entry and by reducing metabolic demand, which would 
preserve ATP stores that are essential for pumping Ca^ "^  out of the cell. The tissue 
expression of AiARs may also be a limiting factor for acute protection. For example, an 
allosteric enhancer of AiAR binding offered neuroprotection in neonates (Hailes et al.,
1997). Similarly, A%AR receptor expression in monocytes and macrophages in the brain 
was shown to be reduced in patients with multiple sclerosis (Johnston et a l, 2001)
A]AR activation also mediates ischaemic preconditioning in neuronal tissue, as 
well as cardiac tissue. In the brain, adenosine release, Ai receptor activation and the 
opening of K \ tp  channels play a central role in preconditioning (Heurteaux et at., 1995). 
It has recently been demonstrated that cross-tolerance exists between potentially damaging 
stimuli and many of these interactions involve adenosine receptors. For example, a 
sublethal kainate seizure protects against a subsequent ischaemic episode and vice versa 
(Plamondon et al., 1999). This suggests that similar molecular mechanisms may be 
utilised in both responses.
1.8.3. Role Of AiAR Activation In Asthma
Aeorosolized adenosine can cause mast-cell-dependent bronehoconstriction in 
asthmatic subjects but bronchodilatation in nonasthmatics (Cushley et a l, 1983; Meade et
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al., 2001; Nyce, 1999). In addition, the nonselective adenosine receptor antagonist, 
theophylline, is widely used as an antiasthmatic drug, although its precise mechanism 
remains unknown (Linden, 2001). The AiAR represents a desirable therapeutic target for 
the treatment of asthma for several reasons. Firstly, evidence suggests that asthma may 
result in a disease-associated upregulation of AiARs, with AiARs found overexpressed in 
allergic rabbits and rats (Ali et al., 1994; El-Hashim et al., 1996). Secondly, bronchial 
smooth muscle of human asthmatics was also shown to contract in an Ai-dependent 
manner (Nyce, 1999). Thirdly, the AiAR is rapidly upregulated in bronchial smooth 
muscle tissue exposed to human asthmatic serum (Nyce, 1999). Finally, selective 
inhibition of the synthesis of AiAR with antisense oligonucleotides demonstrated a marked 
reduction in the number of AiARs in the lung and attenuation of airway constriction to 
adenosine, histamine and dustmite allergen (Nyce, 1999). Recent evidence, however, 
shows that degranulation of rat RBL 2H3 mast-like cells and perivascular mast cells of the 
hamster cheek pouch is mediated by activation of the A3AR (Ramkumer et al., 1993). In 
contrast, the A2bAR has been implicated as the receptor subtype that facilitates the release 
of allergic mediators from canine BR and human HMC-1 mastocytoma cells (Auchampach 
et al., 1997; Feoktistov and Biaggioni, 1995). Occupation of the A2aAR generally resulted 
in either no bronchospasm or relaxation (Linden, 2001; Meade et al., 2001). Therefore, a 
precise role for the AiAR in the treatment of asthma remains to be determined. Recent 
evidence suggests that at least two different mechanisms of bronchospasm exist. One, 
involving the AiAR, functions in mast cell depleted animals and involves a direct 
interaction with nerve or muscle. The second mechanism involves mast cells stimulated via 
activation of A2bARs or A3 ARs (Meade et al., 2001).
1.9 SIP Receptors
Over the past decade, a degree of confusion has arisen over the intracellular and 
extracellular actions of SIP. While the intracellular targets of SIP have yet to be 
elucidated, intracellular SIP has been implicated in the mobilisation of intracellular 
calcium independently of IP3, activation of ERK, inhibition of stress-activated protein 
kinase (SAPK)Zc-Jun N-terminal kinase (INK) and suppression of apoptosis (Spiegel and 
Milstien, 2000). However, the discovery in 1998 that SIP acts on cell surface G-protein- 
coupled receptors showed that extracellular SIP mediates a number of biological effects, 
including some effects previously attributed to intracellular SIP (Lee et al., 1998).
The extracellular effects of SIP are due to its binding to specific members of the 
Endothelial Differentiation Gene (EDG) family of GPCRs. The EDG receptors are a sub­
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family of GPCRs consisting of 8  members, EDGl-8 . However, only EDGl, 3,5,6 and 8  
are selective SIP receptors (Hla et a l, 2001; Pyne and Pyne, 2000a, Pyne and Pyne, 
2000b). EDG2, 4 and 7 are selective for lysophosphatidic acid (LPA), a bioactive 
phospholipid with similar biological effects and structure to SIP (Contos et a l, 2000; 
Fukushima et al., 2001). The EDG family of proteins can be subdivided, according to 
amino acid sequence similarity, into three groups: (1) EDGl, 3, 5 and 8  (around 50% 
identical); (2) EDG2, 4, and 7 (around 55% identical); and (3) EDG6  which is about 35- 
42% identical to the other EDG proteins (Lynch and Im, 1999). The EDG2, 4, 7 group is 
about 35% identical to the EDGl, 3, 5, 8  group. In addition, the EDG2, 4, 7 group each 
contain an intron in the region of the gene encoding the 6 ^^  transmembrane domain (TM6 ) 
which is not present in the EDGl, 3, 5, 8 group (Contos and Chun, 1998). The EDG 
proteins also share partial homology with the cannabinoid receptor subfamily (<30%), 
indicative of the EDG proteins being lipid-selective receptors and also suggestive of a 
possible common ancestral gene (Lynch and Im, 1999).
As described for the adenosine receptors, the EDG proteins are integral membrane 
proteins that are glycosylated and are predicted to have seven transmembrane-spanning 
domains. However, each EDG receptor possesses distinguishing structural elements that 
have yet to be fully related to any aspects of ligand binding or signalling. For example, the 
substitution of alanine for proline in the usual seventh transmembrane NPXXY sequence 
of EDG4, which is conserved in the other EDG proteins and most GPCRs (Goetzl and An,
1998). In addition, a recent study has shown that the basic amino acids within EDGl, 
Arg^^  ^and Arg^^ ,^ ion pairs with the phosphate of SIP (Parrill et a l,  2000). Also, the SIP 
receptors, EDGl, 3, 5, 6 , and 8  all share an anionic residue corresponding to the Glu^^  ^
residue defined in EDGl to interact with the ammonium moiety of SIP (Parrill et al.,
2000). In contrast, the LPA-specific receptors, EDG2, 4 and 7 have a neutral glutamine 
residue at this position which could interact with the neutral hydroxyl group in LPA 
(Parrill et al., 2000). The C-terminal of EDG3 is unique amongst the SIP-specific group 
of EDG receptors in that it contains a putative class I SH3 interaction motif (RASPIQP), 
important in tyrosine kinase signalling. Also, the last three amino acids of the EDG5 C- 
terminal (TVV) represent a consensus PDZ domain interaction motif.
1.9.1. The EDGl Receptor
EDGl was the first SIP receptor to be cloned and was originally identified as an 
early immediate gene product induced in phorbol ester-differentiated human umbilical vein 
endothelial cells (HUVECs) (Hla and Maciag, 1990). It is expressed in most mammalian
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tissues with the highest expression found in skeletal structures undergoing ossification, in 
endothelial cells and in the Purkinje cell layer of the cerebellum (Fukushima et ah, 2001; 
Spiegel and Milstien, 2000). The EDGl receptor was also the first EDG receptor shown to 
be specific for S IP, therefore providing the impetus for the recent surge of interest in S IP 
as an extracellular mediator (Lee et al., 1998; Okamoto et al., 1998; Zondag et a l, 1998). 
EDGl was also reported to act as a low-affinity receptor for LPA to induce EDGl 
phosphorylation (Lee et al., 1998). However, a separate study using membranes of Sf9 
cells co-expressing EDGl and Gi2 failed to elicit any biological effects (Windh et ah,
1999). Other studies have not observed competition of [^^P]S1P binding by LPA (Lee et 
al., 1998; Van Brooklyn et al., 1999). Additionally, LPA did not function as an agonist for 
the murine analog of EDGl, //7bi, when transfected into RH7777 cells (Zhang et a l, 1999).
EDGl signalling is involved in cell migration, the formation of new blood vessels 
and vascular maturation (Hla et al., 2001, Pyne and Pyne, 2000a, Pyne and Pyne, 2000b, 
Spiegel and Milstien, 2000) (Table 4). A recent study using EDGl-expressing Sf9 cells 
demonstrated that EDGl activation by SIP results in the activation of a variety of G- 
protein family members, including Gu, Gi2, Gis, Go and G% but not Gs, Gq, G n  or G n 
(Windh et al., 1999). EDGl signalling via a Gj/o-coupled mechanism has been 
demonstrated in a number of cell types, such as transfected Chineses hamster ovary 
(CHO), HEL, Cos-7 and Sf9 cells, and often results in extracellular signal-regulated kinase 
(ERK) activation and the inhibition of adenylyl cyclase activity (Okamoto et al., 1998; 
Pyne and Pyne, 2000b; Zondag et al., 1998). EDGl activation by SIP activates 
phosphoinositide 3-kinase (PI3K) via the heterotrimeric Gi protein, leading to the 
activation of the serine/threonine kinase Akt and phosphorylation of the Akt substrate, 
endothelial nitric oxide synthase (eNOS), shown to be involved in endothelial cell 
chemotaxis (Lee et al., 2001; Morales-Ruiz et al., 2001; Igaraishi and Michel, 2000; 
Igaraishi and Michel, 2001).
EDGl activation also regulates the activation state of small GTPases of the Rho 
family, namely Rac and Rho, which are downstream of the heterotrimeric G-proteins and 
are involved in the regulation of cytoskeletal rearrangements (Lee et al., 2001; Paik et al., 
2001; Hobson et al., 2001). It has recently been shown that the EDGl-induced G, -  and 
PI3K- dependent activation of Akt leads to the phosphorylation of EDGl at Thr^^  ^located 
within the third intracellular loop (Lee et a l, 2001). This activates Rac via an unknown 
mechanism and the subsequent signalling pathways required for cortical actin assembly, 
lamellopodia formation and chemotaxis (Lee et a l, 2001). In addition, HEK293 cells
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transfected with EDGl have also been shown to stimulate PTx-insensitive, Gi2/i3-mediated 
Rho pathways that regulate morphogenesis, such as adherens junction assembly and 
induction of placental (P)- and epithelial (E)- cadherin expression (Lee et al., 1998, Lee et 
ah, 1999; Liu et ah, 2000). In contrast, it has recently been observed that EDG3 and 
EDG5, but not EDGl, mediate an increase in the amount of GTP-bound Rho in CHO cells 
(Takuwa et al., 2001). Therefore, it is possible that, since EDGl receptor cannot couple to 
Gi2/i3 , the EDGl receptor-dependent activation of Rho must be through a different 
mechanism which has yet to be defined and which may also be dependent upon cell type. 
A recent study showed that EDGl, along with EDG3, regulates signalling pathways 
required for HUVEC morphogenesis into capillary-like networks (Lee et al., 1999). 
Therefore, one possible mechanism of EDGl activation of Rho could therefore be through 
a cross-talk mechanism with EDG3. Interestingly, EDGl has recently been shown to be 
involved in a cross-talk mechanism with the platelet-derived growth factor (PDGF) 
receptor (Hobson et al., 2001; Rosenfeldt et al., 2001). The concept of EDGl cross-talk 
will be discussed elsewhere in the physiological context of angiogenesis.
1.9.2 The EDG3 and EDG5 Receptors
Both the EDG3 and the EDG5 receptors are widely expressed, with the EDG3 
receptor being primarily expressed in the heart, lung, kidney and brain whereas the EDG5 
receptor is abundant in the heart and lung but less so in the brain of the adult rat and mouse 
(Fukushima et al., 2001; Pyne and Pyne, 2000a; Pyne and Pyne, 2000b; Spiegel and 
Milstien, 2000; Takuwa et al., 2001). However, the EDG5 receptor is more prominent in 
the brain during embryonic development, suggesting a role for EDG5-mediated signalling 
in neuronal development (Fukushima et al., 2001; MacLennan et al., 1994). The EDG3 
and EDG5 receptors couple to the Gi, Gq, G12 and G13 heterotrimeric G-proteins (An et al, 
1998; An et al, 1999, Ancellin and Hla, 1999). Consequently, it has been demonstrated in 
CHO cells, HEL cells, Jurkat T cells and HTC4 hepatoma cells that EDG3 and EDG5 are 
coupled to the stimulation of phospholipase C and Ca^^ mobilisation via both PTx- 
sensitive and PTx-insensitive G proteins, most likely Gi and Gq/n respectively (An et al., 
1999; Gonda et al, 1999; Kon et al, 1999; Okamoto et al., 1999). EDG3 and EDG5 also 
mediate MAPK activation almost exclusively via Gi in CHO cells (Takuwa et al, 2001). 
EDG5 was observed to activate JNK and p38MAPK in a PTx-insensitive manner (Gonda 
et al., 1999). A recent study demonstrated that EDG5 activation resulted in an increase in 
adenylate cyclase activity in CHO cells (Kon et al., 1999). However, direct coupling of
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EDG5 to Gs was not observed in membranes of Sf9 cells (Windh et al., 1999). It remains 
to be determined whether or not EDG5 is directly coupled via Gs to adenylate cyclase.
EDG3 and EDG5 also regulate the activity of small GTPases. Both EDG3 and 
EDG5 have been shown to activate Rho through a Gi2/13-dependent mechanism, resulting 
in stress fibre formation, cell rounding, neurite retraction and serum response element- 
driven transcriptional activation (Buhl et al., 1995; Kozasa et al., 1998; Pyne and Pyne, 
2000a; Pyne and Pyne, 2000b; Takuwa et al., 2001). Interestingly, a recent study using 
transfected CHO cells has shown that, whereas EDGl and EDG3 result in a PI3K- 
dependent activation of Rac, EDG5 inhibited Rac activation and subsequently membrane 
ruffling and cell migration (Okamoto et al., 2000). The physiological significance of this 
observation is illustrated by the fact that EDG5 is expressed in cells in which SIP is an 
inhibitor of cell migration, such as melanoma cells and vascular smooth muscle cells 
(Okamoto et al., 2000) (Table 4),
1.9.3. The EDG6 And EDG8 Receptors
The EDG6  and EDG8  receptors represent the most recently identified and therefore 
the most poorly characterised SIP receptors. The EDG6  receptor exhibits the most 
restricted expression pattern of all the SIP receptors, being expressed primarily in 
lymphoid and haematopoeitic tissues as well as the lung (Fukushima et al., 2001; Takuwa 
et al., 2001). The EDG8  receptor is expressed in a variety of tissue types but is highly 
expressed in the brain, specifically in white matter, and in the spleen (Fukushima et al., 
2001; Im et al., 2000; Im et al. 2001; Takuwa et al., 2001). The EDG6  receptor has been 
shown to mediate S IP-induced PLC activation, intracellular Ca^^ mobilisation and MAPK 
activation, all of which are blocked by PTx treatment (Fukushima et al., 2001). EDG8  has 
been shown to couple to Gi/o and G12 but not Gs or Gq/n (Im et al., 2000; Malek et al., 
2001). In a recent study using CHO cells transfected with EDG8 , SIP treatment resulted 
in a PTx-sensitive inhibition of forskolin-induced cAMP accumulation and a PTx- 
insensitive activation of JNK and inhibition of serum-induced activation of ERK 1/2 
(Malek et al., 2001). The inhibitory effect of SIP on ERKl/2 activity was abolished by 
treatment with orthovanadate, suggesting the involvement of a tyrosine phosphatase 
(Malek et al., 2001) (Table 4).
1.10. The LPA Receptors
The remaining members of the EDG family of GPCRs, namely EDG2, 4, and 7, are 
activated by LPA. EDG2 is expressed widespread outside the nervous system and is 
expressed prominently in testis and intestine (Contos et al., 2000; Fukushima et al., 2001;
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Pyne and Pyne, 2000b; Takuwa et al., 2001). EDG2 is also prevalent in the myelinating 
cells of the adult nervous system where LPA promotes the Gi-mediated PI3K/Akt- 
dependent survival of myelinated Schwann cells from the peripheral nervous system 
(Weiner and Chun, 1999). In addition, EDG2 is also expressed in several cancers, 
suggesting a pathological role for receptor-mediated LPA signalling (Furui et al., 1999). 
EDG2 couples to Gi/o, which leads to cell proliferation (Fukushima et al., 2001, Hla et al., 
2001). In addition, EDG2 is also coupled to the Rho pathway, leading to actin 
rearrangement and cell proliferation (Fukushima et al., 2001, Hla et al., 2001; Weiner and 
Chun, 1999). EDG4 is a high-affinity LPA receptor that activates the Gq pathway (Contos 
et al., 2000; Fukushima et al., 2001). It is constitutively expressed in CD4^ T cells and 
inhibits the secretion of interleukin-2 (EL-2) (Hla et al., 2001). EDG4 couples to Gi and 
Gq, which mediates LPA-induced PLC activation and leads to intracellular Ca^^ increases 
and inositol phosphate production (Contos et ah, 2000; Fukushima et al., 2001; Hla et al.,
2001). EDG4 receptor expression is strongly induced in ovarian cancer cell lines where it 
regulates the transcription of immediate-early genes and cellular proliferation (Goetzl et 
al., 1999). EDG7 is abundantly expressed in testis, heart and frontal regions of the 
cerebral cortex (Contos et al., 2000; Fukushima et al., 2001). Studies of EDG7 function 
within mammalian and insect cell lines have demonstrated an LPA-dependent, PTx- 
insensitive increase in PLC activity and intracellular Ca^^ concentration, suggesting that 
EDG7 is coupled primarily to Gq (Fukushima et ah, 2001) (Table 4).
1.11 The Role Of SIP-Dependent Activation Of EDGl In Angiogenesis
One of the most important biological roles of EDGl is in the process of 
angiogenesis, defined as the formation of new blood vessels from pre-existing ones (Figure 
1.9). This process constitutes an integral component of many physiological events, such as 
embryonic development, wound healing and the menstrual cycle, each of which are 
defined by a requirement for new vessel formation to simultaneously supply oxygen and 
nutrients and remove waste products (Cross and Claesson-Welsh, 2001; Griffioen and 
Molema, 2000; Richard et al., 2001). Angiogenesis is also critically important in a number 
of pathological conditions associated with blood vessel formation. For example, excessive 
angiogenesis has been linked with solid and haematologic tumour progression, chronic 
inflammation present in rheumatoid arthritis and Crohn’s disease, endometriosis, and 
diabetic retinopathy (Carmeliet and Jain, 2000; Cross and Claesson-Welsh, 2001; Griffioen 
and Molema, 2000; Richard et al., 2001). The process of angiogenesis involves a number 
of steps; 1) initiation; 2) endothelial cell migration and proliferation 3) differentiation and
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4) maturation of the neovasculature (Cross and Claesson-Welsh, 2001; Griffioen and 
Molema, 2000) (Figure 1.9). These steps are regulated by a number a factors, with the 
control of each factor representing a clinically important challenge (Carmeliet and Jain, 
2000; Fan et al., 1995; Griffioen and Molema, 2000). Recent studies have suggested that 
the regulation of SIP-dependent activation of EDGl represents such a challenge (Hobson 
et al., 2001; Kimura et al., 2000; Lee et al., 1999; Lee et al., 2001; Liu et al., 2000; 
Rosenfeldt et al., 2001).
1.11.1. Initiation of Angiogenesis
Conditions of hypoxia or ischaemia provide the most common initiation stimulus 
for angiogenesis to occur (Carmeliet and Jain, 2000; Griffioen and Molema, 2000). This 
usually results in a NO-mediated relaxation of the vascular muscle and, in turn, causes 
morphological changes of the endothelial cells that facilitate the binding of mitogens 
(Griffioen and Molema, 2000). Vascular endothelial growth factor (VEGF), an important 
mediator of angiogenic initiation, is known to act on VEGF receptors (VEGFRs) to induce 
vasodilatation via NO production and increased endothelial cell permeability, allowing 
plasma proteins to enter the tissue and form a fibrin-rich provisional network (Cross and 
Claesson-Welsh, 2001; Dvorak, 1986; Griffioen and Molema, 2000; Ziche et al., 1997). In 
hypoxic tissues, the hypoxia inducible factor-1 (HIF-1) has a central role in inducing the 
transcription of genes that are involved in glycolysis and angiogenesis, especially VEGF 
(Cross and Claesson-Welsh, 2001; Griffioen and Molema, 2000; Ryan et al., 2000; 
Saaristo et al., 2000). To date, there are three known VEGF tyrosine kinase receptors; 
VEGFR-1 (Flt-1), VEGFR-2 (KDR or Flk-1) and VEGFR-3 (Flt-4) (Cross and Claesson- 
Welsh, 2001). VEGFR-1 and VEGFR-2 are expressed mainly in the vascular endothelium 
whereas VEGFR-3 is mostly restricted to the lymphatic endothelium (Cross and Claesson- 
Welsh, 2001). Endothelial cell penetration into new areas of the body is then achieved by 
degradation of the basal membrane by matrix metalloproteinases (MMPs) (Cross and 
Claesson-Welsh, 2001; Griffioen and Molema, 2000). Recent studies have also 
demonstrated that SIP activation of EDGl results in an Akt-dependent phosphorylation of 
eNOS (Igaraishi and Michel, 2001; Kwon et al., 2001; Lee et al., 2001; Morales-Ruiz et 
al., 2001). This suggests that EDGl activation may affect vasodilatation in conjunction 
with VEGF and would therefore implicate EDGl activation in the initiation of 
angiogenesis.
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1.11.2. Endothelial cell migration and proliferation
Directional endothelial cell motility is driven by a number of chemoattractants that 
bind GPCRs (interleukin- 8  and fMIP) or growth factors, such as VEGF and fibroblast 
growth factor (FGF) (Cross and Claesson-Welsh, 2001; Griffioen and Molema, 2000; 
Richard et al, 2001). EDGl has been shown in a number of studies to regulate cell 
migration (Hobson et aL, 2001; Kimura et al., 2000; Lee et al., 2000; Lee et al., 2001; 
Morales-Ruiz et al., 2001; Rosenfeldt et al., 2001). For example, low concentrations of 
SIP increased migration of endothelial cells and EDGl-expressing HEK293 cells whereas 
high SIP concentrations inhibited cell migration (Wang et al., 1999). A study using CHO 
cells expressing either EDGl, EDG3 or EDG5 showed that CHO/EDG5 cells did not 
migrate whereas CHO/EDGl and CHO/EDG3 cells migrated in a PTx-sensitive manner 
following SIP exposure (Kon et al., 1999). A recent study showed that EDGl-induced 
endothelial cell chemotaxis was mediated via a Gi/PI3K/Akt-dependent activation of Rac 
(Lee et al., 2001). However, the inhibition of NO production had no effect on SIP- 
induced endothelial cell chemotaxis whereas VEGF-dependent chemotaxis was blocked 
(Morales-Ruiz et al., 2001).
The plasmin-mediated mobilisation of FGF from the endothelial cell matrix 
represents an important step in endothelial cell migration and proliferation (Cross and 
Claesson-Welsh, 2001; Griffioen and Molema, 2000; Richard et al, 2001). The classical 
FGFs, FGF-1 and FGF-2, mediate their biological effects via 4 tyrosine kinase receptors, 
namely FGFR-1, 2, 3, and 4 (Cross and Claesson-Welsh, 2001). FGF-2 consists of a high 
molecular weight (hmw) and a low molecular weight (Imw) form of FGF (Griffioen and 
Molema, 2000). Imw FGF binding to the endothelium during angiogenesis causes FGFR 
down-regulation, increased motility, proliferation and proteinase activity and also 
modulates levels of integrins (Griffioen and Molema, 2000). Integrins are transmembrane 
proteins which bind to extracellular matrix (ECM) proteins or cell surface ligands where 
they influence the activity of the basal cell cycle machinery consisting of cyclin-dependent 
kinase complexes and can mediate anchorage-dependent cell death (Cross and Claesson- 
Welsh, 2001; Griffioen and Molema, 2000). hmw FGF may act upon endothelial cell 
proliferation after nuclear translocation in the endothelial cells (Cross and Claesson-Welsh, 
2001; Griffioen and Molema, 2000). In addition, VEGF has been shown to also affect 
endothelial cell proliferation by activating MAPK via a NO/cGMP dependent process 
(Griffioen and Molema, 2000). Interestingly, SIP has been shown to act synergistically 
with FGF and VEGF in promoting angiogenesis (Lee et al., 1999). Also, recent evidence
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suggests that SIP-dependent activation of EDGl, along with EDG3, results in the Rho- 
dependent activation of integrin avPs and pi-containing integrins, leading to the formation 
of initial focal contacts required for cell spreading and migration (Paik et al., 2001). avPa 
has also been shown to function in a synergistic manner with VEGF in the processes of cell 
migration and proliferation (Soldi et al., 1999).
1.11.3. Differentiation Of The Neovasculature
Following endothelial cell proliferation, the newly formed neovasculature is 
remodelled into capillary-like networks by a process of morphogenesis (Cross and 
Claesson-Welsh, 2001; Griffioen and Molema, 2000) (Figure 1.10). Morphogenesis 
involves the folding of epithelial cell sheets into tubes and other related structures and is 
typically regulated via connection sites for actin filaments known as adherens junctions 
(Alberts et al., 1994). Cell-matrix adherens junctions allow cells to grip the extracellular 
matrix. Cell-to-cell adherens junctions occur in various forms. In non-epithelial tissues, 
these cell-to-cell adherens junctions form small punctate/streak-like attachments that 
connect actin filaments in the cortical cytoplasm of adjacent cells (Alberts et al., 1994; 
Evers et al., 2000; Griffioen and Molema, 2000). In epithelial sheets, cell-to-cell adherens 
junctions make up a continuous adhesion belt (zonula adherens) around each of the 
interacting cells in the sheet, located near the apex of each cell (Evers et al., 2000; Alberts 
et al., 1994). Adhesion belts in adjacent epithelial cells are directly opposed and the 
interacting plasma membranes are held together by transmembrane linker proteins that are 
members of the family of Ca^^-dependent cell-cell adhesion molecules called cadherins 
(Evers et al. 2000; Alberts et al., 1994). The family of cadherins consists of around 12 
members, including vascular endothelial (VE)-cadherin, found in the vascular 
endotheliam; E-cadherin, found in epithelial cells; N-cadherin, found in nerve, muscle and 
lens cells and P-cadherin, found in placenta and epidermal cells (Alberts et al., 1994). 
Each cell contains a contractile bundle of actin filaments adjacent to the adhesion belt and 
running parallel to the plasma membrane that are attached via a set of intracellular 
attachment proteins; a-, P-, and y-catenin, vinculin, a-actinin and plakaglobin (Alberts et 
al., 1994; Griffioen and Molema, 2000; Jones et al., 2001). The actin bundles in adjacent 
cells are linked via cadherins and attachment proteins, resulting in an extensive 
transcellular network. It is the contraction of this network that mediates morphogenesis.
EDGl activation has been shown to regulate many of the above components that 
are involved in morphogenesis and this typically involves the activation of the small
24
GTPases, Rac and Rho (Hla et ah, 2001; Pyne and Pyne, 2000a, Pyne and Pyne, 2000b, 
Lee et al., 1999). Rac and Rho are known to be involved in the SIP-stimulated 
translocation of VE-cadherin and P-catenin to cell-cell junctions (Lee et al., 1999). Also, 
SIP treatment in HUVECs results in the activation of EDGl and EDG3 receptors which, in 
turn, activate Rac and Rho dependent adherens junction assembly and cytoskeletal 
rearrangement which ultimately results in the morphogenesis of HUVECs into capillary­
like networks (Lee et al., 1999). Interestingly, the action of SIP is in contrast to the action 
of VEGF, which is known to disrupt adherens junctions (Hla et al., 2001; Lee et al., 1999). 
As described previously, SIP stimulation of EDGl and EDG3 receptors expressed in 
HUVECs results in the activation of otvps- and Pi-containing integrins (Paik et al., 2001). 
In addition to regulating cell spreading and migration, antagonists of ttvPs and Pi- 
containing integrins inhibited S IP-induced endothelial cell morphogenesis in a three- 
dimensional fibrin matrix (Paik et al., 2001).
1.11.4. Maturation of Neovasculature
Once the neo vasculature has been formed, endothelial cells must deposit a new 
basement membrane and recruit surrounding vessel layers composed of mural cells, such 
as pericytes in small vessels and smooth muscle cells in large vessels (Griffioen and 
Molema, 2000; Richard et al., 2001; Saaristo et al., 2000). The recruitment of mural cells 
is largely dependent upon the synthesis and secretion of PDGF within endothelial cells 
(Cross and Claesson-Welsh, 2001; Griffioen and Molema, 2000). On endothelial cell- 
mural cell contact, a latent form of transforming growth factor-P (TGF-p), produced by 
both endothelium and mural cells, is activated in a plasmin-mediated process (Griffioen 
and Molema, 2000). Activated TGF-p induces changes in myofibroblasts and pericytes, 
leading to the formation of a quiescent vessel, ECM production and maintenance of growth 
control (Griffioen and Molema, 2000). Angiopoietins and receptor tyrosine kinases Tiel 
and Tie2 are critical for the communication of endothelial cells with the surrounding 
mesenchyme (Griffioen and Molema, 2000; Jones et al., 2001; Lin et al. 1997). Tiel 
function is related to endothelial cell differentiation and establishing blood vessel integrity 
whereas Tie2 is important for vascular network formation and is only expressed on 
endothelial cells (Jones et al., 2001). Angiopioetin-1 (Ang-1) and Angiopioetin-2 (Ang-2) 
are Tie2-specific ligands that activate or antagonize Tie2 signalling respectively (Davis et 
al., 1996; Jones et al., 2001; Maisonpierre et al., 1997). Vessels in embryos lacking Tie2 
or Angl demonstrated that endothelial cells failed to associate properly with underlying
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support cells, indicating that Tie2 signalling may facilitate recruitment of, and tight 
association with, adjacent periendothelial cells (Patan, 1998; Suri et al., 1996). The 
persistent expression and phosphorylation of Tie2 in quiescent adult endothelium also 
suggests a role for Tie2 in transducing a sustained survival signal (Jones et al., 2001; 
Wong et al., 1997). In human glioblastomas, a cell-specific up-regulation of Tie2, Ang-1 
and Ang-2 during tumour progression was detected in a pattern compatible with a role in 
tumour-induced angiogenesis (Griffioen and Molema, 2000; Stratmann et al., 1998).
Studies on EDGl knockout mice showed that EDGl is essential for vascular 
maturation as EDGl gene disruption resulted in impaired vascular maturation due to the 
failure of mural cells to migrate to arteries and capillaries to reinforce them (Liu et al.,
2000). In fact, although EDGl null embryos died in utero due to massive hemorrage, they 
exhibited normal vasculogenesis and a substantially normal blood vessel network, yet were 
severely impaired in the recruitment of smooth muscle cells and pericytes to the vessel 
walls and this was attributed to their defective migration (Liu et al., 2000), Extracellular 
SIP can directly stimulate EDGl on VSMCs, facilitating their migration to vessel walls or, 
alternatively, can stimulate EDGl expressed in endothelial cells that in turn may recruit 
vascular smooth muscle cells (VSMCs) (Liu et al., 2000) (Figure 1.11). Recent studies 
have demonstrated that the effect of EDGl on vascular maturation can be largely attributed 
to the cross-talk between EDGl and PDGF receptor signalling mentioned previously 
(Hobson et al., 2001; Rosenfeldt et al., 2001). Cell migration toward PDGF, which 
stimulates sphingosine kinase and increases intracellular SIP, was dependent upon EDGl 
expression in a number of cell types, including HEK293 cells, human aortic smooth 
muscle cells (ASMCs) and mouse embryonic fibroblasts (MEFs) (Hobson et al., 2001). It 
was therefore suggested that spatially and temporally localised generation of SIP by 
activation of sphingosine kinase in response to PDGF results in restricted activation of 
EDG that in turn activates Rac, resulting in an increase in cell motility (Hobson et al.,
2001). A recent study has subsequently demonstrated that the PDGF-induced cytoskeletal 
rearrangements, lamelipodia extensions and cell motility are abrogated in EDGl null 
fibroblasts (Rosenfeldt et al., 2001). Also, PDGF-induced focal adhesion formation and 
activation of FAK, Src and S APK 2 were disregulated in the absence of EDGl (Rosenfeldt 
et al., 2001). However, EDGl was not involved in mitogenicity and survival effects 
induced by SIP or PDGF (Rosenfeldt et al., 2001). Hence, it was suggested that EDGl 
acted as an integrator linking the PDGFR to lamellipodia extension and cell migration. 
Cells then migrate towards PDGF, enhancing PDGF receptor signalling and therefore
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acting as a positive feedback mechanism (Hobson et ah, 2001; Rosenfeldt et ah, 2001) 
(Figure 1.12).
1.12 GPCR Regulation
GPCR signal transduction must be properly regulated in order to prevent 
overstimulation, achieve signal termination and render the receptor responsive to 
subsequent stimuli. Desensitisation of GPCRs is defined as the process whereby receptor 
signalling responses plateau and then diminish despite the continuous presence of agonist 
(Ferguson, 2001). The mechanism of GPCR desensitisation involves a number of different 
processes. Rapid, homologous desensitisation is thought to involve receptor uncoupling 
from its associated G-protein(s) within a few minutes of agonist exposure and seems to 
involve receptor phosphorylation (Appleyard et al., 1999; Bouvier et al., 1998; Jockers et 
al., 1996; Palmer et al., 1995; Small et al., 2001; Xiao et al., 1999). Receptor 
intemalisation, or sequestration, away from the cell surface that not only reduces the 
number of cell surface receptors available but may also facilitate receptor 
dephosphorylation and subsequent resensitisation upon agonist removal (Cavalli et al., 
2001; Ferguson, 2001; Koenig and Edwardson, 1997; Mukherjee et al., 1997). After 
several hours of agonist exposure, receptor down-regulation may occur where there is a 
decrease in the total number of receptors expressed (Bouvier et al., 1989; Clark, 1986; 
Ferguson, 2001; Law et al., 1982; Tsao et al., 2001). This requires an increase in gene 
expression to compensate for the loss of expressed reeeptor protein (Collins et al., 1989; 
Tsao et al., 2001).
1.12.1 GPCR Desensitisation
GPCR desensitisation can vary from complete inhibition (visual/olfactory systems) 
to attenuation (PzAR) (Ferguson, 2001; Sakmar, 1998; Zhang et al., 1997). In the case of 
many GPCRs, the ability or inability to undergo agonist-induced receptor phosphorylation 
is integral to the subsequent rate and extent of receptor desensitisation (Clark et al., 1999; 
Ferguson, 2001; Palmer et al., 1996). GPCR desensitisation has been shown in a number 
of cases to be regulated by phosphorylation by G-protein receptor kinases, an*estins and 
second messenger-dependent kinases (Appleyard et al., 1999; Ferguson, 2001; Jockers et 
al., 1996; Oakley et al., 1999; Tang et al., 1998; Yuan et al. 1994). Desensitisation can 
also occur at the G-protein level. For example, RGS proteins (regulators of G protein 
signalling) can increase the rate of GTP hydrolysis bound to Gi and Gq a-subunits and 
therefore attenuates signalling via Gi-and Gq- regulated signalling pathways (Dohlman and
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Thomer, 1997; Ferguson, 2001; Hepler, 1999). The most well defined example of rapid 
GPCR desensitisation is that of the P2-adrenergic receptor (Jockers et ah, 1996; Luttrell et 
al., 1999; McLean et a l, 1999; Menard et al., 1997; Moffett et ah, 1993). Some GPCRs, 
although not all, seem to share similar regulatory mechanisms, including the thrombin, mi- 
muscarinic, and rhodopsin receptors (Ferguson, 2001). In this case, the predominant form 
of agonist-induced P2AR desensitisation is caused by a conformational change of the 
agonist-occupied receptor that facilitates receptor phosphorylation by G-protein receptor 
kinases (GRKs) (Ferguson et a l, 2001; Jockers et al., 1996; Menard et al., 1997; Pierce 
and Lefkowitz, 2001). Following P2AR phosphorylation, a scaffold protein, P-arrestin, 
binds to the phosphorylated receptor and uncouples the receptor from heterotrimeric G- 
proteins (Giadarov et al., 1999; Luttrell et al., 1999; Menard et al., 1997, Miller and 
Lefkowitz, 2001). p-arrestin not only desensitises the receptor but also functions as a 
clathrin adaptor, mediating receptor sequestration via clathrin-coated vesicles (Giadarov et 
al., 1999; Luttrell et al., 1999; Menard et al., 1997, Miller and Lefkowitz, 2001; Takei and 
Haucke; 2001) (Figure 1.13).
1.12.2. Second Messenger-Dependent Kinases
The activation of second messenger-dependent kinases results in receptor 
phosphorylation independently of agonist occupation. This subsequently causes so-called 
“heterologous” receptor desensitisation as agonist occupancy is not required (Ferguson,
2001). In the case of the P2AR, phosphorylation by PKA of a consensus site within its 
third intracellular loop causes partial uncoupling of the receptor from Gs (about 40-60%) 
(Yuan et al., 1994). This mechanism is usually triggered by very low occupancy of 
receptor (2-5nM epinephrine) as it requires only small increases in cAMP to fully activate 
PKA, and is rapid, with a ti/2 of 1-2 min (January et al., 1997). This is in contrast to GRK- 
mediated phosphorylation, where the EC50 for GRK-mediated phosphorylation approaches 
the Kd for agonist binding (50-200 nM epinephrine) (Hausdorff et al., 1997; January et al., 
1997; Clark et al., 1988). Therefore, as the concentration of agonist increases, P2AR 
desensitisation moves from being almost exclusively PKA-mediated towards a 
progressively larger GRK-mediated mechanism. Additionally, the time course of GRK- 
mediated phosphorylation usually occurs within seconds (Clark et al., 1999; Ferguson et 
al., 2001). The relatively slower time-course of second messenger-mediated receptor 
phosphorylation can be attributed to the time required to activate the second messenger 
kinase whereas GRK-mediated phosphorylation only requires the appropriate
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confoimational change of the receptor. Interestingly, phosphorylation of P2ARS by PKA 
has also been shown to switch the receptor from Gg to Gi coupling (Daaka et al., 1997). In 
addition to PKA, a number of other second messenger-dependent kinases are involved in 
GPCR desensitisation. For example, PKC has been shown to phosphorylate and 
desensitise a number of Gi- and Gq-coupled GPCRs, including aie-adrenoceptor and the 
type lA  angiotensin II receptor (Diviani et al., 1997; Liang et al., 1998; Tang et al., 1998),
1.12.3. G-Protein Receptor Kinases
GRKs constitute a family of receptor kinases consisting of seven members, namely 
GRKl-7 (Ferguson, 2001; Pierce and Lefkowitz, 2001). Each member contains a central 
common catalytic domain, an N-terminal domain that controls substrate recognition and 
contains a conserved RGS domain, and a C-terminal domain responsible for targeting 
GRKs to the plasma membrane. The GRK family can be subdivided into three groups: 1) 
GRKl (rhodopsin kinase) and GRK7 (cone opsin kinase); 2) GRK2 (P-adrenergic kinase 
1, PARKl) and GRK3 (P-adrenergic kinase 2, PARK2) and 3) GRK4, GRK5, and GRK6 . 
GRKl and GRK7 are fames ylated at CAAX motifs in their carboxyl termini, with GRK I 
also shown to be regulated by the Ca^^ sensor protein, recoverin (lacovelli et al., 1999; 
Inglese et a l, 1992). The translocation of GRK2 and GRK3 to the plasma membrane are 
each regulated by phosphatidylinositol 4,5-bisphosphate binding to a region that exhibits 
sequence homology to a pleckstrin homology (PH) domain contained within the carboxyl- 
terminal domains of GRK2 and GRK3 (Pitcher et al., 1992; Touhara et al., 1994). The 
GRK5 carboxyl-terminal domain contains a stretch of 46 basic amino acids that mediates 
interactions with plasma membrane-phospholipid . The activity of GRK5 decreases in the 
presence of PKC whereas GRK2 activity is increased (Chaung et al., 1995; Chuang et al., 
1996; Winstel et al., 1996). Calmodulin associates with the N-terminal of GRK5 to 
decrease the ability of the kinase to bind the receptor and phospholipids and decreases 
GRK5 activity by promoting the autophosphorylation of serine and threonine residues 
distinct from those involved in kinase activation (Pronin and Benovic, 1997; Pronin et al., 
1997; lacovelli et al., 1999). The plasma membrane localisation of GRK4 and GRK6  is 
regulated by the palmitoylation of cysteine residues within their C-termini (Stoffel et a l, 
1994; Stoffel et a l, 1998) (Figure 1.14).
The GRKs can selectively phosphorylate serine and threonine residues within the 
3'^ intracellular loop (m2 mAchR and oCz^ AR) or the C-terminal tail (rhodopsin and P2AR) 
of agonist-occupied GPCRs (Ferguson et a l, 2001). In addition, GPCRs can isomerise to
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an activated conformation in the absence of agonist and therefore GRKs may also 
contribute to basal GPCR phosphorylation (Pie et al., 1994; Rim and Oprian, 1995). An 
agonist-induced conformational change in GPCRs exposes two physically and functionally 
distinct domains. One contains the sequence that is phosphorylated by GRK and the 
second acts as an activator of these kinases (Chen et al., 1993; lacovelli et al., 1999). For 
example, the sites within the m2-muscarinic receptor phosphorylated by GRK2 and the 
domains able to activate this kinase were found to be located in different intracellular 
regions of the receptor (lacovelli et al., 1999; Nakata et al., 1994).
1.12.4. Arrestins
The GRK-mediated phosphorylation of clusters of serine and threonine residues in 
C-tails may regulate stability of receptor/arrestin complexes (Miller and Lefkowitz, 2001; 
Oakley et al., 1999). The an'estins are adaptor proteins that preferentially bind agonist- 
activated and GRK-phosphorylated GPCRs, with which where they form a complex that 
results in receptor uncoupling from G-proteins, can target the receptor for internalisation 
via clathrin-coated vesicles and can mediate the activation of alternative signalling 
pathways (Ferguson, 2001; Gaidarov et a i, 1999; Luttrell et al., 1999; Miller and 
Lefkowitz, 2001; Pierce and Lefkowitz, 2001). The arrestin family is subdivided into 2 
groups: a) visual arrestin (S antigen) and cone arrestin (X-arrestin/C-arrestin) and b) P- 
arrestins (P-arrestinl and P-arrestin2 ) (Ferguson, 2001; Miller and Lefkowitz, 2001; Pierce 
and Lefkowitz, 2001). Visual arrestin is found within rod outer segments and is localised 
primarily to the retina (Smith et al., 1994). C-arrestin is highly enriched in retina and 
pineal gland but is localised primarily within cone photoreceptors in the retina (Craft et ah, 
1994). p-arrestins are ubiquitously expressed, with the highest expression found within 
neuronal tissues and the spleen where they regulate signalling of many different GPCRs 
(Attramadal et al., 1992; Pierce and Lefkowitz, 2001). Studies on crystal structure, as well 
as mutagenesis studies, of visual arrestin identified 3 functional domains (a secondary 
receptor-binding domain, a receptor activation domain and a phosphate sensor domain) and 
two regulatory domains, located at the amino terminal and carboxyl-terminal (Ferguson, 
2001; Gurevich et ah, 1995; Granzin et al., 1998). Within the N-terminal domain of P- 
arrestinl and P-arrestin2, but not the visual arrestins, there is a proline-rich region (Luttrell 
et al., 1999). The C-terminal region contains clathrin- and p-adaptin-binding domains that 
are conserved among nonvisual arrestins (Krupnicke et a l, 1997; Laporte et al., 2000) 
(Figure 1.15).
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1.12.5. The Role Of Arrestins In Clathrin-Mediated GPCR Internalisation
Many receptors undergo agonist-induced endocytosis and recycling back to the 
plasma membrane (Ferguson, 2001; Pierce and Lefkowitz, 2001; Takei and Haucke, 2001). 
For the P2AR and many other GPCRS, such as the angiotensin ATiaR, the endothelin ETa 
receptor and the D2 dopamine receptor, endocytosis involves GRK- and arrestin-dependent 
recruitment of GPCRs to plasma-membrane clathrin-coated pits and then their invagination 
and pinching off to form intracellular clathrin-coated vesicles (Brodin et al., 2000; 
Ferguson, 2001; Pierce and Lefkowitz, 2001; Takei and Haucke, 2001) (Figure 1.13). 
Clathrin is composed of three light and three heavy chains that form a three-legged 
structure called a triskelion (Brodin et al., 2000; Takei and Haucke, 2001) (Figure 1.16). 
The triskelions then assemble into a basket-like convex framework of hexagons and 
pentagons that form the coated pits on the cytoplasmic surface of the plasma membranes 
(Brodin et a l,  2000; Schmid, 1997; Takei and Haucke, 2001). One of the main 
components of the coats formed during membrane endocytosis is an adaptor protein (AP) 
called AP2. The AP2 complex consists of four subunits: two large lOOkDa subunits (a- 
adaptin, which binds to clathrin, dynamin and Eps 15 and P2-adaptin, essential for clathrin 
coat formation), one medium size 50kDa subunit (p,2, which recognises tyrosine-based 
internalisation signals) and a small 17kDa subunit (a2) (Brodin et al., 2000; Ferguson, 
2001; Takei and Haucke, 2001) (Figure 1.16). In clathrin, the P-arrestin binding domain is 
localised to residues 89-100 of the amino-terminal globular region in the terminal domain 
of the clathrin heavy chain at the distal end of each clathrin triskelion (Goodman et al., 
1997). The p-arrestin domain involved in binding to the P2-adaptin subunit of the AP2 
complex is also localised to the carboxyl terminus (Ferguson, 2001; Brodin et ah, 2001). 
In particular, two arginine residues (R394and R396) in P-arrestin2 mediate binding to p2- 
adaptin in vitro (Laporte et al., 2000). The binding of P-arrestins to P2-adaptin is 
independent of clathrin binding (Laporte et al., 2000). In addition, whereas P2AR/P- 
arrestin complexes lacking the P-arrestin clathrin binding motif redistributed to coated pits, 
receptor/P-aiTestin complexes lacking the P2-adaptin binding site did not (Laporte et al.,
2000). Therefore, p-arrestin interactions with the AP-2 complex, rather than with clathrin, 
are necessary for the initial targeting of receptors to coated pits (Laporte et al., 2000). P- 
arrestins bind to both the clathrin heavy chain and the p2-adaptin subunit of AP2 
(Ferguson, 2001; Brodin et al., 2000). The coat also contains a monomeric adaptor 
protein, A PI80 (Figure 1.16), which interacts with AP2 and may regulate vesicle size
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(Brodin et al., 2000). The formation of clathrin-coated pits is assisted by synaptotagmin 
(Figure 1.16), an AP-2 binding protein that facilitates vesicle recycling by promoting 
coated pit nucléation (Brodin et al., 2000; Ferguson, 2001; Takei and Haucke, 2001).
The pinching off of clathrin-coated vesicles is largely dependent upon the action of 
a large GTPase called dynamin (Figure 1.16) and is ATP-dependent (Brodin et al., 2000; 
Takei and Haucke, 2001). Overexpression of Dynamin K44A, a dominant negative form of 
dynamin lacking GTPase activity, blocked both P2AR and ATiaR internalisation (Brodin 
et ah, 2000; Ferguson, 2001; Gagnon et al., 1998; Tsao et al., 2001; Zhang et al., 1996). 
Dynamin self-assembles into a helical structure that wraps around the necks of forming 
vesicles and facilitates their pinching off from the membrane (Brodin et al., 2000; Takei 
and Haucke, 2001). Dynamin can interact with amphiphysin and syndapins, which link 
endocytosis with the actin cytoskeleton (Brodin et al., 2001; Takei and Haucke, 2001). 
The accessory protein amphiphysin (Figure 1.16) acts as a binding partner for clathrin, AP- 
2 and dynamin and has been shown to recruit dynamin to clathrin-coated pits (Brodin et 
ah, 2001; Takei and Haucke, 2001). A number of other accessory proteins are involved in 
clathrin-mediated endocytosis. These include: synaptojanin, an inositol phosphatase that 
regulates PIP2 metabolism and the stability of clathrin-AP2 coats; endophilin, a 
lysophosphatidic acid acyl transferase involved in pit maturation and vesicle fission, and 
epsin and Eps 15, both of which are interacting partners for the a-adaptin subunit of AP2 
(Brodin et al., 2001; Cavalli et al., 2001; Ferguson, 2001; Mukherjee et al., 1997; Simpson 
et al., 1999; Takei and Haucke, 2001) (Figure 1.16).
Components of the endocytic machinery described above, particularly dynamin and 
clathrin, have been shown to be regulated as a result of the P-arrestin-mediated activation 
of ERK (Ahn et al., 1999; Ferguson, 2001; Miller and Lefkowitz, 2001; Miller et al., 2000; 
Pierce and Lefkowitz, 2001). Recent evidence has shown that several components of the 
ERK pathway form complexes with P-arrestins and are then recruited to GPCRs in an 
agonist-dependent manner (DeFea et al., 2000; Luttrell et al., 1999; Miller and Lefkowitz,
2001). The role of p-arrestins as molecular adapter proteins was extended to components 
of the ERK pathway with the discovery that P-arrestin could recruit the non-receptor 
tyrosine kinase Src to activated P2ARS (Luttrell et al., 1999). Src molecules associated 
with P-arrestin and activated P2ARS were found to be dephosphorylated on Tyr530 and 
thus catalytically active (Luttrell et a l, 1999; Miller and Lefkowitz, 2001). Recruitment of 
active Src to agonist-occupied receptor leads to phosphorylation of the adaptor protein She,
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formation of Shc-Grb2 complexes and mediates, as well as ERK activation, the 
phosphorylation of dynamin and clathrin (Luttrell et al., 1999; Miller and Lefkowitz, 
2001).
1.12.6. Trafficking Through Endocytic Organelles
Following internalisation, receptors are delivered to peripheral early endosomes 
(Cavalli et al., 2001; Ferguson, 2001; Mukherjee et a l, 1997). The small GTPase Rab5 is 
one of the key regulators of this process and cycles between GTP- and GDP-bound form, 
and GTP hydrolysis depends on a specific GEP, Rabex-5 (Cavalli, et al., 2001; Ferguson, 
2001; Takai et a l, 2001). Rab5 often contributes to the formation of endocytic vesicles, 
the trafficking of vesicles to early endosomes and the fusion of endocytic vesicles with 
early endosomes (Cavalli et al., 2001; Ferguson, 2001). Once delivered to early 
endosomes, recycling receptors such as the P2AR and the transferrin receptors are returned 
to the cell suface, at least in part via recycling endosomes (Ferguson, 2001; Pierce and 
Lefkowitz, 2001). The small GTPase, Rab4 is also involved in the recycling pathway 
where it regulates the budding and/or recycling of receptor-bearing recycling vesicles 
(Cavalli et al., 2001; Ferguson, 2001; Seachrist et al., 2000). In contrast to recycling 
receptors, some endocytosed receptors targeted for downregulation are transported from 
early to late endosomes where they are then targeted to lysosomes for degradation 
(Gruenberg and Maxfield, 1995). Transport from early to late endosomes is mediated 
through intermediates exhibiting a characteristic multi vesicular appearance called 
multivesicular bodies (MVBs) or endosomal carrier vesicles (ECVs). In mammalian cells, 
ECVs/MVBs, once formed on early endosomes, move towards late endosomes on 
microtubules and then dock onto and fuse with late endosomes (Cavalli et al., 2001; 
Gruenberg and Maxfield, 1995) (Figure 1.17). Little is known about the possible cross­
talk between late endosomes/lysosomes and signalling pathways. However, recent studies 
identified a novel 14 kDa protein that interacts with the MAPK scaffold protein MPI on 
late endosomes/lysosomes but its function remains unclear (Cavalli et al., 2001). In 
addition, protein ubiquitination has been implicated at multiple steps of the endocytic 
pathway from the internalisation reaction to the maturation of endosomes and lysosomal 
delivery (Cavalli et al, 2001; Ferguson, 2001; Shenoy et a l, 2001). For example, a P2AR 
mutant lacking lysine residues, which was not ubiquitinated, was internalised normally but 
was degraded ineffectively (Shenoy et a l, 2001).
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1.12.7. Alternative Pathways Of Internalisation
Although clathrin-mediated internalisation represents the most common mechanism 
for GPCR internalisation, receptors can also internalise via pathways that are independent 
of both clathrin and p-arrestin (Anderson, 1998; Cavalli, 2001; Ferguson, 2001; Mukherjee 
et ah, 1997). One possible route of entry involves cell surface microdomains containing 
cholesterol and glycosphingolipids (rafts), which are believed to play an important role in 
the internalisation of the IL-2 receptor (Anderson, 1998; Cavalli, 2001; Ferguson, 2001; 
Mukherjee et al., 1997). Rafts can form flask-shaped invaginations smaller than clathrin- 
coated pits termed caveolae, when associated with caveolin (Anderson, 1998). These 
structures have been reported in a variety of cell types, including smooth muscle cells, 
fibroblasts, adipocytes, endothelial cells and many epithelial cells (Anderson, 1998; Kogo 
and Fujimoto, 2000; Mineo et al., 1996; Oh et al., 1998; Parton, 1996). Although much 
less is known about the molecular mechanism involved, both the agonist-occupied P2AR 
and the bradykinin B2 receptors were shown to be localised in caveolae as determined by 
electron microscopy studies (de Weerd et al., 1997; Ferguson, 2001; Haasemann et al., 
1998; Okamoto et al., 2000). Other GPCRs, such as the angiotensin type 1 and m2 
muscarinic acetylcholine receptors also undergo agonist-dependent sequestration in this 
microdomain, as demonstrated by the recovery of receptor proteins in caveolin-rich 
fractions (Feron et al., 1997; Ishizaka et al., 1998). In many cases, cell-type is crucial in 
determining the favoured pathway of receptor internalisation. For example, the P2AR 
internalises in some cell types via clathrin-coated pits but internalises via caveolae in other 
cell types, such as A431 cells (Ferguson, 2001; Kallal and Benovic, 2000; Raposo et al., 
1989). The endothelin ETa receptor has also been shown to internalise via both pathways 
in a cell-type dependent manner (Okamoto et al., 2000). The form of internalisation 
pathway can also determine the intracellular trafficking of the receptor (Okamoto et al., 
2000).
1.13 The Study Of GPCR Cell Surface Distribution And Agonist-Induced 
Internalisation Using Green Fluorescent Protein (GFP)
Classical approaches to studying GPCR internalisation include radioligand binding, 
physical fractionation techniques and immunofluorescence (Kallal and Benovic, 2000). 
However, the recent application of green fluorescent protein (GFP) as a tool in the study of 
agonist-induced GPCR internalisation has proved invaluable (Drmota et al., 1998; Kallal 
and Benovic, 2000; McLean et ah, 1999; Milligan, 1999). The gene encoding GFP was
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originally isolated from the jellyfish Aequoria victoria in 1992 (Prasher et ah, 1992). GFP 
is an autofluorescent protein of 238 amino acids that emits green light with an emission 
maximum of 509nm upon fluorescent excitation at 488nm derived from either standard 
fluorescence microscope light sources or fluorescein isothiocyanate (FITC) excitation and 
emission filters (Tsien, 1998). The use of GFP in the study of receptor internalisation has 
been used for a variety of GPCRs, including the cholecystokinin CCKi receptor, P2AR, 
thyrotropin-releasing hormone TRHi receptor and the vasopressin V2 receptor (Drmota et 
ah, 1998; McLean et ah, 1999; Schulein et ah, 1998; Tarasova et ah, 1997).
There are a number of advantages gained from using GFP (Kallal and Benovic, 
2000; Milligan, 1999). Since there are no cofactors or substrates required for fluorescence, 
the time and expense of using primary and secondary antibodies on fixed cells can be 
avoided. GFP-expressing cells can also be studied on living cells in real time so that the 
dynamics of protein trafficking can be observed. Cells expressing GFP can also be fixed, 
as GFP is relatively chemically resistant. Also, since GFP is covalently attached to the 
protein of interest, nonspecific fluorescence is avoided. One of the major disadvantages of 
using GFP is that the expression of GPCR-GFP chimeras in cells results in the labelling of 
protein biosynthetic compartments, such as the endoplasmic reticulum and Golgi, which 
can influence the interpretation of results (Kallal and Benovic, 2000). Many examples of 
GFP-tagging of GPCRs, such as the P2AR and TRHi receptor, have shown that the 
addition of GFP has no effect on the receptor’s ability to bind ligand and that the ability to 
generate second messengers and to desensitise was unaffected (Drmota et ah, 1998; 
McLean et ah, 1999; Schulein et ah, 1998; Tarasova et ah, 1997). However, GFP-tagging 
may result in altered properties of the receptor. Hence, careful experimental comparisons 
to untagged proteins should be made prior to visualisation studies using confocal 
microscopy.
A number of studies have used GPCR-GFP chimeras in conjunction with red 
fluorescent markers that label specific cellular organelles or membranes. Also, antibodies 
or proteins conjugated to rhodamine, Texas Red or other red fluorescent compounds that 
localise to specific organelles or membranes can be used in combination with the GPCR- 
GFP chimeras (Kam et ah, 2001; Kallal et ah, 1998; Kallal and Benovic, 2000; 
McConalogue et ah, 1999; Tarasova et ah, 1998). By observation of the GPCR-GFP and 
the red fluorescent component in the same cell, any potential co-localisation can be readily 
ascertained. Compounds that are commonly used with GPCR-GFP chimeras include
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rhodamine-dextran and LysoTracker Red, which label late endosomes and lysosomes, 
respectively and rhodamine-transferrin, which labels early endosomes and endocytic 
recycling compartments. Most GPCR-GFP chimeras, including the P2AR and the TRHi 
receptor, were shown to enter transferrin-containing endosomes rapidly after exposure to 
an agonist and co-localise with tetramethylrhodamine isothiocyanate (TRITC)-transferrin 
or Texas-Red transferrin (Kallal and Benovic, 2000). Also, studies using fluorescent 
dextran- or Lysotracker red-tagged lysosomes demonstrated that receptors, such as the 
CXCR-4-GFP receptor, accumulate in lysosomes whereas other receptors, such as the 
CCKi-GFP receptor, did not show any lysosomal co-localisation (Tarasova et ah, 1997; 
Tarasova et al.., 1998).
In addition to co-localisation studies, GPCR-GFP chimeras can be used for FRAP 
(fluorescence recovery after photobleaching) in order to examine receptor mobility in the 
membrane. This is where a small area of the cell membrane is bleached with a high 
intensity laser and recovery of fluorescence into the bleached area is used to measure 
protein diffusion rate within membranes (Barak and Benovic, 2000; Milligan, 1999). The 
FRAP technique has demonstrated that P2AR-GFP has a rapid diffusion rate, similar to 
other plasma membrane proteins (Barak et al., 1997). In contrast, the gonadotrophin 
releasing hormone receptor tagged with GFP (GnRHR-GFP) membrane diffusion rate was 
reduced in the presence of agonists and antagonists (Nelson et al., 1999). Because some 
receptors have been shown to oligomerize upon activation (Herbert and Bouvier, 1998), 
changes in membrane mobility might reflect the formation of receptor oligomers. Another 
application of GFP relies on the use of newer GFPs, such as the cyan and yellow GFPs, in 
the technique of FRET (fluorescence resonance energy transfer) (Barak and Benovic, 
2000; Milligan, 1999; Pollok and Heim, 1999). This is where the excitation of one 
fluorophore results in an emission that excites a second fluorophore. Such emission is a 
measure of the interaction between two proteins as energy transfer is inversely proportional 
to distance and is detectable only if fluorophores are within 7 nm of each other (Barak and 
Benovic, 2000). The FRET technique could potentially be an important measure of 
transient agonist-mediated GPCR-protein interactions.
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1.14 Aim
The aim of this project is to examine the phosphorylation and internalisation of the 
adenosine Ai receptor and the sphingosine-1-phosphate receptor, EDGl. Distinct 
differences exist amongst GPCRs in relation to the processes of receptor phosphorylation 
and internalisation. However, as described previously, one of the most well characterised 
examples of GPCR phosphorylation and internalisation is the P2AR. Therefore, this will 
provide a basis for studying the regulation of EDGl and Ai receptors. Studies using the 
AiAR will also be compared with concurrent studies using the A3AR, an adenosine 
receptor with a similar structure and exhibiting similar biological effects.
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Figure 1.1: The Structure Of The Ribonucleoside. Adenosine
Adenosine is a ribonucleoside consisting of a D-ribose sugar and the nitrogenous base, 
adenine. The sugar and the base are attached by an N-glycoside bond between the C-1’ of 
the sugar and of adenine. The 5’ position of the ribose group and the position of the 
adenine ring, important in ligand binding, are illustrated.
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Figure 1.2: Synthesis And Metabolism Of Adenosine
A substrate cycle exists between AMP and adenosine through the opposing effects of 
5’nucleotidase and adenosine kinase, thereby regulating intracellular' adenosine formation 
upon changes in intracellular AMP concentration. Additionally, substantial amounts of 
adenosine may be formed from the breakdown of adenine nucleotides that are present in 
the granules of autonomic nerves, platelets and mast cells. Adenine nucleotides are rapidly 
converted to adenosine by a family of ecto-ATP/ADPases including CD39 (NTPDase 1) 
and ecto-5’ nucleotidases including CD73. Extracellular adenosine then acts upon G- 
protein-coupled cell surface adenosine receptors to produce specific biological effects. 
Excess adenosine can be degraded to inosine and finally uric acid via adenosine 
deaminase. Non-concentrative bi-directional adenosine (or nucleoside) transporters 
equilibrate changes in intracellular and extracellular adenosine concentrations. Figure 
adapted from Mullane and Bullough, 1995
Key: 1) 5’nucleotidase; 2) ecto-5’ nucleotidase; 3) adenosine deaminase 4) AMP 
deaminase; 5) adenosine kinase; 6) purine nucleoside phosphorylase; 7) hypoxanthine 
phosphoribose transferase; 8) ecto-ATP/ADPases including CD39 (NTPDase 1) and ecto- 
5’ nucleotidases including CD73.
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Figure 1.3; Structure Of The Bioactive Phospholipid, Sphingosine-l-Phosphate
Sphingosine-1-phosphate (SIP) is a naturally occuring bioactive lysophospholipid. Its 
structure consists of one long hydrocarbon chain on a three-carbon backbone containing a 
phosphate group.
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Figure 1,4: SIP Production And The Sphingolipid Rheostat Model
Sphingolipid metabolism is a dynamic process resulting in the formation of a 
number of bioactive metabolites including ceramide, sphingosine and SIP. Following 
sphingomyelinase activation, sphingomyelin is hydrolysed to ceramide, thought to be 
involved in cell growth aiTest, differentiation and apoptosis. Ceramide is then converted to 
sphingosine by ceramidase. Sphingosine has been shown to inhibit PKC and induce 
apoptosis. Finally, sphingosine can be phosphorylated by sphingosine kinase to produce 
SIP, implicated in cell growth and inhibition of ceramide-mediated apoptosis. Metabolism 
of SIP is catalysed by both a pyridoxal phosphorylation-dependent lyase located in the ER, 
which degrades SIP to phosphoethanolamine and paimitaldehyde, and by a phosphatase 
which converts SIP back to sphingosine. Therefore, the dynamic balance between the 
concentration of all the bioactive sphingolipid metabolites helps determine cell fate. This 
is commonly known as the “sphingolipid rheostat”.
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Sphingolipid Production And Cell Fate
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Figure 1.5: The Prototypical Structure Of A G-Protein-Coupled Receptor
A prototypical GPCR consists of seven transmembrane-spanning a-helical domains, with 
an N-terminal extracellular domain and a C-terminal intracellular domain. The diagram 
illustrates the representative structure of a GPCR for small ligands such as biogenic amines 
and nucleosides. The central core, essential for ligand binding, is comprised mainly of 
domains II, III, V, and VI. Domains I and IV are peripherally sequestered. The sites of 
glycosylation, thought to be involved in receptor trafficking to the membrane, are also 
shown. Figure adapted from Ulloa-AguiiTe et al, 1999.
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Figure 1.6: The Function Of The G-Protein
The binding of agonist to a GPCR changes the conformation of the receptor which 
promotes the exchange of GDP for GTP on the G protein a-subunit to allow the 
dissociation of the a  and Py subunits. The free oc and Py subunits are then able to interact 
with effector molecules to evoke cellular responses. The intrinsic GTPase activity of the a  
subunit hydrolyses GTP to GDP, allowing reassociation of the a  and py subunits. The 
inactive G protein is subsequently reformed and signalling is terminated.
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Table! : The Subfamily Of Ga-Subunits
The table shows the main members of the Ga subfamily.
Table adapted from Ulloa-Aguine et aL, 1999
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Figure 1.7: The Regulation Of Small G-Protein Activity
Small G-proteins exist in two interconvertible forms: - GDP-bound inactive and 
GTP-bound active. Following stimulation from an upstream signal, GDP dissociates from 
the GDP-bound form followed by the binding of GTP, resulting in the activation of 
downstream effectors. The GTP-bound form is then converted back to the inactive GDP- 
bound foim via the intrinsic GTPase activity of the small G-protein, resulting in the release 
of the bound downstream effectors. The rate-limiting step of GDP/GTP exchange is the 
dissociation of GDP from the GDP-bound form. A regulator, termed a GEP, which is, in 
turn, regulated by an upstream signal, can increase the rate of this dissociation. The GEP 
interacts with the GDP-bound small G-protein to release bound GDP to form a binary 
complex of small G-protein and GEP. GEP is then replaced by GTP, resulting in the 
formation of the active GTP-bound form. GDP/GTP exchange reactions of Rho/Rac/Cdc42 
and Rab are also regulated by Rho GDI and Rab GDI respectively, which inhibit both the 
basal and the GEP-stimulated dissociation of GDP from the GDP-bound form and keeps 
the small G-protein in the inactive GDP-bound form. Figure adapted from Takai et ah, 
2001 .
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Table 2: The Adenosine-Specific Family Of GPCRs
The table demonstrates the main family members of the adenosine-specific family of 
GPCRs, namely the AiAR, A2aAR, A2bAR and A3AR. The G-protein coupling, effects 
and main agonists and antagonists are shown for each receptor subtype.
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Figure 1.8; The Role Of AiARs In The Process Of Early And Delayed Ischaemic 
Preconditioning
A short ischaemic insult results in the release of adenosine. Subsequent AiAR activation 
then results in the stimulation of PKC, tyrosine kinase and MAPK pathways which, in turn, 
open Katp channels in the sarcolemma, mitochondria, or both, or in translocation to the 
nucleus of NF-kB and the subsequent synthesis of protective proteins such as heat shock 
proteins (HSPs) and the mitochondrial foi*m of the antioxidant superoxide dismutase 
(MnSOD). Synthesis and release of nitric oxide (NO) from both endothelial (eNOS) and 
inducible (iNOS) forms of nitric oxide synthase from both myocardial and non-myocardial 
sources can also result in early and delayed protection respectively. Figure adapted from 
Rubino and Yellon, 2000.
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Table 3; The EDG Family Of GPCRs
The table demonstrates the main family members of the SIP- and LPA-specific family of 
GPCRs, namely EDG 1-7. For each receptor subtype, the main agonist, G-protein 
coupling, effects and tissue distribution are shown.
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Figure 1.9: Schematic Of The Process Of Angiogenesis
Angiogenesis, the formation of new blood vessel from pre-existing ones, involves a 
number of steps; 1) initiation; 2) endothelial cell migration and proliferation 3) 
differentiation and 4) maturation of the neovasculature. These steps are regulated by a 
number of factors, such as PDGF, VEGF, and angiopoietin. Recently, S IP-dependent 
activation of EDG 1 has been shown to be heavily involved in specific parts of this process. 
Figure adapted from Griffioen and Molema, 2000.
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Figure 1.10: The Role Of EDGl In The Process Of Endothelial Cell Morphogenesis
In epithelial sheets, cell-to-cell adherin junctions make up a continuous adhesion belt 
(zonula adherens) around each of the interacting cells in the sheet, located near the apex of 
each cell (Panel A). Adhesion belts in adjacent epithelial cells are directly opposed and the 
interacting plasma membranes are held together by linker proteins called cadherins. Each 
cell contains a contractile bundle of actin filaments, adjacent to the adhesion belt parallel to 
the plasma membrane, that are attached via a set of intracellular attachment proteins; a-, 
p-, and y-catenin, vinculin, a-actinin and plakaglobin (Panel B). The actin bundles in 
adjacent cells are linked via cadherins and attachment proteins, resulting in an extensive 
transcellular network. It is the contraction of this network that mediates morphogenesis 
(Panel A).
EDGl activation regulates many of the components involved in morphogenesis via 
the activation of Rac and Rho. Rac and Rho are known to be involved in the S IP- 
stimulated translocation of VE-cadherin and P-catenin to cell-cell junctions. Also, SIP 
treatment in HUVECs results in the activation of EDGl and EDG3 receptors which, in 
turn, activate Rac and Rho dependent adherens junction assembly and cytoskeletal 
rearrangement which ultimately results in the morphogenesis of HUVECs into capillary­
like networks. Panel A adapted from Alberts et a l, 1994. Panel B adapted from Jones et
fl/., 2001.
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Figure 1.11: The Role Of EDGl In The Process Of Endothelial Cell Migration
Extracellular SIP can directly stimulate EDGl on VSMCs, facilitating their migration to 
vessel walls or, alternatively, can stimulate EDGl expressed in endothelial cells that in 
turn may recruit VSMCs. This results in the recruitment of smooth muscle cells and 
pericytes to the vessel walls and contributes to endothelial cell maturation. Figure adapted 
from Liu et ciL, 2000.
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Figure 1.12: Cross-Talk Between The PDGF Receptor And The EDGl Receptor And 
Its Role In Cell Migration
Cell migration toward PDGF, which stimulates sphingosine kinase and increases 
intracellular SIP, has been shown to be dependent upon EDGl expression. PDGF- 
dependent-generation of SIP via activation of sphingosine kinase results in the EDGl- 
dependent activation of Rac, leading to cell migration towards PDGF. Figure adapted 
from Hobson et a i, 2001.
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Figure 1.13: Internalisation Of The B?AR Receptor
Agonist-induced P2AR desensitisation is caused by a conformational change of the 
agonist-occupied receptor that facillitates receptor phosphorylation by G-protein receptor 
kinases (GRKs). Following P2AR phosphorylation, the scaffold protein P-arrestin binds to 
the phosphorylated receptor and uncouples the receptor from heterotrimeric G-proteins. P- 
arrestin not only desensitises the receptor but also functions as a clathhn adaptor, 
mediating receptor sequestration via clathrin-coated vesicles. Figure adapted from Pierce 
et a i, 2001.
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Figure 1.14: The Family Of G-Protein Receptor Kinases (GRKs)
GRKs consist of 7 members, GRKl-7, Each member contains a central catalytic domain, 
an N-terminal domain for substrate recognition and containing a conserved RGS domain 
and a C-terminal domain for targeting GRKs to the plasma membrane. The GRK family 
can be subdivided into 3 groups: 1) GRKl (rhodopsin kinase) and GRK7 (cone opsin 
kinase); 2) GRK2 (p-adrenergic Idnase 1, pARKl) and GRK3 (P-adrenergic kinase 2, 
PARK2) and 3) GRK4, GRK5 and GRK6. Figure adapted from Ferguson, 2001.
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Figure 1.15: The Family Of Arresting
The arrestins are adaptor proteins that preferentially bind agonist-activated and GRK- 
phosphorylated GPCRs where they fomi a scaffold complex that results in receptor 
uncoupling from G-proteins, often targets the receptor for internalisation via clathrin- 
coated vesicles and can mediate the activation of alternative signalling pathways. The 
arrestin family is subdivided into 2 groups: a) visual arrestin (S antigen) and cone arrestin 
(X-aiTestin/C-aiTestin) and b) p-arrestins (p-amestinl and p-arrestin2). The structure of 
arrestins constitute 3 functional domains (a secondary receptor-binding domain, a receptor 
activation domain and a phosphate sensor domain) and two regulatory domains, located at 
the amino terminal and carboxyl-terminal. Within the N-terminal domain of p-arrestin 1 
and p-aiTestin2, but not the visual arrestins, there is a proline-rich region (underlined in 
panel A). The black box in panel A illustrates the clathrin- and p-adaptin-binding domains 
within the C-teiminus of non visual arrestins. Panal B demonstrates the functional 
differences between visual and nonvisual arrestins that arise as the consequence of the 
clathrin (bold) and p2-adaptin (bold and asterisked) binding domains amongst nonvisual 
arrestins. Figure adapted from Ferguson, 2001.
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Figure 1.16: Components Of The Endocvtic Machinery
A. Clathrin: three-legged triskelion, with each leg containing a heavy and a light chain. 
The N-terminal globular region of the heavy chain interacts with P-arrestin.
B. AP-2: tetrameric adapter protein that links the clathrin shell to the membrane via 
interactions between its p2 and a2 subunits with membrane proteins. P-arrestin interacts 
with the P2 subunit.
C. AP180: Involved in regulating the size of the clathrin-coated pit. Contains PIP2- 
binding epsin amino-teiTninal homology (ENTH) domain and clathrin assembly domains.
D. Synaptotagmin: binds AP-2 within synaptic vescles and allows vesicle recycling via 
coated pit nucléation. Contains protein kinase C homology 2 (C2A, C2B) domains.
E. Dynamin: multi-domain protein with GTPase domain, a phospholipid-binding 
pleckstrin homology (PH) domain, GTPase effector domain (GED) and a proline-rich 
domain within its C-terminal (PRD) which interacts with SH3 domains of other accessory 
proteins such as amphiphysin. Main role of dynamin is in the budding of the pits from the 
membrane.
F. Endophilin: Converts lysophosphatidic acid within membrane to phosphatidic acid via 
LPA-ATas domain and facilitates invagination of the coated pit.
G. Amphiphysin: Interacts with dynamin to facilitate fission. Contains clathrin/AP-2 
binding and SH3 domain.
H. Epsin: bind to clathrin, AP-2 and PIP2 . Contains epsin amino-terminal homology 
(ENTH), Asp-Pro-Tip (DPW) and Asp-Pro-Phe (NPF) domains.
I. Synaptojanin: inositol phosphatase that regulates PIP2 metabolism and the stability of 
clathrin-AP-2 coats. Contains suppressor of actin 1 (Sad), 5’phosphatase, PRD and NPF 
domains.
J. Auxilin: J-domain protein that assists the ATPase heat shock cognate protein TOkDa 
(hsp70) in the uncoating and disassembly of clathrin coated vesicles.
Figure adapted from Brodin et a l, 2000; Takei and Haucke, 2001
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Figure 1.17: Trafficking Of Internalised GPCRs
Agonist-activated receptors (green) are phosphorylated by GRK (P), facilitating their 
interaction arrestin molecules (blue). Once internalised, receptors are delivered to 
peripheral early endosomes where they are dephosphorylated by a GPCR-specific 
phosphatase (GRP). The small GTPase Rab5 often contributes to the formation of 
endocytic vesicles, the trafficking of vesicles to early endosomes and the fusion of 
endocytic vesicles with early endosomes. Once delivered to early endosomes, recycling 
receptors such as the P2AR and the transferrin receptors are returned to the cell surface via 
recycling endosomes. The small GTPase, Rab4 regulates the budding and/or recycling of 
receptor-bearing recycling vesicles. In contrast to recycling receptors, some endocytosed 
receptors targeted for downregulation are transported from early to late endosomes where 
they are then targeted to lysosomes for degradation through the action of intermediates 
with a characteristic multi vesicular appearance called multivesicular bodies (MVBs) or 
endosomal carrier vesicles (ECVs). In mammalian cells, ECVs/MVBs, once formed on 
early endosomes, move towards late endosomes on microtubules and then dock onto and 
fuse with late endosomes.
Figure adapted from Cavalli et al„ 2001; Ferguson, 2001
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Chapter 2
Materials and Methods
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2.1 Materials
All reagents used were of the highest grade commercially available and obtained from the 
following suppliers:
Alexis Corporation^ San Diego, CA, USA
Dithiothreitol
BDH Chemicals Ltd., Poole, UK
Acrylamide, coverslips
Calbiochem-Novabiochem (UK) Ltd., Nottingham, UK 
Forskolin, PMA, SIP
Costar, Cambridge, MA, USA
75cm^ tissue culture flasks, 6( 
tissue culture plates, cryovials
0mm and 100mm tissue culture dishes, 6-, 12- and 24- well
Cruachem, Glasgow, UK 
Oligonucleotides
Fisher Scientific, Loughborough, Leicestershire, UK
HEPES, sodium dodecyl sulphate, EDTA, DMSG, ethidium bromide solution, glacial 
acetic acid, methanol, ethanol, concentrated HCl, sodium fluoride, sodium phosphate
GIBCO BRL Life Technologies, Paisley, UK
Phenol:chloroform:isoamyl alcohol, LipofectAMINE, newborn calf serum, OptiMEM, 
phosphate-free Dulbecco’s Modified Eagle’s Medium (PF-DMEM)
Melford, Chelsworth, Ipswich, Suffolk, UK
Kanamycin
Merck, Darmstadt, Germany
Bactotryptone, agar
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Molecular Probes
Alexa™594-conjugated goat-anti-mouse IgG
New England Biolabs Inc., Beverley
Protein molecular weight marker, restriction enzymes
NEN Life Science Products Inc., Boston
ECL reagents, ^^P-orthophosphate, X-ray film
Pierce, Rockford, IL  61105, USA
EZ-Link™ Biotin-LC-Hydrazide, HRP-streptavidin
Promega, Southampton, UK
T4 DNA ligase, SV mini-prep kit, G-418 sulphate, restriction enzymes
Qiagen, Crawley, West Sussex 
Gel purification kit, plasmid maxi kit
Research Biochemicals International, Natick, MA, USA 
(R)-PIA, NECA
Roche Molecular Biochemicals/Boehringer-Mannheim, Mannheim, Germany
Tris, DNA molecular weight marker, restriction enzymes, anti-HA mouse monoclonal IgG
(clone 12CA5), adenosine deaminase
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA 
GPP rabbit polyclonal IgG
Sigma-Aldrich Company Ltd., Poole, Dorset, UK
Triton X-IOO, soybean, benzamidine, pepstatin A, bovine serum albumin, fatty acid free 
bovine serum albumin, protein A-Sepharose, sodium periodate, bisacrylamide, HRP- 
conjugated goat anti-rabbit IgG, HRP-conjugated goat anti-mouse IgG, HRP-streptavidin, 
thimerosal, bromophenol blue, bichinchonic acid, sodium azide, 3-[(3-Cholamidopropyl)- 
dimethylammino]-1-propane sulfonate (CHAPS), agarose, deoxycholic acid, myelin basic
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protein (MBP), polyethylenimine, ninhydrin, ammonium hydroxide, isobutyric acid, 
ampicillin, adenosine deaminase, paraformaldehyde, N,N,N’,N’- 
tetramethylethylenedi amine (TEMED), Phenylmethy 1 sulphon ylfluoride (PMSF), 
chlorpromazine, 8-bromo-cGMP, Ham’s F-12, Dulbecco’s Modified Eagle’s Medium 
(DMEM), Phosphate-buffered saline (PBS) (sterile), foetal bovine serum (FBS), trypsin, 
penicillin/streptomycin, L-glutamine
Stratagene
P/m Turbo DNA polymerase
Tocris/Semat Technical (UK) Ltd., St. Albans, Herts., UK
A23187
Whatman International Ltd., Maidstone, UK
GF/C glass fibre filters
A mutant human AiAR cDNA in which the Cys 309 was changed to Ala was a gift from 
Dr Mark Olah, University of Cincinnati College of Medicine, Cincinnati, OH
9E10 monoclonal antibody specific to myc-epitope, was prepared in-house at Duke 
University, Durham, NC by Dr Tim Palmer
Purified GRK2 and GRK5 were a gift from Jeffrey L. Benovic, Kimmel Cancer Centre, 
Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia 
PAI9107
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2.2 Cell Culture And Transfections
2.2.1 Cell Maintenance
CHO cells were maintained in Ham’s F-12 medium and HEK293 cells were 
maintained in DMEM, supplemented with 10%(v/v) FBS, penicillin (lOOunits/ml), 
streptomycin (100p,g/ml) and 1% L-glutamine in a 37°C humidified atmosphere containing 
5% CO2. Cells stably expressing adenosine or EDGl receptors were maintained in the 
appropriate medium supplemented with G-418 in order to optimise receptor expression by 
maintaining selection pressure. Cells were routinely passaged 1:8. Confluent T-75 flasks 
were washed with PBS without CaCl2 and MgCb. Cells were detached by the addition of 
2ml of trypsin, followed by incubation at 37°C. 6mls of medium were then added to the 
flasks and the cells pipetted gently to allow resuspension. Cells were either passaged into 
flasks to maintain the cell line or seeded into dishes for experimental analysis.
2.2.2 Transient Expression Of cDNA Expression Constructs
cDNA expression constructs were transiently transfected into either HEK293 or CHO cells 
using a Lipofectamine-mediated transient transfection protocol. Cells were plated into 6- 
well dishes at the appropriate density such that they would be 70-80% confluent the next 
day. Transfection mixes of 0.24ml OptiMEM, 2pg plasmid DNA and 4|Li1 lipofectamine 
were prepared in sterile microfuge tubes for each well. The tubes were then incubated at 
room temperature for 15-45 minutes. During this incubation, each cell monolayer was 
washed once with 2 ml/well OptiMEM and then given 0.75ml/well of OptiMEM. 
Following the 15-45 minute incubation, the Lipofectamine-DNA-OptiMEM mixes were 
added to each well and incubated for 3 hours at 37°C. The mixture from each well was 
then removed and replaced with 3ml/well of growth medium. Cells were analysed 48-72 
hours post-transfection.
2.2.3 Stable Expression of cDNA Expression Constructs
CHO or hamster lung CCL-39 fibroblast stable cell lines were generated by cotransfecting 
cells with the appropriate cDNAs subcloned into pcDNA3.1 and pSVNeo in a 20:1 ratio 
using a modified calcium phosphate precipitation/glycerol shock procedure. A confluent 
T-75 of plain CCL-39 fibroblasts, routinely grown in Dulbecco’s modified Eagle’s 
medium, or CHOs, maintained in Ham’s F-12 medium, were split 1:5, adding 1/5* of cells
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to a 100mm dish. The next morning, after reaching 50-70% confluency, the cells were 
given fresh media. In the afternoon, the following transfection mix was added to a sterile 
Falcon tube: 30jig pcDNA3.1 and 1.5 pg of the appropriate cDNA containing pSVNeo to 
confer G418 resistance. This was made up to a final volume of 375 p,l with sterile water. 
125 p.1 IM CaClz solution was then added. Finally, using a sterile 1ml pipette, 0.5ml 2X 
Hepes buffered saline solution (HBSS) (280mM NaCl, 50mM HEPES, 1.5mM Na2HP0 4 , 
pH 7.13) was added slowly to the tube, and mixed by gently bubbling air into the mix in 
the tube for approximately 30 seconds until the solution becomes slightly milky due to the 
formation of a fine calcium phosphate precipitate. The mix was left at room temperature 
for 40 minutes and then added dropwise to the cells in the 100mm dish. Following a 4-5 
hour incubation at 37“C, the media was aspirated and the cells rinsed with 5ml PBS. The 
cells then underwent glycerol shock by incubating with 2ml of a 15% (v/v) glycerol 
solution (1.5 ml sterile glycerol, 3.5ml sterile water, 5ml 2XHBSS) for exactly 2 minutes at 
37°C. The glycerol solution was then aspirated off and the cells washed three times with 
PBS and incubated with 10ml regular medium overnight. On day 3, the medium was 
changed on the cells. On day 4, the cells were split for selection with 0.4mg/ml G418 into 
5 dishes representing a 2:5, 1:5, 1:10, 1:20 and a 1:40 cell suspension. After selection in 
G418, resistant colonies were isolated, expanded and screened for receptor expression by 
western blotting and, in the case of the GFP constructs, fluorescence following excitation 
at 488 nm using an argon/krypton laser.
2.3 Molecular Biology
2.3.1 Preparation Of Antibiotic Agar Plates
LB agar (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, with 1.5% 
(w/v) agar) was prepared, autoclaved and allowed to cool before the addition of the 
appropriate antibiotic (either ampicillin at 50|ig/ml or kanamycin at 30pig/ml). The liquid 
LB was poured into 90mm diameter Petri dishes and allowed to solidify and sweat 
overnight at room temperature. Plates were then stored at 4°C until required.
2.3.2 Preparation of competent XLl Blue E.coli
An overnight culture of XLl Blue E.coli was grown in 3ml of LB broth containing 
50pg/ml tetracycline. The next day, 250ml of LB broth was inoculated with the culture 
and grown with aeration until the cells reached log phase. The cells were then transferred
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into two 250ml centrifuge tubes on ice and left for 1 hour. Log phase was defined when 
the optical density (ODeoo) reached approximately 0.35-0.375. Cells were spun at 3468g at 
4^C for 2 0  minutes, the supernatant decanted and the cells resuspended and washed in V4 
starting volume of ice-cold O.IM MgCL. Following a second 20 min centrifugation, the 
cells were resuspended in V4 starting volume of ice-cold 15% (v/v) glycerol with O.IM 
CaClz. 250|il of resuspended cells were each aliquoted into sterile microfuge tubes on dry 
ice/methanol, to induce rapid freezing, and stored at -80°C until required.
2.3.3 Transformation Of Competent E. Co//
Approximately 30-50 ng of DNA was added to a plastic Falcon tube on ice. 50^1 
of thawed competent E.coli were added and the DNA and E.coli mix incubated on ice for 
10 min. The tubes were then incubated for 5 minutes in a 37°C water bath. 0.5ml LB/tube 
was then added and the tubes were then incubated for 45 min at 37°C. 200jal from each 
transformation was then plated out onto an LB agar plate supplemented with the 
appropriate selection antibiotic and incubated overnight at 37°C.
2.3.4 Preparation Of Plasmid DNA
Transformed colonies were picked from agar plates and grown overnight in 5-10 
mis of LB broth containing the appropriate antibiotic. Plasmid DNA was prepared using 
the Promega™ Wizard Plus SV miniprep purification system as per the manufacturer’s 
instructions. Larger quantities of DNA were obtained by transferring an initial overnight 
culture into 500ml of LB broth containing the appropriate antibiotic and grown overnight. 
DNA purification was achieved obtained using the Qiagen plasmid maxi kit system. The 
concentration of DNA obtained was determined by measuring the absorbance at 260nm 
(A260) of a 1:50 dilution of each preparation in sterile H2O, assuming that 1 absorbance unit 
was equivalent to 50p.g/ml of double stranded DNA.
2.3.5 Digestion Of Plasmid DNA
1-2 pg of plasmid DNA was digested in a volume of 15^1 using the buffer 
conditions recommended by the manufacturer with 2-4 units of the appropriate restriction 
enzyme. Digested DNA was analysed by agarose gel electrophoresis in which samples 
were prepared by the addition of a 1:3 dilution of loading buffer. Electrophoresis took 
place on a 1% (w/v) gel containing 2.5mg/ml ethidium bromide at 75 V for 20-30 minutes
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in a TAE buffer (40mM Tris-acetate, ImM EDTA, glacial acetic acid). DNA purification 
from excised agarose gel chips was achieved using Qiagen QIAquick gel purification kit, 
as per manufacturer’s instructions.
2.3.6 Ligation of DNA fragments
Ligation of vector DNA was carried out overnight at 4°C in a reaction volume of 
lOfxl containing 30mM Tris-HCl, pH 7.8, lOmM MgCli, lOmM DDT, ImM ATP, T4 
DNA ligase vector and insert DNA at a ratio of 1:4. Ligated DNA was then transformed 
into competent E.coli as described in section 2.3.3.
2.3.7 Construction Of HA-AiAR-GFP And HA-Ai(Cys309-AIa)AR-GFP Receptor 
Constructs
The HA-AiAR-GFP and HA-Ai(Cys309-Ala)AR-GFP constructs were generated by PCR 
using the pCMV5/HA epitope-tagged WT (Ren and Stiles, 1994) and Cys309-Ala human 
AiAR cDNAs as templates. Standard PCR reactions contained, in a volume of 100|al, 
lOOng template DNA, lOOj^M dNTP’s, 50pmol sense/anti sense primers, 0.002 units Vfu 
turbo, lOfil 10-fold concentrated amplification buffer and 5% (v/v) DMSO. The reaction 
was initiated by a dénaturation cycle of 95°C for 5 min followed by 30-40 cycles of a 95°C 
(1 min) denaturing step, 55°C (1 min) annealing step and 72°C (1.5 min) extension step. A 
final cycle of 95°C (1 min), 55°C (1 min) and 72°C (10 min) was added before reactions 
were placed at 4°C until required. For each receptor, the primers used were: - 
5’-ATTTGGAATTCCCACCArGCCGCCCTCCATCTCAGC-3’ (sense) and 
5 ’ -ATTTGGGTACCGCAGCGTAGTCTGGGAC-3 ’ (antisense)
The sense primer was designed to remove the N-terminal HA epitope tag sequence and add 
an EcoPl site (bold) upstream of a consensus Kozak sequence (underlined) and the AiAR 
initiating Met (italics). The antisense primer was designed to remove the AiAR stop codon 
and add an Xbal site (bold). This allowed in-frame fusion of the C-terminally HA epitope- 
tagged AiAR open reading frames with GFP following subcloning of the EcoWUXbal- 
digested PCR products with the similarly digested modified pEGFP-Nl cDNA in which 
the initiating Met of the GFP open reading frame was mutated to Ala.
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2.3.8 Construction Of EDGl Receptor Constructs
(i) Generation Of Human MycEDGl cDNA Expression Construct: - This was generated by 
PCR using a pcDNA/EDGl template. The following primers were used: -
dCATTGAAGCTTCCACCATGGGGCCCACCAGCGT (sense) 
dCATTGTCTAGAGGAAGAAGAGTTGA (antisense)
The sense primer incorporated a HindUl site (bold) upstream of a consensus Kozak 
sequence (underlined) and the EDGl initiating methionine (italics). The antisense primer 
was designed to remove the EDGl stop codon and add an Xbal site. This allowed in­
frame ligation of the EDGl coding region with that of the myc-His epitope tag following 
ligation of the digested PCR product with a similarly digested pcDNA3.1/
myc-HisA vector (Invitrogen).
(ii) Generation OfMycEDG A51, A32 and A l l  cDNA Expression Constructs: - These were 
generated by PCR using the pcDNA3.1/myc-His-EDGl receptor as a template. The 
primers are shown below: -
dTCTGGCTAACTAGAGAACC(sense)
dATTTGCTCTAGAGCACTTGCAGCAGGACATGAT (antisense (A51)) 
dATTTGCTCTAGAGAATTCCCATGCCGGCGATGAT (antisense (A32)) 
dATTTGCTCTAGACTCTGGGTTGTCCCCTTCGTCTTTCTG (antisense (A12))
The same sense primer was used to for all three truncation mutants and was designed to 
anneal upstream of the Hindlll site of the EDGl receptor. The anti sense primers for each 
of the truncation mutant were designed to anneal either 12-, 32-, or 51 amino acids 
upstream of the EDGl C-terminal tail for the appropriate truncation mutant and to add an 
Xbal site (bold). This allowed in-frame ligation of the HindSHXbal- P C R  
products with a similarly digested pcDNA3.1/myc-HisA vector.
(Hi) Generation O f MycEDGl-GFP And MycEDGlA51-GFP cDNA Expression 
constructs:- These were generated by PCR using the pcDNA3.1/myc-His-EDGl receptor
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and the pcDNA3.1/myc-His-EDGlA51 receptor as templates for the pcDNA3.1/myc-His- 
EDGl-GFP and pcDNA3.1/myc-His-EDGlA51-GFP constructs respectively. The primers 
used are shown below: -
dTCTGGCTAACTAGAGAACC (sense)
dCATTGGGATCCCGATGGTGATGGTGATGATG (antisense)
The sense primer was as described for the truncation mutants above. The anti sense 
primer was designed to remove the stop codon in the myc-His tag of the EDGl and 
EDG1A51 receptors with that of GFP following ligation of Tf/n^/HEBamHI-digested PCR 
product with a similarly digested pEGFPAlal vector.
2.3.9 Confirmation Of cDNA Receptor Subcloning
All the above reactions sites were confirmed by overnight double digestion of the 
constructs with the appropriate restriction enzymes. The completed digests were ran out 
on 1% agarose gels at 75 V in TAE buffer. Correct subcloning of the receptors was 
confirmed by the use of dideoxynucleotide sequencing.
2.4 Experimental Techniques
2.4.1 Preparation Of SIP
Img of commercially supplied SIP (Calbiochem) was resuspended in 0.66ml of methanol 
to give a final SIP concentration of 4mM. The tube was capped tightly and transferred to 
an 80°C oven. The SIP was then vortexed every 5 min until it had gone visibly into 
solution. The SIP solution was then pipetted into 25|xl aliquots in brown glass vials. The 
methanol solvent was then evaporated off using a nitrogen gas stream. The tubes were 
then capped and stored at -80°C. Reconstitution of SIP was achieved by adding 0.25 ml 
serum-free medium supplemented with 0.5mg/ml fatty acid-free BSA to give a working 
SIP stock concentration of 400|liM. Following addition of “medium + BSA”, the vial was 
vortexed repeatedly to resuspend the SIP.
2.4.2 Preparation Of Cell Extracts For Immunoblotting
Confluent monolayers in 6-well dishes were kept on ice and washed three times with PBS. 
Cells were solubilized by scraping into 250|il of immunoprécipitation buffer (50mM
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Hepes, pH 7.5, 5mM EDTA, lOmM sodium fluoride, lOmM sodium phosphate, O.lmM 
phenylmethylsulfonyl fluoride, and 1 0 p.g/ml each of soybean trypsin inhibitor, leupeptin, 
and pepstatin A). The lysate was then transferred into ice-cold microfuge tubes. The cells 
were solubilized by a 1 hour incubation on a rotating wheel at 4°C. Lysates were clarified 
by centrifugation (14000g for 15 minutes, 4°C) and supernatants assayed for protein 
content. BSA standards ranging from 0-2mg/ml were used to obtain a best-fit straight line 
of a plot of A492 versus protein concentration in a bicinchonic acid (BCA) based protein 
assay using the graph package “Prism v20.” The protein concentrations of lOjil samples 
of each unknown extract were calculated from the equation of the best-fit straight line 
obtained from the BSA standards.
2.4.3 SDS-PAGE And Immunoblotting
Samples solubilised in immunoprécipitation buffer were equilibrated for protein 
concentration. The appropriate quantity of Laemmli sample buffer (50nM Tris (pH 6 .8 ), 
10% (v/v) glycerol, 12% (w/v) SDS, few grains of bromophenol blue, 1.6mg/ml 
dithiothreitol) was then added to each to sample to give a total volume of 30pl per sample. 
Samples were separated by SDS-PAGE using a 10% acrylamide resolving gel (10% (w/v) 
acrylamide, 0.3% (w/v) bisacrylamide, 0.4M Tris (pH 8 .8 ), 0.1% (w/v) SDS, 3% (v/v) 
glycerol, 0.01% (w/v) ammonium persulphate and 0.001% (v/v) TEMED) and 3% 
acrylamide stacking gel (3% (v/v) acrylamide, 0.1% (v/v) bisacrylamide, O.IM Tris (pH 
6 .8 ), 0.1% (w/v) SDS, 0.01% (w/v) ammonium persulphate and 0.001% (v/v) TEMED). 
Electrophoresis of the samples was carried out at 150 V in conjunction with prestained 
protein markers (6.5-175 kDa) in a running buffer containing 27.4mM Tris, 0.19M glycine 
and 0.1% (w/v) SDS until the dye front reached the end of the gel. The resolved proteins 
were then transferred to nitrocellulose at 400mA for 45 min in transfer buffer containing 
24.7mM Tris, 0.19M glycine and 20% (v/v) methanol. Following transfer, the 
nitrocellulose was washed briefly in PBS and incubated for 1 hour in Blotto (5% (w/v) 
skimmed milk in PBS supplemented with 0.2% (v/v) Triton X-100) to block non-specific 
protein binding sites. Membranes were then incubated for 1 hour with the appropriate 
dilution of primary antibody in fresh Blotto. The membranes were then washed three 
times for lOmin with Blotto followed by two brief washes in PBS. Membranes were then 
incubated for 1 hour with HRP-conjugated secondary antibody made in high-detergent 
blotto (10% (v/v) Blotto in PBS supplemented with 1.02% (v/v) Triton X-100 and 0.1%
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(w/v) SDS). The membranes were then washed three times for 10 min in Blotto, followed 
by three washes with PBS for 10 min. Membranes were then incubated for 1 min at room 
temperature with ECL reagents (1ml solution A, 1ml solution B). Immunostained protein 
was then visualised by autoradiography.
2.4.4 Immune Complex Kinase Assay Of ERK Activation
Quiescent CCL39 and CCL39/mycEDGl cells in 100mm dishes were stimulated with 
increasing concentrations of SIP. Reactions were quenched by placing the cells on ice and 
washing rapidly with ice-cold PBS then quenched reactions. Cells were then solubilised in 
0.7ml detergent lysis buffer and clarified extracts equalised for protein content prior to 
immunoprécipitation for 2 hours at 4°C with 50pl of a 50% suspension of protein A- 
Sepharose beads and 5pi ERK 1-specific antiserum (Cook et al., 1993). Immune 
complexes were isolated by centrifugation and washed three times (1 ml/wash) with lysis 
buffer (lOmM Hepes, pH 7.5, 2mM EDTA, 0.25 M sodium chloride supplemented with 
0.1 mM PMSF, lOpg/ml soybean trypsin inhibitor and lOpg/ml benzamidine). All 
remaining buffer was removed from immune complexes following the last rinse using a 
fine-gauge Hamilton syringe. Immune-complex kinase assays were then performed by 
adding 30pl kinase buffer containing 10 pM ATP, 100 pCi/ml [y-^^P]ATP, and lOOpg/ml 
myelin basic protein (MBP). Kinase reactions took place at 30°C for 30 min and were 
stopped by adding lOpl of 4xSDS-PAGE sample buffer and boiling for 10 min. MBP 
samples were fractionated by SDS-PAGE using 14% (w/v) polyacrylamide resolving gels 
and stained with Coomassie Brilliant Blue. Gels were then dried and the amount of ^^ P 
incorporated into MBP determined by pho sphorimaging.
2.4.5 Phosphoamino Acid Analysis
Following SDS-PAGE, resolved proteins were transferred to a polyvinylidene difluoride 
membrane. After overnight autoradiography, the region of the membrane corresponding to 
phosphorylated EDGl was excised, hydrated and, following purging with nitrogen, 
hydrolysed at 110°C in 0.2ml 5.7 M hydrochloric acid for 90 min. The hydrolysate was 
then lyophilised and resuspended in chromatography buffer supplemented with 
phosphoamino acid standards. After spotting onto cellulose-coated plastic-backed plates, 
samples were subjected to ascending chromatography in an isobutyric acid, 0.5M 
ammonium hydroxide (5:3, v:v) buffer system (Duclos et al., 1991). Standards were
69
visualised by ninhydrin staining and ^^P-labelled amino acids identified by 
autoradiography. Phosphorylated amino acids were identified by comparison with 
ninhydrin-stained standards.
2.4.6 Whole Cell Receptor Phosphorylation
Cells were plated into 6-well dishes at a density of 1x10^ cells/well and cultured overnight. 
When using cell lines expressing one of the EDGl constructs, the cells were serum-starved 
for 16-20 hours in serum-free Dulbecco’s modified Eagle’s medium. The next day, the 
cells were washed twice with 3ml phosphate-free Dulbecco’s modified Eagle’s medium 
and incubated for 90 minutes at 37°C with 0.75ml of the same medium supplemented with 
50pCi/well [^^ P] orthophosphate. After stimulation with the indicated agonists, added as a 
2X concentrated dose in 0.75ml, reactions were terminated by placing the cells on ice and 
washing the monolayers twice with 3ml of ice-cold phosphate-buffered saline. All 
subsequent procedures were carried out at 4°C unless indicated otherwise. Cells were 
washed three times with PBS and solubilized by scraping into an initial 250pl of 
immunoprécipitation buffer. The lysate was then transferred into ice-cold microfuge tubes. 
The wells were then washed in another 250|Lil of immunoprécipitation buffer which was 
subsequently transferred to the appropriate microfuge tube. The cells were then 
solubilized and analysed for protein content as described in 2.4.2. Equivalent amounts of 
soluble protein from each sample were then made up to 400|Li1 with immunoprécipitation 
buffer and added to microfuge tubes containing lOOjLil 0.2% (w/v) IgG-free bovine serum 
albumin and, in the case of myc-tagged constructs, 50|Li1 of a 50% (v/v) suspension of 
9E10-conjugated protein G-Sepharose beads for 1 hour. HA-tagged constructs were 
incubated with 20|il 50% suspension of protein-A Sepharose beads, lOOp.1 0.2% (w/v) IgG- 
free BSA in the presence of l|ig  12CA5. Following overnight incubation on a rotating 
wheel, immune complexes were isolated by brief centrifugation, washed three times with 
1ml immunoprécipitation buffer and eluted from the beads by the addition of 30|xl 
Laenunli sample buffer and incubation at 37^C for 1 hour, vortexing every 15 minutes. In 
the case of lysates containing one of the adenosine receptors, the immune complexes were 
washed twice with immunoprécipitation buffer supplemented with 0.2M ammonium 
sulphate and once with imunoprecipitation buffer alone. Analysis was by SDS-PAGE 
using 10% (w/v) polyacrylamide resolving gels as described in section 3.3 and
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autoradiography for between 16 and 40 hours at -80°C. Quantitation was by either 
densitometric scanning of autoradiographs or phosphorimaging.
2.4.7 In Vitro Receptor Phosphorylation Assays With Purified GRKs
Confluent monolayers of transfected cells in 100 mm dishes were washed with ice-cold 
PBS and scraped into 5ml/dish of lysis buffer (lOmM HEPES, pH 7.5, 2mM EDTA, 
0.25M sodium chloride supplemented with O.lmM PMSF, 10j4g/ml soybean trypsin 
inhibitor and 10|ig/ml benzamidine). The cells were then transferred to a tight-fitting 
glass-on-glass Dounce homogeniser on ice and homogenised by 20 up-and-down strokes. 
Following a 15 min incubation on ice, the membranes were pelleted by centrifugation at 
14,000g for 15 min. The supernatant was then discarded and the pellet resuspended in 5ml 
lysis buffer as before. The membranes were then re-homogenised, left on ice and 
centrifuged as described previously. The pellet was then resuspended in 5 ml GRK assay 
buffer (25mM Hepes, pH 7.5, 2.5mM EDTA and 7.5mM MgCl2 supplemented with 
protease inhibitors) by homogenisation and re-centrifuged. The pellet was then 
resuspended in 220p,l GRK assay buffer. Assays consisted of 40pl membrane suspension, 
40|Li 1 kinase mix (GRK assay buffer supplemented with 0.25mM ATP, 0.88mM 
dithiothreitol, 0.15 | l iM  okadeic acid and 10 jaCi [y-^^P]ATP), lOp.1 vehicle or 50nM 
purified GRK, and lOjxl of vehicle or SIP. After incubation at 30°C for 5 min, reactions 
were terminated by placing the tubes on ice and adding 0.5 ml/tube stop solution (O.IM 
sodium phosphate, pH 7.5, lOmM EDTA). Membranes were pelleted by 
microcentrifugation (14,000g, 10 min) and the resulting pellets solubilised in 0.3ml 
immunoprécipitation buffer by rotation for 60 min at 4°C. After the removal of insoluble 
material by centrifugation, detergent extracts were equalised by protein assay prior to 
receptor immunoprécipitation with 9E10 and analysis by SDS-PAGE and autoradiography 
as described in Section 2.5.5. For rhodopsin phosphorylation experiments, urea-treated 
bovine rod outer segments (ROS) were employed. In this case, each assay consisted of 
GRK assay buffer containing 0.5pl ROS and 2pCi [y-^^P] ATP. In these experiments, 
reactions were terminated by the addition of 15p,l Laemmli sample buffer prior to analysis 
of rhodopsin phosphorylation by SDS-PAGE and autoradiography.
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2.4.8 Biotin labelling-immunoprecipitation Assay Of Cell Surface Receptor 
Expression
Cells were plated into 6 -well dishes at a density of 1x10*^  cells/well and cultured overnight. 
Cell lines expressing EDGl constructs were then serum-starved for 16-20 hours in serum- 
free Dulbecco’s modified Eagle’s medium. The next day, the cells were washed in the 
appropriate medium followed by the addition of 0.75 ml/well of the same medium. 
Incubations were initiated by the addition of 0.75ml medium supplemented with either 
vehicle or 2X concentrated dilution of drug as indicated in the Figure Legends. Reactions 
were terminated by placing the cells on ice and washing the monolayers three times with 
3ml ice-cold PBS. All subsequent procedures were performed at 4^C unless stated 
otherwise. The alcohol groups on the cell surface glycoproteins were oxidised to 
aldehydes by a 30 minute incubation with 0.75ml/well lOmM sodium periodate in PBS. 
Following the removal of periodate and washing with PBS, the monolayers were washed 
twice with 3ml O.IM sodium acetate, pH 5.5, and incubated for 30 minutes in 0.75ml/well 
of the same buffer supplemented with ImM biotin-LC-hydrazide. This reacts with the 
newly formed alcohol groups thereby labelling all cell-surface glycoproteins with biotin. 
Labelling was terminated by removal of the biotin-LC-hydrazide solution and washing the 
monolayers three times with 3ml PBS. Cells were then solubilised for receptor 
immunoprécipitation as described for the whole cell phosphorylation assay (Section 2.4.6). 
Following fractionation of immunoprecipitated receptors by SDS-PAGE, proteins were 
transfen'ed to a nitrocellulose membrane. Non-specific protein binding sites were blocked 
by incubation in Blotto and cell-surface biotin-labelled receptors were then identified by 
incubation of the membrane with 1 jag/ml HRP-conjugated streptavidin for 60 minutes at 
room temperature. Following three lOmin washes with Blotto and two washes with PBS, 
reactive proteins were visualised by enhanced chemiluminescence. Agonist-induced loss 
of cell-surface receptor was quantitated by densitometric scanning of non-saturating blots
2.4.9 Saturation radioligand binding assays with H-DPCPX in isolated membranes
Confluent 75cm^ flasks of COS cells transfected with either HA-AiAR or HA-Ai(C309- 
Ala)AR receptor constructs were placed on ice and washed three times with 10ml ice-cold 
PBS. The cells were scraped from the bottom of the flask into the PBS and transferred to a 
pre-chilled 13ml non-sterile centrifuge tube on ice. Cells were pelleted by a 17640g for 10 
minute spin at 4^C. The supernatant was then removed and the pellet resuspended in 1ml
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of lysis buffer (lOmM Tris, 5mM EDTA, pH 7.5 at 4”C). Cells were disrupted by 20 up- 
and-down strokes in a tight-fitting glass-on-glass Dounce homogeniser. The homogenate 
was removed to a microfuge tube and membranes pelleted by centrifigutation at 14 OOOg 
for 15 minutes.
On removal of the supernatant, the pellet was resuspended in 4mls of radioligand binding 
buffer (50mM Tris, lOmM MgCE, ImM EDTA, pH 8.26 at 4°C) and transferred to the 
homogeniser. Ijiil of stock ADA, added to give a final concentration of 0.47units/ml, was 
used to degrade endogenous adenosine prior to resuspension of the membrane pellet by 
Dounce homogenisation (20 up-and-down strokes). 150p,l of the membrane suspension 
was added immediately to duplicate assay tubes containing tritiated radioligand, ranging 
from 0.25-8.OnM, and incubated at 37^C for 45-60 minutes in a shaking water bath at 
which point equilibrium was reached. Non-specific binding was defined in parallel by the 
inclusion of (R)-PIA to a final concentration of 10|iM. Reactions were terminated by 
filtration using a Brandel cell harvester and rapid washing with three washes with wash 
buffer (binding buffer supplemented with 0.01% (w/v) CHAPS) over glass fiber filters 
pretreated with 0.3% (v/v) polyethyleneimine. Filter discs for each sample were then 
incubated in 5ml/disc of scintilillant overnight at 4°C in scintillation vials and counted on a 
scintillation counter (Beckmann Instrumnents Inc., Fullerton, CA).
Non-specific counts were subtracted from the total counts and the resulting values plotted 
against [^H-DPCPX] nM. To determine the total number of receptors expressed (Bmax) and 
the equilibrium dissociation constant (Kd), the data was fitted to a nonlinear regression 
equation using the graph package “Prism”. A bichinchonic acid (BCA) protein assay, as 
described in section 3.2, was used to determine the |Lig of protein added per tube. 
Combining the calculated Bmax, final assay volume in litres and p,g of protein added per 
tube, the receptor level was expressed in pmol/mg. An example of this calculation is 
shown in Appendix 1.
2.4.10 Confocal laser microscopy
Live cell analysis of HA-AiAR and HA-Ai(Cys309-Ala)AR cell surface expression was 
carried out using CHO cells grown on glass coverslips. The coverslips were mounted on 
the imaging chamber and maintained at 37°C in Krebs-Ringer-HEPES-BSA (KREB) 
buffer (120mM NaCl, 5mM KCl, 1.2mM MgSOd, 1.2mM CaClz, 20mM HEPES, 1.2mM 
Na2HP0 4 , lOmM glucose, 0.1% (w/v) BSA). (R)-PIA was applied in KRHB buffer. For
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fixed cell analysis of GFP-tagged receptors, cells were grown on coverslips and treated 
with vehicle or agonist. The cells on the coverslips were then washed with PBS and fixed 
for 20 min at room temperature using 4% (w/v) paraformaldehyde in 5% (w/v) 
sucrose/PBS (pH 7.2).
Cell surface expression of EDGl truncation mutants was visualised by 
immunofluorescence. Following two washes with 3ml/coverslip of PBS, the cells were 
fixed in 1.5ml/coverslip of 4% (w/v) paraformaldehyde as described above. Cells were 
then washed again with PBS and permeabilised for 3 min with 0.4% (v/v) Triton X-100 in 
PBS. Antibody dilutions were prepared in 0.1% (v/v) new bom calf serum (NBCS)/0.2% 
(w/v) gelatin/PBS. The primary anti-myc 9E10 antibody was used at a 1:200 dilution and 
Alexa 594-conjugated anti-mouse IgG was used at 1:400 dilution. lOOjil of antibody 
dilution for each coverslip was placed onto Nescofilm, before the coverslips were placed 
onto the antibody solution with the cells facing downwards and incubated at room 
temperature for 1 hour. Cells were then washed twice with PBS/NBCS/gelatin and placed 
onto nescofilm with secondary antibody for a further 1 hour. Coverslips were then washed 
twice with 3ml/coverslip of PBS/NBCS/gelatin and once with 3ml/coverslip of PBS prior 
to mounting on microscope slides with 7p,l/coverslip of 40% (v/v) glycerol in PBS.
Cells were visualised using a Zeiss Axiovert 100 laser scanning confocal 
microscope (Zeiss, Oberkochen, Germany) using a Zeiss Plan-Apo 63 x 1.4 NA oil 
immersion objective, pinhole of 20 and electronic zoom between 1 and 4. GFP was 
excited using a 488 nm argon / krypton laser and detected with 515-540 nm band pass 
filter. The Alexa 594-conjugated anti-mouse antibody was excited at 543 nm and detected 
with a long pass band filter 590 nm. The images were manipulated with Zeiss LSM or 
MetaMorph software (Universal Imaging Corporation, West Chester, PA).
2.4.11 Statistical Analysis
All statistical analysis, unless stated otherwise was carried out using the Student t- 
test was as described in the Graphpad software, “Prism 3.0”. Elsewhere, statistical 
analysis using ANOVA was as carried out using the “Graphpad” software as indicated in 
the figure legends.
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Chapter 3
Functional Analysis Of The Regulation Of The 
Human AiAR Receptor
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Introduction
In cardiac myocytes, adenosine exerts protective effects by binding to both the Ai 
and the A3 AR subtypes (Ralevic et al., 1998; Lozza et al., 1997, Carr et al., 1997; Mullane 
et al., 1995). Both of these receptors are coupled to Gi-proteins to elicit similar 
cardioprotective effects (Nyce et al., 1999; Ralevic et al, 1998). However, the AiAR and 
A3AR are controlled by distinct regulatory mechanisms designed to dampen, or 
desensitise, receptor signalling (Palmer et al, 1996). In this Chapter, the regulation of 
AiAR function and the basis for this differential pattern in desensitisation between the 
Ai AR and A3AR will be examined.
Desensitisation is defined as the process whereby GPCR signalling responses 
plateau and then diminish despite the continuous presence of agonist (Palmer and Stiles, 
1997). This can involve a number of several temporally and mechanistically distinct 
processes:- 1) receptor uncoupling from its associated G-protein. This occurs within a few 
minutes and is thought to involve receptor phosphorylation (Palmer and Stiles, 1997; Gao 
et al, 1999; Nie et al, 1997; Menard et al, 1997); 2) receptor internalisation away from the 
cell surface. This reduces the number of cell surface receptors available for agonist 
binding and also facilitates receptor dephosphorylation and resensitisation following 
agonist removal (Lefkowitz, R.J. et a l 1998; von Zastrow, M. and Kobilka, B.K., 1992; 
Pitcher, J.A. et a l, 1995); and 3) receptor down-regulation which occurs after several 
hours of agonist exposure and describes a decrease in receptor expression (Palmer and 
Stiles, 1997; Gao et al, 1999; lockers et al, 1999; Pak et a l, 1999).
A3AR desensitisation occurs rapidly within minutes of agonist exposure and seems 
to involve pathways of phosphorylation and internalisation similar to those described for 
the P2AR (Palmer and Stiles, 1997; Palmer et al, 1996; Palmer et a l, 1995). In the P2AR 
model, agonist exposure leads to a conformational change in the receptor, facilitating 
receptor phosphorylation by a GRK (Ciruela et al, 1997; Ferguson, 2001). It has recently 
been proposed that GRK2, or a kinase of similar substrate specificity, phosphorylates the 
agonist-occupied A3AR (Palmer and Stiles, 1997; Palmer et al, 1996). The binding of 
GRK to the receptor leads to the recruitment and binding of the scaffolding protein, “P- 
arrestin” to the phosphorylated receptor, resulting in receptor uncoupling (Benovic et al, 
1987; Menard et al 1997). P-arrestin not only desensitises the receptor but also directs 
receptor trafficking by functioning as an adaptor protein and targeting the P2AR to 
clathrin-coated vesicles where the receptor is sequestered into the cell (Menard et al.
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1997). The receptor is then either degraded or recycled back to the cell surface (Menard et 
al, 1997; Ferguson, 2001; Tsao et al, 2001).
In contrast to the A3AR, desensitisation of the AiAR requires prolonged agonist 
exposure, ranging from 15 minutes to several hours or even days (Ralevic et al., 1998; Gao 
et a l, 1999; Palmer and Stiles, 1997; Ciruela et al., 1997; Saura et al., 1998). Differences 
in the amino acid sequences between the C-terminal tails of the A%AR and A3AR appear to 
be crucial to the differences in receptor regulation. Whereas the C-teiminal region of the 
A3AR is rich in serine and threonine residues, the AiAR has only one such 
phosphorylation site (Figure 3.1). The importance of the C-terminal region in determining 
subtype-specific desensitisation was demonstrated in a study using stably expressing wild 
type (WT) and chimeric Ai and A3ARS in CHO cells (Palmer et al, 1996). While human 
AiARs were neither phosphorylated or desensitised following 10 minutes of R-PIA 
treatment, a chimeric A1-A3 adenosine receptor in which the C-terminus domain of the 
AiAR distal to the predicted site of palmitoylation was replaced by the corresponding 
region of the A3AR was able to undergo rapid functional desensitisation and agonist- 
stimulated phosphorylation (Palmer et al, 1996). This suggested that differences in the 
amino acid sequences between the AiAR and the A3AR C-terminal domains are crucial to 
the differences in agonist-dependent phosphorylation. More specifically, the inability of 
the AiAR to undergo rapid agonist-dependent phosphorylation in CHO cells was attributed 
to a lack of potential GRK phosphorylation sites in its cytosolic domains (Palmer et al., 
1996; Palmer and Stiles, 1997). Therefore, the lack of potential phosphorylation sites 
within the C-terminus of the Ai AR may result in differences in receptor desensitisation and 
internalisation.
In this chapter, the AiAR has been characterized in terms of its structure and 
function in relation to the phenomenon of receptor desensitisation. This has been achieved 
using CHO cell lines stably expressing epitope-tagged human AiARs (Figure 3.2) and 
human AiARs tagged with GFP (Figures 3.8, 3.9). This facilitated the examination of the 
sub-cellular localisation of any internalised AiAR following sustained agonist exposure. 
Concurrent studies using epitope- and GFP- tagged rat A3ARS (Figures 3.8, 3.11) also 
allowed comparisons to be made between the A%AR and the A3AR. Finally, the role of 
palmitoylation in AiAR regulation was addressed by using an Ai(Cys309-Ala)AR-GFP 
construct (Figures 3.15, 3.16).
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Results
To facilitate identification and isolation of recombinant receptors for these studies 
of the AiAR, the human AiAR and rat A3AR open reading frames were tagged with a six- 
amino acid haemagglutinin epitope (DVPDYA) and then stably expressed in CHO cells as 
described in the Methods section. This epitope is recognized by the monoclonal antibody, 
12CA5, enabling immunoprécipitation of the epitope-tagged receptors in studies of 
phosphorylation and cell surface expression to be carried out. Expression of the HA-AiAR 
and HA-A3AR was confirmed by cell-surface biotinylation (Figure 3.2). Receptor 
expression levels were determined using cell surface biotinylation (Figure 3.2), 
immunostaining (Figure 3.3) and saturation binding studies (Figures 3.10, 3.12). 
Immunostaining gave a measure of total receptor expression whereas cell surface 
biotinylation measured glycosylated receptors expressed on the cell surface. Saturation 
binding studies using the As-selective agonist radioligand, ^^^I-AB-MECA selectively 
bound the population of A3ARS in the active (R*) conformation. By comparison, the 
AiAR-selective antagonist radioligand [^H]DPCPX binds irrespective of the G-protein- 
coupling status of the receptor and will therefore give a more representative reflection of 
the entire AiAR population. Previous assays of adenylate cyclase inhibition have also 
shown that the WT HA-AiAR and WT HA-A3AR cell lines represent functional, viable 
cell lines (Palmer et a l, 1995; Palmer et a l, 1996).
Whole cell phosphorylation studies were performed to demonstrate the distinct 
effects of agonist stimulation on the phosphorylation of the HA-AiAR and the HA-A3AR. 
A 10 min treatment of 5p,M R-PIA resulted in a strong phosphorylation of the HA-A3AR. 
However, in the same experiment, 12CA5 failed to immunoprecipitate any phosphorylated 
HA-A]AR following treatment with R-PIA for lOmins at 37^C, suggesting that the HA- 
AiAR is not phosphorylated in the presence of agonist (Figure 3.3, n=3). This is consistent 
with previously published data showing that, whereas the HA-A3AR is phosphorylated 
rapidly following agonist stimulation, the HA-AiAR is resistant to phosphorylation 
(Palmer et al., 1996). The same study suggests that these differences may be due to a lack 
of serine and threonine phosphorylation sites within the C-terminal domain of the AiAR 
distal to its site of palmitate attachment at Cys 309 (Palmer et al., 1996).
Cell-surface receptor biotinylation assays were carried out to determine what 
effects the differential patterns of agonist-dependent phosphorylation between the HA- 
AiAR and the HA-A3AR had on receptor internalisation. After 7 hours of sustained 5p,M
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R-PIA treatment, a loss of 55+4% of biotinylated cell surface HA-AiARs was observed as 
compared with vehicle-treated controls (p<0.05, n=3) with a ti/2 of 90 mins (Figure 3.4). 
In contrast, a 1 hour treatment of IjiM R-PIA resulted in a loss of 78+6% of HA-AsARs as 
compared with vehicle-treated controls (p<0.05, n=3) with a ti/2 of 10 mins (Figure 3.5). 
This shows that, in contrast to the HA-A3AR, loss of HA-AiAR from the cell surface 
following sustained agonist exposure is a slower, less extensive process.
Changes in HA-AiAR cell surface expression were then characterized using 
biotinylation studies in the presence of R-PIA and the selective Ai AR antagonist, DPCPX. 
Given that HA-AiAR loss from the cell surface was maximal after a 2 hour agonist 
exposure, this time point was therefore chosen for all subsequent studies of HA-Ai AR loss 
from the cell surface. Figure 3.6 shows a concentration-response of cell surface loss using 
the AiAR agonist, R-PIA. Significant cell surface loss required a dose of around l|iM  
(IC5o=0.71|uM) with a maximal dose of 10p.M R-PIA resulting in a loss of 44±5 % cell 
surface HA-AiAR (versus vehicle treated controls (set at 100%), p<0.05, n=3, Figure 3.6). 
The effect of 5p.M R-PIA was completely antagonised by a 30 minute pretreatment with 
lOnM DPCPX, a selective AiAR antagonist (100±19% AiAR cell surface expression as 
compared with vehicle treated controls (set at 100%), p>0.05, N/S, n=3, Figure 3.7), 
suggesting that the loss of cell surface receptors induced by R-PIA is agonist-specific. 
Interestingly, pretreatment with l^M  DPCPX resulted in a significant increase in the level 
of cell surface receptors (122±17% AiAR cell surface expression versus vehicle-treated 
controls (set at 100%), p<0.05, n=3. Figure 3.7).
Fluorescent tagging of GPCRs with GFP has aided the characterisation of many 
examples of GPCR regulation, most notably the P2-adrenergic receptor (Kallal et al, 1998; 
Barak et al., 1997; Drmota et al., 1998; Lee et al., 1998). Whereas biochemical assays 
such as biotinylation of cell surface receptors provide a good quantitative measure of 
agonist-dependent changes in receptor cell surface expression, GFP tagging of the receptor 
provides a means of visualising agonist-dependent receptor trafficking. Therefore, the 
addition of a GFP tag onto the C-terminal allowed visualisation of the movement of the 
H A-AiAR and the HA-A3AR in response to agonist exposure using laser-scanning 
confocal microscopy (Figure 3.8). In particular, GFP tagging could provide further 
support for the distinct differences in agonist-dependent loss of cell surface receptor 
observed between the HA-AiAR and the HA-A3AR subtypes using cell surface 
biotinylation.
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Expression of the HA-AiAR-GFP protein was confirmed by immunoblotting using 
an anti-GFP antibody against the GFP tag (Figure 3.9). Expression of the HA-A3AR-GFP 
construct was illustrated using a cell surface biotinylation assay (Figure 3.11). Saturation 
binding studies on COS-P cells transiently transfected with either HA-AiAR or HA-AiAR- 
GFP using the AlAR-selective radioligand [^H]DPCPX showed that fusion of GFP on to 
the C-terminus of the WT HA-AiAR had no significant effect on either the Bmax or Kd 
value (Figure 3.10, Table 4). In addition, radioligand binding studies on COS-P cells 
transiently expressing either A3AR or A3AR-GFP using the A3-selective agonist 
radioligand ^^^I-AB-MECA showed no significant differences between the Kd or Bmax 
values of each receptor (Figure 3.12, Table 4). Therefore, as with the HA-AiAR, the 
addition of a GFP tag onto the C-terminal tail of the HA-A3AR had no significant effect on 
receptor binding. As mentioned previously, the detection of the A3AR population using 
^^^I-AB-MECA is selective to G-protein coupled receptors and is therefore influenced by 
the proportion of A3ARS in the active state under basal conditions.
The HA-AiAR-GFP construct was transiently transfected into CHO cells and then 
exposed to a 1 hour treatment of 5|aM R-PIA and examined in live cells in real-time by 
laser-scanning confocal microscopy. Figure 3.13 shows that, prior to agonist treatment, the 
HA-AiAR-GFP is expressed exclusively on the cell surface. Following a 1 hour agonist 
treatment, the HA-AiAR-GFP remained expressed on the cell surface and no pools of 
internalised receptor were detectable (Figure 3.13). This is in contrast to the HA-A3AR- 
GFP receptor where a 30 minute exposure to agonist resulted in the almost complete re­
distribution of the cell surface receptors from the plasma membrane into punctate 
intracellular vesicles (Figure 3.14).
A crucial link in the process of Ai AR short-term desensitisation and internalisation 
could be between palmitoylation of the receptor and the structure of the cytosolic tail. Like 
most GPCRs, such as rhodopsin, Pz-adrenergic and vasopressin Via receptors (Hawtin et 
ah, 2001, Konig et a l, 1989; Moffet et al., 2001) the human AiAR has a cysteine residue 
representing a potential palmitoylation site in its C-terminal domain (Tucker et al., 1993). 
In addition, a recent study has shown that the AiAR is palmitoylated following agonist 
stimulation and that this palmitoylation is abolished following the mutation of Cys309 to 
Ala, which cannot be palmitoylated (Gao et al., 1999). However, the effect of AiAR 
palmitoylation in terms of receptor internalisation has yet to be determined.
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In order to test whether the integrity of Cys309 had any effect on AiAR cell surface 
expression, the residue was mutated to a non-palmitoylatable Ala residue. A Cys309-Ala 
mutated HA-Ai AR-GFP construct was then produced to allow visualisation of any changes 
in cell surface expression in the presence of agonist (Figure 3.15). Analysis by 
immunoblotting using the monoclonal anti-GFP antibody showed that the HA-AiAR-GFP 
and the HA-Ai(Cys309-Ala)AR-GFP receptors are expressed to the same levels and 
migrate at the same relative molecular mass (Figure 3.16). The HA-Ai(Cys309-Ala)AR- 
GFP construct was transiently expressed in CHO cells and exposed to a 1 hour treatment of 
5|xM R-PIA and examined in live cells in real-time by laser-scanning confocal microscopy. 
Figure 3.17 shows that there is no visible internalisation of the mutated receptor following 
60 minutes of 5|iM R-PIA exposure. The fact that mutation of Cys309 to Ala had no 
visible effect on the internalisation of the receptor suggests that palmitoylation of Cys309 
in the C-terminus of the AiAR has no beaiing on the short-term rate of A]AR 
internalisation.
Both cell surface biotinylation and confocal microscopy confirm that, in CHO cells, 
the R-PIA-dependent loss of HA-AiAR from the cell surface is markedly slower and less 
complete than the HA-A3AR. It was therefore important to determine whether the loss of 
cell surface receptors observed in the biotinylation assays represented a change in total 
receptor expression as opposed to receptor internalisation away from the cell surface. 
Radioligand binding studies using the AiAR-selective radioligand [^H]DPCPX were 
carried out on total cell membranes prepared from CHO/HA-AiARs following a 20 hour 
treatment with 5p,M R-PIA. 20 hours of agonist exposure resulted in a significant HA- 
AiAR down-regulation, with a 44.7+12.4% decrease in Bmax in comparison to untreated 
controls observed following 7 hours of 5|LtM R-PIA exposure (p<0.05, w=3. Figure 3.18). 
Interestingly, the time course of this decrease in Bmax is similar to the time course of the 
loss of cell surface receptor, with a ti/2 of approximately 60 mins (Figure 3.18). This 
suggests that the loss of HA-AiAR from the cell surface may be due to down-regulation of 
the receptor.
Discussion
As stated in the introduction, activation of the adenosine A%AR is important in the 
biological defence against ischaemic damage. Therefore, AiAR regulation may provide a 
potentially useful therapeutic target for drugs aimed at combating cardiac disease.
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However, very little is known about the mechanisms regulating AiAR signalling. To 
address this, the current study has used point-mutated and GFP-fused chimeric human 
AiARs in order to characterize the processes regulating the sub-cellular distribution of the 
AiAR in response to sustained agonist exposure. The regulation of the human AiAR was 
also compared with the regulation of the rat A3AR using epitope- and GFP- tagged rat 
A3ARS.
The rat and human forms of the A3AR exhibit a relatively low level of identity 
(72% between each species) and this is reflected in distinct pharmacological characteristics 
of each type of A3AR (Olah and Stiles, 2000; Palmer and Stiles, 1995). For example, the 
agonists R-PIA and NECA are equipotent at the rat A3AR (Olah and Stiles, 2000). 
Importantly, however, studies examining stable cell lines of either the rat or the human 
forms of A3AR transfected into CHOs demonstrated that both receptors have a similar 
desensitisation profile (Palmer et al., 1997). Additionally, the adenosine human AiAR and 
rat A3AR subtypes are both Gi-coupled, are similar in structure and elicit similar biological 
responses upon exposure to adenosine. Therefore, the rat A3AR provided a good model 
with which to compare the regulation of human Ai AR.
Despite the similarities exhibited between the human AiAR and the rat A3AR, each 
subtype exhibits very distinct regulatory patterns of phosphorylation and internalisation. 
For instance, in CHO cells, the HA-A3AR is strongly phosphorylated when exposed to 
agonist, whereas the HA-AiAR appears to be phosphorylation-resistant (Figure 3.3). A 
possible explanation for the lack of phosphorylation observed with the AiAR is that the 
receptor may be partially glycosylated resulting in a differential processing of the receptor 
compared to the A3AR. However, consensus sites for N-linked glycosylation (N-X-S/T 
where “X” may be an amino acid except P) exist on the second extracellular loops of all 
the ARs, with the A3AR possessing two additional sites within the N-terminal domain. 
Studies have shown that the AiAR is a single subunit glycoprotein with a molecular mass 
of 34-41 kDa which varies among the tissues or species (Gonzalezcalero et al., 1992; 
Nakata, 1992; Schwabe et al., 1993). For example, the molecular mass of purified AiAR 
from human brain membranes shown to be 35kDa (Nakata, 1992). Additionally, 
endoglycosidase F treatment on purified AiAR reduces the molecular mass to around 
30kDa (Nakata, 1992). Figures 3.2 and 3.3 demonstrate that the HA-tagged human AiAR 
has a molecular mass of around 40kDa. Additionally, cell surface AiARs can be easily 
detected using cell surface biotinylation of glycosylated receptors (Figure 3.2). This would 
suggest that the lack of phosphorylation of AiARs observed following agonist exposure is
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due to the lack of phosphorylation sites within the C-terminal tail, as opposed to partial 
processing of the receptor.
A previous study has shown that a chimeric A1-A3AR form of the AiAR in which 
the last 14 amino acids of the A3AR have been fused distal to the predicted palmitoylation 
site within the AiAR behaves pharmacologically like the AiAR but is rapidly 
phosphorylated and undergoes internalisation in a similar way to the A3AR (Palmer et al., 
1996). Since GPCR phosphorylation is often a prerequisite for internalisation, this 
difference implies that differences in the regulatory processes of phosphorylation and 
internalisation are due to the lack of serine and threonine phosphorylation sites within the 
C-terminal of the AiAR. It appears, however, that phosphorylation and subsequent 
desensitisation for the AiAR is tissue-specific. For example, an agonist-stimulated 
increase in phosphorylation of the AiAR has been described in DDTiMF-2 cells in 
association with receptor uncoupling from G-proteins and desensitisation (Ciruela et al., 
1997; Saura et al., 1998; Nie et al., 1997). Interestingly, the lack of serine and threonine 
residues in the carboxyl tail did not prevent rapid, ligand-induced desensitisation in 
DDTiMF-2 cells. However, the short term desensitisation and phosphorylation of the 
A]AR in DDTiMF-2 cells demonstrates that the appropriate cellular environment is 
important in conferring specific mechanisms of receptor regulation. There is also evidence 
that receptor phosphorylation may not always be required for GPCR internalisation. A 
study of a mutant aiB-adrenergic receptor with a 147 amino acid tmncation of the C- 
terminal tail showed no decrease in agonist-induced inositol-1,4,5,-trisphosphate 
accumulation, compared to the wild-type receptor (Garrard et al., 1998). Interestingly, 
while the truncated receptor was resistant to desensitisation and was not phosphorylated in 
response to epinephrine, it was able to undergo agonist-dependent internalisation, albeit 
more slowly than the wild-type receptor.
Previous studies have demonstrated that AiAR internalisation is a slow, incomplete 
process requiring hours of agonist exposure. For example, despite the fact that short term 
phosphorylation and desensitisation of the AiAR was found using DDTiMF-2 cells, 
maximal internalisation was still only seen after several hours (Ciruela et al., 1997; Saura 
et al., 1998; Nie et al., 1997). In CHO cells, there is a 55±4% loss of cell surface AiARs 
after 7 hours of R-PIA exposure (Figure 3.4). This is also a slow process (ti/2=90 hours. 
Figure 4) as compared with the A3AR (ti/2= 10 mins. Figure 3.5) and is in contrast to most 
of the other GPCRs studied to date where maximal internalisation is typically achieved by
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around 30 minutes (Ciruela et ah, 1997; Ralevic et al., 1998). In addition, the loss of cell 
surface AiARs expressed in CHOs is an agonist-dependent process, where an R-PIA- 
dependent decrease in biotin-labelled cell surface receptors was shown to be inhibited in 
the presence of the AiAR antagonists, DPCPX (Figure 3.7).
Visualisation of AR-GFP chimeras using laser-scanning confocal microscopy 
demonstrated that a sustained exposure to 5|xM R-PIA does not result in any detectable 
movement of HA-AiAR-GFP from the cell surface (Figure 3.13). In contrast, there is a 
marked translocation of HA-A3AR-GFP from the plasma membrane into distinct punctate 
intracellular vesicles following a 30 minute exposure to 5pM R-PIA (Figure 3.14). This 
correlates well with the biotinylation studies of cell surface receptor expression and 
provides further evidence that, whereas there is rapid, significant loss of A3AR from the 
cell surface, agonist exposure results in a far slower, less complete loss of cell surface 
AiAR. In addition, mutation of the site of AiAR palmitoylation had no effect on the 
translocation of the AiAR from the cell surface following a 1 hour exposure of 5pM R-PIA 
(Figure 3.17). This result is consistent with a previous study showing that point mutation 
of Cys309 had no effect on receptor-G-protein coupling, effector activation or down- 
regulation in response to sustained agonist exposure of stably transfected HEK293 cells 
(Gao et al., 1999).
The effect of palmitoylayion on receptor signalling and regulation varies amongst 
GPCRs. For example, it was shown in rhodopsin that a synthetic polypeptide from the 
fourth intracellular loop created by palmitoylation of Cys residues in the membrane- 
proximal portion of the C-terminus is capable of interacting with Gt (Konig et a l, 1989). 
Additionally, the P2AR has been shown to be palmitoylated at a cysteine residue at 
position 341 in its C-terminus (Moffet et ah, 1993; Mouillac et al., 1992; Horstmeyer et 
al., 1996) and it was proposed that P2AR palmitoylation permits the anchoring of the C- 
terminal tail of the receptor to the membrane to form a fourth intracellular loop (Moffet et 
al., 1993; Mouillac et al., 1992). Hence, the absence of a palmitate anchor may lead to a 
structural organisation of the carboxylic tail, exposing otherwise unavailable 
phosphorylation sites for kinases such as PKA and pARK (Moffet et al., 1993). The 
observation that agonist treatment did not significantly increase the high basal level of 
receptor phosphorylation of a p2(Cys341-Ala )AR mutant is consistent with a role for 
palmitoylation in regulating agonist-promoted phosphorylation (Moffet et al., 1993). 
Consistent with this hypothesis, it has been shown that agonist exposure enhances the
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incorporation of palmitate into human PaARs overexpressed in Sf9 cells (Mouillac et al., 
1992). This suggests that receptor activation increases the turnover rate of receptor-linked 
palmitate. Hence, a rapid acylation-deacylation cycle may provide a mechanism for the 
regulation of protein function and that dynamic regulation of receptor palmitoylation may 
serve as a mechanism for revealing phosphorylation sites.
However, Cys palmitoylation of other GPCRs has been shown to have no effect on 
G-protein coupling. For example, disruption of a 2A-adrenergic receptor palmitoylation was 
shown to have no effect on receptor phosphorylation but instead abolished receptor down- 
regulation (Eason et al., 1994). Additionally, the 5-HT4(a) receptor is know to be 
palmitoylated (Ponimaskin et al., 2001; Ponimaskin et al, 2002). However, non- 
palmitoylated 5-HT4a receptors were indistinguishable from the wild type in their ability to 
interact with Gs, to stimulate adenyly cyclase activity and to activate cyclic nucleotide- 
sensitive cation channels following agonist stimulation (Ponimaskin et al, 2002). 
Interestingly, a palmitoylation-deficient mutant of the vasopressin Via receptor exhibited 
decreased phosphorylation under both basal and agonist-stimulated conditions when 
compared to the wild type receptor yet the mutant receptor has an increased rate of 
sequestration (Hawtin et al., 2001). Hence, the apparent inability of the Cys309 mutation 
to alter AiAR signalling is in contrast to the P2-adrenergic receptor, where mutation of 
Cys341 within the P2AR C-teraiinal tail increases the accessibility of a PKA 
phosphorylation site upon agonist stimulation and therefore increases receptor 
phosphorylation (Moffet et al., 1993; Mouillac et al., 1992). However, other examples 
such as the 5 -HT4A, (%2A-adrenergic, and vasopressin Via receptors illustrate the varied role 
of palmitoylation in GPCR signalling and regulation. In essence, the effect of 
palmitoylation on GPCR signalling is dependent upon the residues surrounding the site of 
palmitoylation and is therefore receptor-specific. Indeed, studies within our lab have 
shown that mutation of Cys302 and Cys305 within the C-terminal domain of the A3AR 
resulted in a marked increase in receptor phosphorylation and rate of internalisation. This 
difference presumably reflects the ability of the WTA3AR to be phosphorylated by GRKs 
in comparison to the phosphorylation-resistant Ai AR.
The fact that a slow agonist-dependent loss of cell surface AiAR expression is 
observed using either CHO or DDT1-MF2 cells would suggest that any AiAR 
internalisation either utilises a unique molecular mechanism involving the 
clathrin/dynamin endocytic machinery or is through a clathrin-independent mechanism. In
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LLC-PKi cells, it has been suggested that AiAR internalisation occurs following their 
translocation to rafts enriched in caveolin and that the putative caveolin binding motif 
within the C-terminal of the A%AR (YAFRIHKF) is involved (Gines et al., 2001). In 
contrast, a separate study showed that 67±5% of adenosine Ai receptors were isolated with 
caveolae from unstimulated rat cardiac ventricular myocytes and, following incubation 
with the AiAR agonist, CCPA, there was rapid translocation of the A; receptors from 
caveolae into non-caveolae plasma membrane (Lasley et al., 2000). Alternatively, the loss 
of cell surface expression may be due to down-regulation. In CHO cells, a radioligand 
binding assay to measure receptor down-regulation demonstrated that the loss of cell 
surface expression and the loss of total receptor expression were temporally similar 
(ti/2=60 mins, Figure 3.18). Therefore, the concomitant decrease in total receptor 
expression level would suggest that, in CHO cells, receptor down-regulation is the major 
determinant of AiAR cell surface expression. This down-regulation could be the result of 
modulation of receptor gene transcription, RNA stability or receptor proteolysis.
In conclusion, the AiAR and the A3AR undergo distinct regulatory pathways of 
phosphorylation and internalisation. The loss of cell surface Ai AR due to agonist exposure 
is a slower, less complete process than the A3AR and this can be attributed to its inability 
to undergo receptor phosphoryation in response to agonist. It also been shown that 
mutation of Cys309, a site of palmitoylation within the A%AR C-terminal tail, does not 
visibly increase the agonist-dependent effect on the translocation of the Ai AR from the cell 
surface. Future work should be aimed at examining the precise mechanisms involved in 
the slow loss of AiA R from the cell surface observed in CHO cells, focusing primarily 
upon mechanisms of receptor down-regulation. This may also help to explain the reported 
variability in AiA R regulation found within different cell types. Future studies should 
examine the potential role of caveolin both in terms of A^AR cell surface expression and 
also in terms of AiAR signalling. The C-terminal tail of the AiA R contains a RxxPxxP 
class I Src Homology 3 (SH3) binding motif (R^^^CQPAPP) proximal to the putative 
caveolin binding site. Therefore, one potential area of interest involves examining the role 
of caveolin in regulating the attachment of the AiA R with proteins containing SH3 
domains. In addition, it remains unclear why it is physiologically beneficial to have the 
AiAR subtype comparatively resistant to regulatory mechanisms of phosphorylation and 
internalisation in comparison to the A3AR. Therefore, future work should also involve
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cardiac myocytes infected with an adenoviral construct of the AiAR in order to study the 
effect of sustained agonist treatment of the Ai AR under conditions of ischaemia.
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Figure 3.1: Alignment Of AiAR And AiAR C-Terminal Domains
The primary sequences of the C-teiminal domains of the human AiAR and the rat A3AR 
are shown. Phosphorylation sites at Thr 307, 318 and 319 of the A3AR are shown in blue.
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Figure 3.2: Cell-Surface Biotinylation Of HA-AiAR And HA-A^AR
CHO cells stably expressing either the HA-AiAR or the HA-A3AR were subjected to cell 
surface biotinylation and solubilised, followed by receptor immunoprécipitation with 
12CA5. This represents one of multiple experiments.
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Figure 3.3: Comparison Of Agonist-Mediated Phosphorylation Of WT Ai And A^ARs
^^P-labelled stably transfected CHO/HA-AiAR and CHO/HA-A3AR cells were treated for 
10 mins with 5pM R-PIA at 37°C in the presence of 0.5units/ml of adenosine deaminase. 
The cells were then solubilised for analysis of AiAR and A3AR phosphorylation by 
immunoprécipitation followed by SDS-PAGE and phosphorimaging. Panel (A) shows an 
immunoblot of the immunoprecipitated samples, demonstrating equal loading of each 
receptor construct. The AiAR is not phosphorylated in the presence of agonist whereas the 
A3AR is strongly phosphorylated, as shown in the autoradiograph in panel (B). Typical 
data is shown from one of three experiments.
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Figure 3.4; Time Course Of Agonist-Mediated Loss Of Cell Surface HA-AiAR
CHO cells stably transfected with the HA-AiAR expression construct were treated with 
vehicle or 5pM R-PIA for 1,2,4,7,or 20 hours at 37^C in the presence of 0.5units/ml 
adenosine deaminase as indicated in the graph. The cells were examined for internalisation 
by cell surface labelling with biotin-LC-hydrazide, followed by immunoprécipitation with 
the 12CA5 antibody. Biotin labelling of untreated AiARs was set at 100% and the results 
following agonist treatment expressed as a ratio of the control. The data from three 
experiments is shown in the graph and expressed as mean+SEM. The graph shows that 
agonist-dependent cell surface loss of AiAR is a slow process (t]/2=90 mins) with a loss of 
60% of cell surface A] AR after 7 hours.
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Figure 3.5: Time Course Of Agonist-Mediated Loss of Cell Surface HA-A^AR
CHO/HA-A3AR cells were treated with vehicle or 5|liM R-PIA for 2,5,15,30 or 60 minutes 
at 37°C in the presence of 0.5units/ml adenosine deaminase as indicated in the graph. The 
cells were examined for internalisation by cell surface labelling with biotin-LC-hydrazide, 
followed by immunoprécipitation with the I2CA5 antibody. Biotin labelling of untreated 
A3AR was set at 100% and the results following agonist treatment expressed as a ratio of 
the control. The data from three experiments is shown in the graph and expressed as mean 
± SEM. The graph shows that, in contrast to the AiAR, agonist-dependent cell surface loss 
of A3AR is a relatively rapid process (ti/2= 1 0 mins) with a loss of around 75% of cell 
surface A3AR after 1 hour.
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Figure 3.6: Effect Of Increasing Agonist Concentration On Loss Of Cell Surface 
AiAR
Stably transfected CHO/HA-AiAR cells were treated for 2 hours with either vehicle or 
InM, lOnM, lOOnM, l|aM or 10|iM R-PIA at 37°C, supplemented with 0.5units/ml 
adenosine deaminase. Cell surface expression was then examined by cell surface labelling 
with biotin-LC-hydrazide, followed by immunoprécipitation with the 12CA5 antibody. 
Biotin labelling of untreated AiARs was set at 100% and the results following agonist 
treatment expressed as a ratio of the control. The data from three experiments is shown in 
the graph and expressed as mean±SEM. The figure shows that a significant loss of cell 
surface A[AR was found following treatment with doses greater than or equal to l|iM  R- 
PIA (EC5o=0.71pM).
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Figure 3.7: Effect Of The AiAR-Selective Antagonist DPCPX On Agonist-Mediated 
Loss Of Cell Surface AiAR
CHO/HA-AiAR cells were pretreated for 30mins with vehicle, InM, lOnm, lOOnM, or 
1 pM DPCPX. The cells were then given a 2 hour treatment with either vehicle or 5|iM R- 
PIA. All additions were at 37°C and were supplemented with 0.5units/ml of adenosine 
deaminase. Cell surface expression was then examined by cell surface labelling using 
biotin-LC-hydrazide. Biotin labelling of untreated AiARs was set at 100% and the results 
following agonist and antagonist treatment were expressed as a ratio of the control. The 
data from three experiments is shown in the graph and expressed as meantSEM. * denotes 
statistically significant changes in cell surface expression versus untreated controls 
(p<0.05). R-PIA-dependent loss of cell surface AiAR was completely antagonised 
following pretreatment with lOnM DPCPX. l|iM  DPCPX pretreatment resulted in a 
significant increase in cell surface receptor levels.
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Figure 3.8: Schematic Diagram Of HA-Ai AR-GFP And H A - A R - G F P  Construct
Epitope-tagged forms of the human AiAR and rat A3AR were tagged with green 
fluorescent protein using either a pCMV5/human HA-AiAR or pCMV5/rat A3AR cDNA 
respectively as a template. The C-terminal HA-tag present on the both the AiAR and the 
A3AR were removed by PCR and ligated into the multiple cloning site of pEGFP-Nl at 
HindlUIKpnl for the AjAR and at HindUl / Smal for the A3AR. The addition of the GPP 
tag allowed visualisation of any movement of the cell surface AiAR and A3AR following 
sustained agonist exposure.
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Figure 3.9: Immunoblotting Analysis Of HA-Ai AR-GFP
CHO cells transiently expressing either the HA-AiAR-GFP or WT-GFP construct were 
solubilised in electrophoresis sample buffer and analysed by SDS-PAGE and 
immunoblotting with the anti-GFP antibody against the GFP tag. This represents one of 
multiple experiments.
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Figure 3.10: Saturation Analysis Of DPCPX Binding Of HA-AiAR and HA- 
A, AR-GFP
Membranes prepared from COS-P cells transiently transfected with either A%AR or AiAR- 
GFP expression constructs were used for saturation radioligand binding assays with 
increasing concentrations of the A;AR antagonist radioligand DPCPX as described in 
the material and methods. This is one of three experiments, composite data from which are 
presented in table 1 .
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Figure 3.11: Ceil-Surface Labelling Analysis Of HA-A^AR-GFP
Non-transfected CHO cells or CHO cells transiently expressing either the HA-A3AR or the 
HA-A3AR-GFP construct were subjected to cell surface biotinylation and receptor 
immunoprécipitation with 12CA5 as outlined in the methods section. The samples were 
solubilised in electrophoresis sample buffer and analysed by SDS-PAGE and probing with 
HRP-streptavidin. Each figure represents one of multiple experiments.
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Figure 3.12: Saturation Analysis Of ^^^I-ABMECA Binding Of HA-A^AR and HA- 
A.AR-GFP
Membranes prepared from COS-P cells transiently transfected with either A3AR or A3AR- 
GFP expression constructs were used for saturation radioligand binding assays with 
increasing concentrations of the A3AR agonist radioligand ^^^I-ABMECA as described in 
the methods section. This is one of three experiments, composite data from which are 
presented in table 1 ,
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Table 4; Pharmacological Characterisation of HA-AiAR, HA-AiAR-GFP. HA-A^AR 
And HA-A^AR-GFP Receptors
Membranes prepared from COS-P cells transiently expressing the indicated HA-AiARs 
were used for saturation radioligand binding assays employing increasing concentrations of 
the AiAR-selective antagonist ligand [^HJDPCPX as described in section. COS-P 
membranes expressing the indicated HA-A3ARS were used for saturation radioligand 
binding assays employing increasing concentrations of the A3AR agonist radioligand 
ABMECA. Results aie presented as means ± standard error from three experiments. * 
indicates no significant differences between the wild type and GFP tagged receptors 
(p>0.05,71=3)
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Figure 3.13; Real-Time Visualisation Of HA-AiAR-GFP Cell Surface Expression 
Following Sustained Agonist Treatment
CHO cells transiently transfected with the HA-AiAR-GFP construct were exposed to a 
sustained treatment of 5jiM R-PIA and examined under live cell conditions by confocal 
microscopy. Under conditions of no agonist treatment, the HA-AiAR-GFP construct was 
expressed on the cell surface. Even after 1 hour of agonist exposure, the HA-AiAR-GFP 
remained on the cell surface with no internal pools of internalised receptor found within 
the cytoplasm. This represents a typical example of three similar experiments.
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Figure 3.14; Real-Time Visualisation Of HA-A^AR-GFP Cell Surface Expression 
Following Sustained Agonist Treatment
CHO cells transiently transfected with the HA-A3AR-GFP expression construct were 
exposed to a sustained treatment of 5[aM R-PIA and examined under live cell conditions 
by confocal microscopy. When exposed to vehicle alone, the HA-A3AR-GFP construct 
was expressed on the cell surface. In contrast to the HA-Ai AR-GFP construct, a 30 minute 
exposure to agonist resulted in a dramatic re-distribution of the HA-A3 AR-GFP receptor 
away from the cell surface and into intracellular pools.
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Figure 3.15; Schematic Diagram Of The HA-Ai(Cvs309-Ala)AR-GFP Expression 
Construct
An epitope-tagged form of the human AiAR containing a mutation at the cysteine residue 
in the C-terminal domain, thought to be a possible site of palmitoylation, to alanine was 
tagged with GFP using a pCMV5/HA-Ai(Cys309-Ala)AR template. The C-terminal HA- 
tag present on the Ai(Cys309-Ala)AR was removed by PCR and ligated into the multiple 
cloning site of pEGFP-Nl at HindSUKpnl. The addition of the GFP tag allowed 
visualisation studies to be earned out to determine the potential effect of palmitoylation on 
the internalisation of the cell surface AiAR following sustained agonist exposure.
103
(2
o ioo
(JQ
Figure 3.16: Immunoblot Analysis Of HA-Ai AR-GFP And HA-Ai(Cvs309-Ala)AR- 
GFP
Samples of CHO cells transiently expressing either the HA-Ai AR-GFP or the HA-Ai(Cys- 
309-Ala)AR-GFP construct were solubilised in electiophoresis sample buffer and analysed 
by SDS-PAGE and immunoblotting with the anti-GFP antibody against the GFP tag. This 
represents one of multiple experiments.
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Figure 3.17; Real-Time Visualisation Of The Effect Of Palmitoylation Of Cvs3Q9 On 
AiAR"GFP Cell Surface Expression Following Sustained Agonist Treatment
The Cys309Ala-mutated Ai AR-GFP construct was transiently transfected into CHO cells 
and observed under live cell conditions by confocal microscopy for any agonist-dependent 
changes in cell surface distribution. With no agonist treatment, the receptor is expressed 
solely on the cell surface. As with the wild type Ai AR-GFP construct, a 1 hour treatment 
with 5jiM R-PIA did not result in any visible changes in cellular distribution. This 
suggests that palmitoylation of Cys309 within the C-terminus of the A%AR does not 
influence internalisation of the receptor in response to sustained agonist exposure. This 
represents a typical example of three similar experiments.
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Figure 3.18: Saturation Analysis of T^ HI DPCPX Binding To HA-AiARs Following A 
20 Hour Agonist Time Course
Membranes prepared from CHO cells stably transfected with the HA-AiAR expression 
construct were treated with vehicle or R-PIA for 1,2,4,7 or 20 hours in the presence of 0.5 
units/ml adenosine deaminase as indicated in the graph. The membranes were then used 
for saturation binding assays as described in the materials and methods using 8 nM [^H] 
DPCPX. This represented a maximal dose of the AiAR antagonist. Data is presented as 
meaniSEM. The graph of three similar experiments shows that there is significant down- 
regulation over 20 hours, with a 44.7 ± 12.4% decrease in Bmax observed after 7 hours in 
comparison to untreated controls. The time course of this decrease in Bmax (ti/2=60 mins) is 
similar to the time course of the loss of cell surface AiAR, suggesting that the loss of 
A|AR from the cell surface may be due to down-regulation of the receptor.
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Chapter 4
Analysis Of The Phosphorylation Of The 
Human EDGl Receptor
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Introduction
SIP is a bioactive lipid released from a number of cells, such as platelets and 
fibroblasts (Goetzl et al., 1998; Van Brooklyn et al., 1998; Liu et al., 1999; Olivera et al., 
1999). SIP initiates a number of cellular effects such as mobilisation of intracellular 
calcium, regulation of cytoskeletal organisation and cell growth, differentiation, survival 
and motility (Goetzl et a l, 1998; Im et al., 1997; Zondag et al. 1998; Van Brooklyn et a l, 
1998; Okamoto et al., 1998; An et al., 1999; Kon et al., 1999; Liu et al., Olivera et a l, 
1999). These effects have been attributed to both the intracellular and extracellular actions 
of SIP (Van Brooklyn et al., 1998; An et a l, 1999; Kon et a l, 1999; Sato et a l, 1999; 
Olivera et a l, 1999).
The extracellular effects of SIP are due to its binding to specific members of the 
EDG family of GPCRs (Olivera et a l, 1999; Sato et a l, 1999; Kon et a l, 1999). While 
this family consists of eight members, termed EDGl-8 , only EDGl, 3, 5, 6  and 8  are high 
affinity SIP receptors (Lynch et a l, 1999; Hla et a l, 2001, Malek et a l, 2001, Im et a l, 
2001). The binding of SIP to the EDGl receptor results in pertussis toxin (PTx)-sensitive, 
Gi-dependent activation of ERK2 and the inhibition of adenylyl cyclase (Sato et a l, 1999; 
Lee et a l, 1998; Lynch et a l, 1999; Ancillin et a l, 1999). In addition, EDGl also 
stimulates the PTx-insensitive, G12/13-mediated activation of Rho-coupled pathways that 
regulate morphogenesis, such as adherens junction assembly and translocation of P- and E- 
cadherin (Kon et a l, 1999; Liu et a l, 1999; Lee et a l, 1999; Ancellin et a l, 1999). EDGl, 
along with EDG3, also regulates signalling pathways required for human umbilical vein 
endothelial cell morphogenesis into capillary-like networks (Lee et a l, 1998). The same 
study also suggested that antagonists of EDGl and EDG3 could attenuate the enhanced 
angiogenesis process associated with solid tumour growth, rheumatoid arthritis and 
diabetic retinopathy (Lee et a l, 1998).
Given the importance of EDGl signalling in processes such as angiogenesis, the 
molecular mechanisms regulating EDGl signalling therefore have tremendous therapeutic 
potential. As described previously, sustained agonist occupation of many GPCRs can 
result in the desensitisation of receptor function; internalisation of the receptor away from 
the cell surface and coupling of GPCRs to alternative signalling pathways (Ferguson, 
2001; Gao et a l, 1998; Zhang et a l, 1999). In many cases, each of these processes are 
dependent upon GPCR phosphorylation on serine and threonine residues within either the 
third intracellular loop and/or C-terminal tail by both second messenger-dependent protein 
kinases, such as PKA and PKC, and GRKs (Ferguson, 2001: von Zastrow et a l, 1994;
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Goodman et al., 1996). In the case of GRK-mediated phosphorylation, the agonist- 
dependent conformational change in the receptor promotes the selective binding of 
arrestins to agonist-activated receptors (Jie Zhang et al., 1999; Barak et al., 1997; Miller 
and Lefkowitz, 2001; Pierce and Lefkowitz, 2001). The binding of arrestin sterically 
uncouples the receptor from heterotrimeric G-proteins, targets many GPCRs for 
internalisation in clathrin coated vesicles and, in some cases, can initiate alternate 
signalling pathways such as the arrestin-mediated increase in ERK and JNK signalling 
found with the P2AR (Jie Zhang et al., 1999; Barak et al., 1997; Miller and Lefkowitz, 
2001; Pierce and Lefkowitz, 2001, Ferguson, 2001).
GPCR phosphorylation may therefore represent a crucial step in both the rapid 
desensitisation of GPCR function and in the subsequent processes of internalisation. This 
was highlighted in the previous Chapter for the Ai and A3 adenosine receptors where the 
phosphorylation-deficient A%AR internalised much slower compared with the rapidly 
phosphorylated A3AR. Hence, in order to begin characterising the regulation of EDGl 
signalling, it is important to first fully characterise EDGl receptor phosphorylation. In this 
Chapter, the molecular mechanisms regulating EDGl phosphorylation in stably transfected 
hamster lung CCL-39 fibroblasts have been characterised in detail. In addition, truncation 
mutants of the EDGl C-terminus were used to define specific regions of EDGl 
phosphorylation
Results
Due to the lack of a selective commercially available antibody against endogenous 
EDGl receptors, a myc epitope tag was incorporated into a human EDGl cDNA 
expression construct (Figure 4.1). This facilitated the identification and isolation of 
recombinant receptors using the monoclonal 9EI0 antibody which recognises the myc tag. 
The construct was stably expressed in CCL-39 hamster lung fibroblasts using a modified 
calcium phosphate precipitation/glycerol shock transfection procedure and stable 
expression of the mycEDGl receptor in CCL-39 cells was then confirmed by 
immunoblotting using the 9E10 (Figure 4.2). Analysis of ERK activation showed that 
mycEDGl activated ERK in the presence of SIP when stably expressed in CCL-39 cells. 
Concentration-response curve analysis of ERK activation at 10 min demonstrated that SIP 
produced a 6-10 fold activation of ERK (EC5o=0.4pM) in mycEDGl-expressing, but not 
parental, CCL39 cells (Figure 4.3, n=3). This demonstrated that the recombinant human
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EDGl receptor remained functional despite the addition of the myc epitope to its C- 
terminus.
To begin the characterisation of EDGl phosphorylation, a whole cell 
phosphorylation study using serum-starved CCL-39/mycEDGl cells was carried out in the 
presence of the agonist, SIP and a number of activators of second messenger-regulated 
kinases (Figure 4.4, n=3). These included IpM PMA, a phorbol ester that activates 
conventional and novel PKC subtypes; 10|iM A23187, a calcium ionophore; lOjiM 
forskolin, an activator of adenylyl cyclase and lOOjuiM 8 -Br-cGMP, non-hydrolysable 
analogue of cGMP that activates protein kinase G (PKG). A 12-25-fold increase in EDGl 
phosphorylation was observed following exposure to 10|iM SIP exposure (range from 20 
experiments) whereas a weaker but still significant increase in EDGl phosphorylation in 
the region 4-8 fold over basal levels was observed under the same conditions following 
lp,M PMA treatment (range from 16 experiments) (Figure 4.4). The other second 
messenger activators failed to induce EDGl phosphorylation (versus a vehicle-treated 
control where S IP-induced EDGl phosphorylation set at 100%, p>0.05, n=3, Figure 4.4).
Previous studies have produced conflicting results with respect to the role of LPA 
in EDGl signalling, with one group suggesting that LPA is a partial agonist for EDGl (Lee 
et al., 1998) whereas other groups have found LPA to have no effect on EDGl activation 
(Windh et al. 1998; Zondag et al., 1998). To resolve this issue, a whole cell 
phosphorylation study of serum-starved CCL-39/mycEDGl cells exposed to SIP, PMA or 
LPA demonstrated that, under conditions where both SIP and PMA resulted in a strong 
phosphorylation of EDGl, no significant increase in phosphorylation was observed over 
basal levels following 100|xM LPA exposure (4.4 ± 2.4 % versus vehicle-treated controls 
where SIP-induced EDGl phosphorylation set at 100%, p>0.05, N/S, Figure 4.5a). The 
inability of LPA to induce significant EDGl phosphorylation was not caused by any 
discrepancies in the integrity of the LPA because LPA was shown to strongly 
phosphorylate EDG2 in related studies within the lab (Figure 4.5b). Hence, EDGl 
selectively undergoes phosphorylation in the presence of SIP and also following activation 
of PKC. In addition, a phosphoamino acid analysis demonstrated that both SIP and PKC 
result in the phosphorylation of serine and threonine residues within the EDGl receptor 
(Figure 4.6).
To further characterise S IP-induced EDGl phosphorylation, a whole cell 
phosphorylation study on serum-starved CCL-39/mycEDG 1 cells was canied out in the
110
presence of a range of SIP concentrations. SIP produced a concentration-dependent 
increase in EDGl phosphorylation (ECgo^ 1.9±0.37pM, n=3, Figure 4.7). A concentration 
of lOpM SIP was subsequently chosen for the remaining experiments as this was shown to 
induce maximal EDGl phosphorylation but remained physiologically relevant. A time 
course of EDGl phosphorylation in the presence of lOp-M SIP showed that 
phosphorylation is a rapid process, with significant EDGl phosphorylation observed after 
the earliest time point examined (15 seconds) and near maximal EDGl phosphorylation 
achieved after 60 seconds (n=3, Figure 4.8). Maximal EDGl phosphorylation was then 
maintained for a further 20 min in the continuous presence of lOjxM SIP (n=3. Figure 4.8). 
lOpM S IP-induced EDGl phosphorylation was also shown to be a reversible process, with 
a significant decrease in EDGl phosphorylation observed after only 30mins of agonist 
removal (44.3±15.6% reduction in SIP-induced EDGl phosphorylation versus maximal 
SIP-induced EDGl phosphorylation (set at 100%), p<0.05, n=3. Figure 4.9). After 2 
hours of agonist removal, phosphorylation of EDGl remained significantly greater than 
basal EDGl phosphorylation but was dramatically reduced from maximal S IP-induced 
EDGl phosphorylation. (86.1±2.5% reduction in SIP-induced EDGl phosphorylation 
versus maximal S IP-induced EDGl phosphorylation, p<0.05, n=3. Figure 4.9).
Using other examples of agonist-dependent GPCR phosphorylation, a potential 
candidate for the kinase involved in S IP-induced EDGl phosphorylation was a member of 
the GRK family. Purified forms of GRK2, representing the GRK2 subfamily of GRKs, 
and GRK5, representing the GRK5 subfamily were chosen to examine the role of GRKs in 
S IP-induced EDGl phosphorylation (Figure 4.10). An in vitro study using membranes 
from serum-starved CCL-3 9/mycEDGl cells incubated in the presence or absence of 
GRK2 or GRK5 showed that a strong S IP-induced EDGl phosphorylation was observed 
following incubation with GRK2 (n=3, Figure 4.11). However, no EDGl phosphorylation 
was observed in the presence of purified GRK5 (n=3, Figure 4.11). The purified forms of 
GRK2 and GRK5 were shown to be functional in a similar in vitro study using the light 
receptor, rhodopsin. A 15 min exposure of light induced receptor phosphorylation in the 
presence of both GRK2 and GRK5, suggesting that both forms were functional (Figure 
4.12, n-3). Therefore, SIP-induced EDGl phosphorylation is specific for GRK2 in vitro.
PMA-induced EDGl phosphorylation was then characterised and compared with 
S IP-induced receptor phosphorylation. A concentration-response of PMA-induced EDGl 
phosphorylation showed that this was concentration-dependent (EC50 =0.1 |iM, n=3, Figure
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4.13). Interestingly, a time course of PMA-induced phosphorylation showed that, in 
contrast to S IP-induced phosphorylation, there is a delayed onset of EDGl 
phosphorylation. Whereas S IP-induced EDGl phosphorylation is near maximal after I 
min, there appears to be a bi-phasic effect following IpM PMA exposure where receptor 
phosphorylation peaks at around 50% of maximal phosphorylation after 5 min, followed 
by a second phase towards maximal phosphorylation after lOmins (w=3. Figure 4.14).
The question remained whether or not S IP-induced EDGl phosphorylation was 
PKC dependent. In other words, could SIP activate PEG that could, in turn, increase 
intracellular calcium and activate DAG. This would result in PKC activation, causing 
EDGl phosphorylation (Figure 4.15). In order to address this point, whole cell 
phosphorylation assays were carried out where serum-starved CCl-39/myc-EDGl cells 
were treated with vehicle, lOpM SIP or ljuM PMA in the presence or absence of 5p,M 
GFI09203X, an inhibitor of conventional and novel PKC subtypes (Martiny-Baron et al., 
1993; Way et al., 2000). Figure 4.16 shows that, in the absence of GF109203X, there is a 
strong S IP-induced phosphorylation and a weaker, but still significant, PMA-induced 
EDGl phosphorylation, as described before. However, in the presence of GF109203X, the 
effect of PMA is virtually abolished (phosphorylation reduced by 78±8% versus vehicle- 
preincubated PMA-treated cells (set at 100%), p<0.05, n=3) whereas S IP-induced receptor 
phosphorylation is barely affected (phosphorylation reduced by 18±10%, p<0.05, n=3) 
(Figure 4.16). This suggests that two phosphorylation pathways exist: an SIP, agonist- 
dependent pathway and an agonist-independent phosphorylation pathway, mediated by 
PKC.
PMA-induced EDGl phosphorylation was then examined in the presence or 
absence of Go6976, an inhibitor of conventional PKC subtypes and rottlerin, an inhibitor 
of novel PKC subtypes, primarily PKC5, (Martiny-Baron et a l, 1993; Gschwendt et a l, 
1994) in order to elucidate the subtypes of PKC involved in EDGl phosphorylation . 
Figure 4.17 shows a preincubation with 5|aM GFX inhibits PMA-induced EDGl 
phosphorylation by 90.3+2.3% (versus maximal PMA-induced receptor phosphorylation 
(set at 100%), /7<0.05, «=3). However, preincubation with Go6976 resulted in a reduction 
in PMA-induced phosphorylation of 47,6±1.5% (versus maximal PMA-induced receptor 
phosphorylation (set at 100%), /?<0.05, n=3) and preincubation with rottlerin reduced 
PMA-induced EDGl phosphorylation by 58.6±8.1% (versus maximal PMA-induced 
receptor phosphorylation (set at 100%), p<0.05, n=3), suggesting the involvement of
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typical and atypical subtypes of PKC (Figure 4.17). In addition, the effects of Go6976 and 
rottlerin were shown to be additive. Preincubation of Go6976 and rottlerin together 
reduced PMA-induced receptor phosphorylation by 85.1+8.6% {versus maximal PMA- 
induced receptor phosphorylation, p<0.05, w=3), reinforcing the suggestion that both 
groups of PKC subtypes are involved in PMA-induced EDGl phosphorylation (Figure 
4.18). However, despite an additive effect being observed following incubation with 
Go6976 and rottlerin together, this was not significantly different to either Go6976 or 
rottlerin alone (p>0.05, N/S, w=3. Figure 4.18)
Since there are two distinct pathways of phosphorylation, it was possible that the 
effect of PMA and SIP on EDGl phosphorylation may involve different phosphorylation 
sites and could therefore be additive. To address this possibility, whole cell 
phosphorylation assays were carried out on CCL-39/mycEDGl cells either treated for 20 
mins with vehicle; pretreated for 10 minutes with IpM PMA, followed by a 10 minute 
treatment with lOpM SIP; pretreated with lOjiM SIP followed by a 10 min treatment of 
IpM PMA; or treated for 10 min with lOpM SIP and l|iM  PMA together. Figure 4.19 
shows that a 10 min pretreatment with IpM PMA, followed by a 10 minute treatment with 
lOjLiM SIP resulted in 89,8+8.2% receptor phosphorylation (versus maximal SIP-induced 
receptor phosphorylation (set at 100%), p>0.05, N/S, n=3). A 10 min treatment of lOjitM 
SIP and IjLiM PMA together induced 122+34% receptor phosphorylation (versus maximal 
SIP-induced receptor phosphorylation (set at 100%), p>0.05, N/S, n=3). A 10 minute 
pretreatment with lOjuM SIP followed by a 10 min treatment of IpM PMA resulted in 
127.4+17.5% receptor phosphorylation (versus maximal S IP-induced receptor 
phosphorylation (set at 100%), p>0.05, N/S, n=3). Therefore, all the treatments involving 
the addition of both SIP and PMA together resulted in a phosphorylation similar to EDGl 
phosphorylation in the presence of SIP alone. Hence, although SIP and PKC induce 
EDGl phosphorylation by distinct mechanisms, each pathway may involve the 
phosphorylation of overlapping sites within the EDGl receptor.
Previous studies have demonstrated that sphingosine kinase, the enzyme 
responsible for the conversion of sphingosine to sphingosine-1 -phosphate within cells, can 
be stimulated by phorbol esters such as PMA (Cuvillier et a l, 1996, Pyne and Pyne, 
2000a; Pyne and Pyne, 2000b). This could potentially increase the concentration of 
intracellular sphingosine-1 -phosphate, which in turn would be released into the 
extracellular space, and lead to an agonist-mediated phosphorylation of EDGl (Figure
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4.20). One of the most commonly used inhibitors of sphingosine kinase is 'D,h-threo- 
dihydrosphingosine (DHS). However, at high doses, DHS inhibits PKC subtypes in 
addition to sphingosine kinase. A previous study has shown that IpM DHS can inhibit 
sphingosine kinase activity (Kohama et al., 1998). Importantly, this concentration of DHS 
had no effect on PKC activation (Tolan et al., 1999), Figure 4.21 shows that, in a whole 
cell phosphorylation study, PMA treatment induced 93.5+12.5% EDGl phosphorylation in 
the presence of lp.M DHS (versus maximal PMA-induced EDGl phosphorylation (set at 
100%), p>0.05, N/S, n=3). Immunoblotting of PMA-dependent ERK activation was 
carried out in parallel to each whole cell phosphorylation study. These acted as a measure 
of PMA-stimulated PKC activity in the presence of DHS. Figure 4.22 demonstrates that 
IpM DHS had no significant effect on PKC activity (103.5±12.2% versus PMA-treated 
EDGl cells (set at 100%), p>0.05, N/S, n=3). This is consistent with previous studies 
(Tolan et al., 1999) and suggests that, at a concentration of lp,M, DHS selectively inhibited 
sphingosine kinase. However, because of the non-selective nature of DHS, this should be 
confirmed in future studies using other approaches, such as oligodeoxynucleotide anti­
sense against sphingosine kinase.
Other examples of GPCR phosphorylation, such as the P2AR, have shown that 
phosphorylation of the C-terminal tail is an important precursor for mechanisms of 
receptor desensitisation and internalisation (Ferguson, 2001: von Zastrow et a l, 1994; 
Goodman et a l,  1996). As shown in the previous Chapter, the lack of potential 
phosphorylation sites within the C-terminal tail of the AiAR was linked with receptor’s 
slow rate of internalisation. In contrast, the A3AR, which is Gj-coupled like the AiAR and 
exhibits similar biological effects, is rapidly internalised following phosphorylation of its 
C-terminal domain. Within the C-terminal tail of the EDGl receptor, there are a number 
of serine and threonine residues distal to the predicted sites for palmitate attachment 
(Figure 4.23). Therefore, a truncation mutant removing the last 51 amino acids of the C- 
terminal tail of the mycEDGl receptor was designed to remove all the potential 
phosphorylation sites within the EDGl C-terminal (Figure 4.24).
The mycEDGlA51 receptor was generated as described in the Materials And Methods 
Chapter and then stably expressed in CCL-39 hamster lung fibroblasts. Stable expression 
of the mycEDGlA51 receptor was confirmed by immunoblotting using 9E10 (Figure 25). 
Whole cell phosphorylation studies were then carried out using WT CCL-39/mycEDGl 
and CCL-39/mycEDGlA51 cells exposed to a 10 min treatment of vehicle, lOpM SIP or
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l|iM  PMA. Figure 4.26 shows that whereas the WT EDGl receptor is phosphorylated in 
the presence of SIP and PM A, neither SIP or PMA were able to stimulate phosphorylation 
of the truncated receptor (Figure 4.26, n=3). Hence, agonist-dependent and agonist- 
independent phosphorylation require the integrity of the last 51 amino acids.
As shown in Figure 4.11, EDGl is preferentially phosphorylated in vitro by GRK2 
rather than GRK5. Within the last 51 amino acids of the C-terminal of EDGl, there are 
two distinct clusters of potential serine/threonine phosphorylation sites, which can be 
removed by the truncation of the last 12 and the last 32 amino acids of the C-terminal of 
the mycEDGl receptor (Figure 4.23). Importantly, distinct clusters of these potential 
phosphorylation sites are located proximal to acidic amino acids, representing potential 
GRK2 phosphorylation sites (Ferguson, 2001). Therefore, the truncation mutants, 
mycEDGl A3 2 and mycEDGlA12 were generated to remove these potential GRK2 
phosphorylation sites (Figure 4.24). Expression of the mycEDGl A12 and mycEDGl A3 2 
receptors was confirmed by immunoblotting using the anti-myc antibody, 9E10 (Figure 
4.27). Wild type mycEDGl, mycEDGl A12 and mycEDGl A3 2 receptor cDNA constructs 
were then transfected into HEK 293 cells and the cells given a 10 minute exposure of 
either vehicle, lOjuiM SIP or IpM PMA in a whole cell phosphorylation study. Receptor 
phosphorylation quantitated using autoradiography was then normalised using a parallel 
blot of receptor expression. Truncation of the last 32 amino acids completely abolished 
both SIP- and PMA- induced phosphorylation. There was no significant difference 
between WTEDGl and EDG1A12 PMA-induced phosphorylation (28.9±5.4% versus 
PMA-induced WT mycEDGl phosphorylation (S IP-induced WT EDGl phosphorylation 
set at 100%), p<0.05, n=3,) (Figure 4.28). However, although S IP-induced 
phosphorylation is maintained following the truncation of the last 1 2  amino acids, maximal 
phosphorylation was significantly less when compared to WT EDGl S IP-induced EDGl 
phosphorylation (47.9±8.7% versus S IP-induced WT mycEDGl phosphorylation (set at 
100%), p<0.05, n=3,) (Figure 4.28).
As described above, SIP induces EDGl phosphorylation in vitro in the presence of 
purified GRK2. An in vitro study was therefore carried out on membranes of HEK293 
cells transfected with WTEDGl, EDG1A32 or EDG1A12 receptor cDNA constructs in 
order to examine the effect of removing the potential GRK2 phosphorylation sites more 
fully. In the presence of purified GRK2, no significant difference was observed between 
S IP-induced EDGl phosphorylation in membranes containing either WTEDGl or
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EDGA12 (Figure 4.29). In contrast, no significant S IP-induced phosphorylation was 
observed using EDGl A3 2-expressing membranes (Figure 4.29). Hence, truncation of the 
last 32 amino acids abolishes S IP-induced phosphorylation in the presence of purified 
GRK2 although phosphorylation is maintained following the truncation of the last 12 
amino acids within the EDGl C-terminal.
Discussion
An important regulatory process of GPCR signalling is receptor phosphorylation. 
In many cases, such as the P2AR and the A3AR, phosphorylation is regarded as the critical 
step necessary to observe both receptor desensitisation and internalisation (Ferguson, 2001; 
(Ferguson, 2001: von Zastrow et ah, 1994; Goodman et al., 1996). For example, the 
previous chapter has demonstrated that the AiAR’s inability to undergo receptor 
phosphorylation is associated with a relatively slow, incomplete loss of cell surface 
receptors following sustained agonist exposure. This chapter has characterised the 
phosphorylation of the SIP receptor, EDGl using a myc-tagged human EDGl receptor and 
a series of C-terminal truncation mutants.
In CCL-39 hamster lung fibroblasts, there is a strong, reversible, agonist-dependent 
phosphorylation of EDGl (Figures 4.7, 4.8 and 4.9). The EC50 value (1.9±0.4pM, Figure 
4.7) for SIP-induced EDGl phosphorylation related to the physiological range of SIP 
concentration in the blood which can reach )xM concentrations upon platelet activation 
(Pyne and Pyne, 2000). However, previous studies have shown that the Kd of SIP for the 
EDGl receptor is between S.lnM (Lee et ah, 1998) and 13.2 nM (Kon et ah, 1999). One 
reason for the differences between the observed EC50 value and the reported Kd values may 
be due to differences in the preparation of SIP between research groups. It should also be 
stressed that many of the biological responses of SIP, such as the mobilisation of Ca^  ^in 
HEK293 cells transfected with EDGl (Van Brocklyn et ah, 1998) and in the rat mast cell 
line RBL-2H3, require pM concentrations of SIP. Due to the unavailability of a reliable, 
radiolabelled form of SIP, it was not possible to carry out binding studies to determine the 
Kd of SIP for EDGl in relation to this set of experiments. Future measurement of the Kd 
for SIP would allow for a more accurate reflection of the calculated EC50 value in relation 
to the comparatively low published Kd value. A measured Kd value may also explain why 
S IP-induced phosphorylation does not mirror the agonist-occupation curve related to the 
published K d .
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SIP also induced EDGl phosphorylation in vitro using CCL-39/mycEDGl 
membranes in the presence of purified GRK2 (Figure 4.11). In contrast, no EDGl 
phosphorylation was observed in the presence of GRK5 (Figure 4.11). This suggests that 
SIP-induced EDGl phosphorylation may be mediated by GRK2. In addition to an 
agonist-mediated phosphorylation of EDGl, a weaker, but still significant, agonist- 
independent phosphorylation of EDGl that was mediated by PKC (Figure 4.16). Whereas 
agonist-dependent EDGl phosphorylation is a rapid process, with a significant 
phosphoryation observed after only 15 seconds (Figure 4.8), PKC-mediated EDGl 
phosphorylation is a more delayed process, with half-maximal phosphorylation only 
observed after 5 min (Figure 4.14). A role for PKC in GPCR phosphorylation and 
desensitisation has been demonstrated in other studies for a number of Gi-and Gq- linked 
GPCRs, including the aiB-adrenoceptor and the type 1A angiotensin II receptor (Diviani et 
al., 1997; Liang et al., 1998; Tang et al., 1998).
Interestingly, LPA exposure failed to induce EDGl phosphorylation (Figure 4.5a). 
This is in contrast to a previous study that showed that EDGl is a low-affinity receptor for 
LPA and that LPA increased EDGl phosphorylation (Lee et al., 1998). However, it has 
also been shown that LPA failed to elicit any biological effects in membranes of Sf9 cells 
co-expressing EDGl and Gn, whereas SIP was effective (Windh et al., 1999, Zondag et 
al., 1998). Other studies have not observed competition of [^^P]S1P binding by LPA (Lee 
et al., 1996; Van Brocklyn et al., 1999). Additionally, LPA did not function as an agonist 
for the murine analog of EDGl, Ip^i, when transfected into RH7777 cells (Zhang et a l, 
1999). One possible explanation for the LPA-induced phosphorylation observed by Lee et 
a l may be that LPA stimulated endogenous LPA receptors, such as EDG2. This could 
have resulted in an indirect phosphorylation of EDGl, possibly mediated by EDG2 
activation of PKC. Alternatively, the activation of endogenous LPA receptors by LPA 
may have induced the release of SIP which subsequently activated EDGl.
A series of PKC inhibitors were used in order to investigate the PKC subtypes 
involved in EDGl phosphorylation. GF109203X, an inhibitor of conventional and novel 
PKC subtypes abolished PMA-induced EDGl phosphorylation (Figure 4.16). Both 
Go6976, an inhibitor of conventional subtypes, and rottlerin, an inhibitor of the novel PKC 
subtype, PKC5 inhibited PMA-induced EDGl phosphorylation by around 50% (Figure 
4.17). This suggested that both conventional and novel subtypes of PKC were involved. 
However, significant inhibition of PMA-induced EDGl phosphorylation was only
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observed at doses of lOOjiM. At this dose, it is known that, in addition to inhibiting PKC5, 
rottlerin also inhibits conventional subtypes as well as other protein kinases such as casein 
kinase II (Way et a l, 2000). Hence, the inhibition observed with rottlerin may be, at least 
in part, due to a kinase other than PKC. Future work should therefore be aimed at the 
possible role of other kinases in PMA-induced EDGl phosphorylation such as casein 
kinase II. Interestingly, a potential site of casein kinase II phosphorylation was identified 
within the area of the EDGl C-terminus implicated in the process of receptor 
internalisation (Liu et ah, 1999). However, casein kinase II is constitutively active and 
would therefore be unlikely to be involved in agonist-dependent processes of 
phosphorylation and desensitisation.
This Chapter has demonstrated that PMA-induced phosphorylation was not the 
result of an increase in intracellular SIP production (Figure 4.21). In addition, SIP- and 
PMA- mediated EDGl phosphorylation are not additive (Figure 4.19). This suggests that, 
although SIP and PMA regulate EDGl phosphorylation by distinct mechanisms, they may 
ultimately be competing for overlapping phosphorylation sites. Phosphoamino acid 
analysis of EDGl demonstrated that SIP and PMA incerased incorporation of phosphate 
into serine and threonine residues (Figure 4.6). In order to narrow down the region of 
phosphorylation within EDGl, a series of EDGl truncation mutants removing clusters of 
potential Ser/Thr phosphorylation sites were analysed. Importantly, both these sites are 
situated proximal to acidic residues, making them potential targets for aciditrophic kinases 
such as GRK2 (Ferguson, 2001) (Figure 4.23). PMA-induced EDGl phosphorylation was 
abolished by the truncation of the last 32 amino acids but was unaffected by the truncation 
of the last 12 amino acids (Figure 4.28). SIP-mediated EDGl phosphorylation was also 
abolished by the truncation of the last 32 amino acids and was significantly attenuated 
following the truncation of 12 amino acids (Figure 4.28). This suggests that residues 
within the last 12 amino acids, as well as residues between the last 32 and the last 12 
amino acids, are involved in S IP-mediated EDGl phosphorylation. In contrast, PMA- 
induced EDGl phosphorylation did not involve the last 12 amino acids of the C-terminal. 
This provides further evidence that SIP- and PMA- induced EDGl phosphorylation occurs 
via distinct mechanisms. In addition, GRK2-dependent SIP-mediated phosphorylation in 
the membranes HEK293 cells transfected with mycEDGl is abolished by the truncation of 
the last 32 amino acids but is maintained following the truncation of the last 12 amino
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acids, suggesting that GRK2-mediated EDGl phosphorylation is located between the last 
12 and the last 32 amino acids of the C-terminal domain of EDGl (Figure 4.29).
Interestingly, truncation of the last 12 amino acids had no significant effect on 
PMA-induced EDGl phosphorylation. Figure 4.23 illustrates that the only threonine 
present within the C-terminus is removed following truncation of the last 12 amino acids. 
However, the phosphoamino acid analysis shows that PMA phosphorylates both serine and 
threonine residues. One other possible target of phosphorylation, therefore, may be 
threonine 236 within the third intracellular loop of EDGl, which also conforms to a 
consensus PKC phosphorylation site. A recent study has implicated this residue in the 
Akt-mediated phosphorylation of EDGl and have shown a role for this phosphorylation in 
SIP-induced Rac activation, chemotaxis and angiogenesis (Lee et aL, 2001). However, 
truncation of the last 32 amino acids abolished both agonist-dependent and agonist- 
independent EDGl phosphorylation. It should be recognised that one possibility that may 
explain the differences in EDGl phosphorylation between the wild type and the truncated 
forms of the receptor could be the loss or disruption of relevant potential kinase docking 
domains for kinases such as GRK2. This also raises the question of whether truncation of 
the C-terminal should affect phosphorylation of residues within the third loop, perhaps 
through changes within the structure of EDGL Therefore, future studies should be aimed 
at more restricted site-directed mutagenesis studies, particularly within the last 32 amino 
acids.
The existence of a mechanism of EDGl phosphorylation which is independent of 
agonist suggests that EDGl phosphorylation can potentially be regulated by signalling via 
other receptors through the activation of PKC. Since EDGl plays an important role in 
angiogenesis, many of the receptors integral to the control of angiogenesis could 
potentially regulate EDGl phosphorylation. EDGl signalling has been shown to regulate 
and be regulated by a number of such receptors. For example, cell migration toward 
PDGF, which stimulates sphingosine kinase and increases intracellular SIP production, 
was dependent upon expression of EDGl (Hobson et al., 2001). Therefore, future work 
should be aimed at examining the role of cross-talk mechanisms between EDGl and other 
receptors, such as other EDG members and receptor tyrosine kinases for PDGF, VEGF and 
FGF2. Another possible candidate could be the angiopoietin receptors, Tiel and Tie2. As 
described previously, Tiel and Tie2 are receptor tyrosine kinases found solely within the 
epithelium that are critical for the communication of endothelial cells with the surrounding 
mesenchyme and are particularly important in blood vessel maturation (Jones et aL, 2001).
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Since the specific involvement of EDGl in blood vessel maturation has recently been 
established, cross-talk between EDGl and Tiel and Tie2 signalling represents a potentially 
important area of future research.
In conclusion, EDGl phosphorylation is regulated by two independent 
mechanisms: 1) an agonist-dependent mechanism acting via GRK2 in vitro and 2) an 
agonist-independent mechanism regulated by the activation of PKC. The sites of 
phosphorylation for both regulatory mechanisms of EDGl phosphorylation are located 
within the last 32 amino acids of the C-terminal tail of EDGl. Future work should be able 
to elucidate the sites of phosphorylation more fully using site-directed mutagenesis. The 
discovery of two regulatory pathways of EDGl phosphorylation implies that EDGl may 
be regulated through signalling via other receptors through the activation of PKC. This has 
potential significance in terms of EDGl regulation in the context of receptor internalisation 
and also in physiological processes such as angiogenesis.
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Figure 4.1: Schematic Diagram Of The Mvc-tagged Human EDGl Receptor
A myc epitope (orange) containing 6 histidine residues (blue) was added to the C-terminus 
of the human EDGl receptor using pcDNA/EDGl as a template. The sense primer 
incorporated a Hindlll site upstream of a consensus Kozak sequence and the EDGl 
initiating methionine, as indicated. The diagram also shows that the antisense primer was 
designed to remove the EDGl stop codon and add an Xbal site. This allowed in-frame 
ligation of the EDGl coding region with that of the myc-His epitope tag following ligation 
of the Hindlll/Xbal-digested PCR product with a similarly digested pcDNAS.l/ myc-HisA 
vector.
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Figure 4.2: Immunoblot Analysis Of The Mvc-Tagged Human EDGl Receptor
CCL-39 fibroblasts stably expressing the mycEDGl receptor were solubilised in 
electrophoresis sample buffer and analysed by SDS-PAGE and immunoblotting using the 
anti-myc 9E10 monoclonal antibody.
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Figure 4.3: Effect Of Increasing SSP Concentrations On ERK Activation In CCL-39 
and CCL-39/MvcEDGl Cells
Serum-starved paiental and mycEDGl expressing CCL-39 cells were stimulated for 10 
min with increasing concentrations of SSP. Endogenous ERKl was then 
immunoprecipitated from soluble cell extracts for immune-complex kinase assay of ERKl 
activity using MBP as the substrate as described in the Methods section. Quantification of 
^^ P incorporation into MBP was deteimined by phosphorimaging. Data represents the 
mean ± SEM of three similai* experiments. SSP produced a 6-10 fold activation of ERK 
(EC5o=0.4|.iM) in mycEDGl-expressing, but not parental, CCL-39 cells.
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Figure 4.4: Effect Of SSP And A Range Of Activators Of Second Messenger Kinases 
On The Phosphorylation Of The Human Mvc-EDGl Receptor
Serum-starved CCL-39/mycEDGl cells were treated for 10 min at 37°C with lOjiM of the 
agonist, SSP and a range of second messenger activators; l|iM  phorbol 12-myristate 13- 
acetate (PMA), an activator of PKC; 10p,M A23187, a calcium ionophore; 10p,M 
Forskolin, an activator of adenylyl cyclase and 100|iM 8-bromo-cGMP, an activator of 
cGMP. The cells were then solubilised for analysis of EDGl phosphorylation by 
immunoprécipitation followed by SDS-PAGE and phosphorimaging. Typical data is 
shown from one of three experiments.
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Figure 4.5a: Comparison Of The Effects Of SSP And LPA On EDGl 
Phosphorylation
^^P-labelled serum stai'ved stably transfected CCL-39/mycEDGl cells were treated with 
either vehicle, 10|liM SSP, l|LtM PMA or lOOjiiM LPA for 10 minutes or with lOOjiiM LPA 
for 30minutes at 37°C. The cells were then solubilised for analysis of EDGl 
phosphorylation by immunoprécipitation followed by SDS-PAGE and phosphorimaging. 
Phosphorylation of CCL-39/mycEDGl cells treated with SIP was set at 100% and results 
from other treatments were expressed as a ratio of the control. The data represents the 
mean ± SEM of three similar experiments. * Denotes a significant decrease (p<0.05) 
versus the level of phosphorylation observed for SSP-induced WT EDGl phosphorylation. 
SSP and PMA both result in phosphorylation of the receptor, with SSP resulting in the 
strongest stimulation. LPA, however, failed to induce phosphorylation, even after a 
100|liM, 30 minute exposure.
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Figure 4.5b: Comparison Of The Effects Of SSP And LPA On EDG2 
Phosphorylation
The mycEDG2 receptor construct was transiently transfected into HEK293 cells. The cells 
were subsequently serum-starved, labelled with ^^P-orthophosphate and then treated with 
either vehicle, lOpM SSP, IpM PMA, lOOpM LPA or the Ca^ "^  ionophore, A23187 for 15 
minutes at 37°C. The cells were then solubilised for analysis of EDG2 phosphorylation by 
immunoprécipitation followed by SDS-PAGE and phosphorimaging. Parallel immunoblot 
analysis of each sample was carried out for each phosphorylation study using the 9E10 
antibody in order to normalise receptor phosphorylation with receptor expression. A 
strong, LPA-dependent EDG2 phosphorylation was observed, demonstrating that were no 
discrepancies in the integrity of the stock LPA used in Figure 4.5a. Typical data is shown 
from one of three experiments.
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Figure 4.6; Phosphoamino Acid Analysis Of The Human Mvc-EDGl Receptor
Serum-starved CCL-39/myc-EDGl cells were treated with either 20jiiM SIP or IpM PMA 
for lOmins at 37“C. The samples were then immunoprecipitated, ran on SDS-PAGE and 
transfeiTed to a PVDF membrane. The region of membrane containing the EDGl receptor 
was then excised, hydrated and hydrolyzed with acid. Phosphorylated amino acids were 
visualised using chromatography by ninhydrin staining and ^^P-labelled amino acids 
visualised by autoradiography. The autoradiograph shows that both SIP and PMA 
treatment result in the phosphorylation of serine and threonine residues.
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Figure 4.7; Effect Of Increasing SSP Concentrations On EDGl Phosphorylation
^^P-labelled serum-stai'ved stably transfected CCL-39/mycEDGl cells were treated with 
vehicle or increasing concentrations of SSP for 5 minutes at 37°C. The cells were then 
solubilised for analysis of EDGl phosphorylation by immunoprécipitation followed by 
SDS-PAGE and phosphorimaging. Maximal SSP-induced EDGl phosphorylation was set 
at 100% and the results from other treatments expressed accordingly. These data represent 
the mean ± SEM of three similar experiments. The results show that SSP-induced EDGl 
phosphorylation is concentration-dependent ( E C 5 0  =1.9±0.37|xM).
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Figure 4.8: Time-Course Of SSP-induced EDGl Phosphorylation
^^P-iabelled serum starved stably transfected CCL-39/mycEDGl cells were treated 
with either vehicle or iOjuM SSP at 37°C for the times indicated in the graph. The cells 
were then solubilised for analysis of EDGl phosphorylation by immunoprécipitation 
followed by SDS-PAGE and phosphorimaging. Maximal SSP-induced EDGl 
phosphorylation was set at 100% and the results from other treatments were expressed as a 
ratio of the control. These data represent the mean ± SEM of three similar experiments. 
SSP-induced EDGl phosphorylation is a rapid process, with a significant phosphorylation 
observed after 15 seconds and is maximal after 10 minutes.
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Figure 4.9: Effect Of SSP Removal On SSP-induced EDGl Phosphorylation
^^P-labelled serum starved stably transfected CCL-39/mycEDGl cells were treated with 
either vehicle or lOp-M SSP at 37°C for 30 minutes. Agonist was subsequently removed 
for 15, 30, 60 or 120 minutes. The cells were then solubilised for analysis of EDGl 
phosphorylation by immunoprécipitation followed by SDS-PAGE and phosphorimaging. 
Maximal SSP-induced EDGl phosphorylation was set at 100% and the results from other 
treatments were expressed as a ratio of the control. These data represent the mean ± SEM 
of tiiree similai- experiments. * Denotes a significant decrease (p<0.05) versus the level of 
phosphorylation observed for SSP-induced WT EDGl phosphorylation. The graph shows 
that SSP-induced EDGl phosphorylation is a reversible process with a significant 
reduction in EDGl receptor phosphorylation observed after 30 minutes of agonist removal. 
After 2 hours of agonist removal, EDGl phosphorylation is close to basal levels.
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Figure 4.10: Schematic Of The G-Protein Receptor Kinase (GRK) Family
The GRK family of kinases is comprised of 7 members. Each kinase selectively 
phosphorylates agonist-activated receptors, facilitating the binding of cytosolic cofactor 
proteins called anestins, which not only uncouple receptors from heterotrimeric G-proteins 
but also targets many GPCRs for internalisation via clathrin-coated pits. The family is 
subdivided into 3 catagories based on sequence and functional homology: - 1) GRKl 
(rhodopsin kinase) and GRK7 (a new candidate cone opsin kinase); 2) GRK2 (g- 
adrenergic receptor kinase 1, |3ARK1) and GRK3 (P-adrenergic receptor kinase 2, 
PARK2); and 3) GRK4, GRK5 and GRK6. Since both GRKl and GRK7 are highly 
specific, they were unlikely to have a role in agonist-dependent phosphorylation of EDGl. 
Therefore, to examine the role of GRKs in S IP-induced EDGl phosphorylation, GRK2 
and GRK5 were chosen to represent ubiquitously expressed members of the 2'^ '^  and 3^  ^
subfamilies.
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Figure 4.11; Effects OF GRK2 And GRK5 On SIP-Induced EDGl Phosphorylation
In Vitro
Membranes from serum-starved CCL-39/mycEDGl cells were incubated with ATP
in the presence or absence of 20|iM SSP alone or in the presence of either 50nM purified 
GRK2 or GRK5 at 37°C. These data represent the mean ± SEM of three similar 
experiments. * Indicates a significant increase (p<0.05) versus the level of phosphorylation 
observed in the absence of agonist. SSP-induced phosphorylation of EDGl occurs in the 
presence of GRK2 but there is no phosphorylation in the absence of GRK or in the 
presence of GRK5, indicating a specific role for GRK2 in SSP-induced EDGl 
phosphorylation in vitro.
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Figure 4.12: Effects Of GRK2 And GRK5 On Light-Stimulated Rhodopsin 
Phosphorylation In Vitro
Urea-treated bovine rod outer segments were incubated either in the dark or illuminated in 
the absence or presence of GRK2 or GRK5. Reactions were stopped by the addition of 
SDS-PAGE sample buffer prior to analysis of light-stimulated rhodopsin phosphorylation 
by SDS-PAGE and autoradiography. A strong light-dependent phosphorylation was 
detectable in the presence of both GRK2 and GRK5, showing that the purified forms of 
GRK2 and GRK5 were both active under the m vitro phosphorylation assay conditions. 
Typical data is shown from one of three experiments.
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Figure 4.13: Effect Of Increasing Concentrations Of PMA On EDGl Phosphorylation
^^P-labeiled serum-starved stably transfected CCL-39/mycEDGl cells were treated with 
either vehicle or increasing concentrations of PMA for 10 minutes at 37°C. The cells were 
then solubilised for analysis of EDGl phosphorylation by immunoprécipitation followed 
by SDS-PAGE and phosphorimaging. Maximal PMA-induced EDGl phosphorylation was 
set at 100% and the results from other treatments were expressed as a ratio of the control. 
These data represent the mean ± SEM of three similar experiments. There is a 
concentration dependent PMA-induced EDGl phosphorylation (EC5o= 0.1 jiM)
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Figure 4.14; Time-Course Of PMA-induced EDGl Phosphorylation
^^P-labelled serum starved stably transfected CCL-39/mycEDGl cells were treated with 
either vehicle or IjuM PMA at 37°C for the times indicated in the graph. The cells were 
then solubilised for analysis of EDGl phosphorylation by immunoprécipitation followed 
by SDS-PAGE and phosphorimaging. Maximal PMA-induced EDGl phosphorylation was 
set at 100% and the results from other treatments expressed accordingly. The data 
represents the mean ± SEM of three similar experiments.
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Figure 4.15; Schematic Of The Potential Role Of PKC In SIP-Induced EDGl 
Phosphorylation
The question remained whether or not S IP-induced EDGl phosphorylation was PKC 
dependent. In other words, could SIP activate PLC which could, in turn, increase both 
intracellular calcium and DAG levels. This would result in PKC activation, causing EDGl 
phosphorylation. To investigate this, SIP- and PMA- induced EDGl phosphorylation was 
measured in the presence of the PKC inhibitor, GF109203X.
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Figure 4.16: Effect Of An Inhibitor Of Conventional And Novel PKC Subtypes On 
SIP- And Protein Kinase C-Induced EDGl Phosphorylation
^^P-labelled semm-starved stably transfected CCL-39/mycEDGl cells were preincubated 
with vehicle or 5pM of the PKC inhibitor, GF109203X (GFX) for 30 min. The cells were 
then incubated for 10 min in the absence of ligand or in the presence of lOpM SSP or IpM 
PMA. All drug treatments were earned out at 37*^ C. The cells were analysed by 
immunoprécipitation followed by SDS-PAGE and phosphorimaging. Maximal SSP- 
induced EDGl phosphorylation was set at 100% and the results from other treatments were 
expressed as a ratio of the control. These data represent the mean ± SEM of three similar 
experiments. * Denotes a significant inhibition (p<0.05) between GFX-preincubated 
PMA-treated cells and vehicle-preincubated PMA-treated cells. \|/ Indicates a significant 
inhibition (p<0.05) between GFX-preincubated SSP treated cells and vehicle-preincubated 
SSP-treated cells.
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Figure 4.17: Effect Of Inhibitors Of Conventional And Non-Conventional PKC 
Subtypes On PMA-induced EDGl Phosphorylation
^^P-Iabelled serum-starved stably transfected CCL-39/mycEDGl cells were preincubated 
for 30 min at 37“C with vehicle or 5p,M GF109203X (GFX), an inhibitor of conventional 
and novel PKC isoform; 10p,M Go6976, an inhibitor of conventional PKC isoforms or 
lOOfiM rottlerin, an inhibitor of novel PKC isoforms, particularly PKCÔ. The cells were 
then incubated at 37°C for 10 min with vehicle or in the presence of lp.M PMA. The cells 
were analysed by immunoprécipitation followed by SDS-PAGE and phosphorimaging. 
Maximal PMA-induced EDGl phosphorylation was set at 100% and the results from other 
treatments were expressed as a ratio of the control. The data represents the mean ± SEM 
of three similar experiments. * Indicates p<0.05 versus phosphorylation observed in PMA- 
treated cells. \{/ Indicates p<0.05 versus inhibition produced by GF109203X. 5jiM 
GF109203X pretreatment abolishes PMA-induced EDGl phosphorylation, whereas an 
approximately half-maximal reduction in PMA-induced phosphorylation was observed 
following a preincubation with either Go6976 or rottlerin. This suggests that conventional 
and novel subtypes of PKC are involved in the PMA-induced phosphorylation of EDGl.
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Figure 4.18: Effect Of Inhibitors Of Conventional And Novel PKC subtypes On 
PMA-induced EDGl Phosphorylation
^^P-Iabelled serum-starved stably transfected CCL-39/mycEDGl cells were preincubated 
at 37"C for 30 min with vehicle or lOpM Go6976, an inhibitor of conventional PKC 
isoforms or lOOjaM rottlerin, an inhibitor of novel PKC isoforms, particularly PKCô either 
alone or together. The cells were then incubated for 10 min in the absence of ligand or in 
the presence of IjiiM PMA. The cells were analysed by immunoprécipitation followed by 
SDS-PAGE and phosphorimaging. Maximal PMA-induced EDGl phosphorylation was 
set at 100% and the results from other treatments were expressed as a ratio of the control. 
The data represents the mean ± SEM of three similar experiments. * denotes a significant 
difference versus PMA-treated cells. ~ indicates a siginificant difference versis Go6976- 
pretreated cells. # indicates a significant difference between rottlerin-pretreated cells.
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Figure 4.19: SIP- And PMA-induced EDGl Phosphorylation Are Not Additive
^^P-labelled serum-stai'ved stably transfected CCL-39/mycEDGl cells were exposed to 
either a 10 min treatment of vehicle, 10)LiM SIP, 1|lIM PMA, or 10|iM SIP and IjiiM PMA 
together. In addition, cells were also either pretreated for 10 minutes with vehicle, IjxM 
PMA, or lOpM SIP together as indicated. All drug treatments were at 37°C. The cells 
were analysed by immunoprécipitation followed by SDS-PAGE and phosphorimaging. 
Maximal SIP-induced EDGl phosphorylation was set at 100% and the results from other 
treatments were expressed as a ratio of the control. The data represents the mean ± SEM 
of three similar experiments. * Denotes a significant difference versus S IP-treated cells. 
No significant differences were observed between EDGl phosphorylation following 
treatments with both SIP and PMA together compared with EDGl phosphorylation in the 
presence of SIP alone.
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Figure 4.20: Schematic Of The Potential Role Of PMA On The Release Of 
Intracellular SSP Via Activation Of Sphingosine Kinase
It is known that, as well as stimulating PKC subtypes, PMA can also activate sphingosine 
kinase, the enzyme responsible for the conversion of sphingosine to sphingosine-1- 
phosphate within cells. It is therefore possible that PMA-induced EDGl phosphorylation 
may be the result of an increase in intracellular SSP. The resultant SIP is then released, 
activating the extracellular EDGl receptor. To examine this, PMA-induced EDGl 
phosphorylation was observed following a preincubation with an inhibitor of sphingosine 
kinase, L-f/ugo-dihydrosphingosine (DHS).
141
(D
C
CO
o
D ) CD
c CO
s z 03
Q . c
CO
CO
X
Q
GO
"O
(D
0
CO
i S
CÜ
-C
o _
ÛL
CO
o
CO _ c
CO 0 _
Figure 4.21; Effect Of L-rfergo-Dihvdrosphingosine. An Inhibitor Of Sphingosine 
Kinase. On PMA-induced EDGl Phosphorylation
“^P-labelled serum-starved stably transfected CCL-39/mycEDGl cells were preincubated 
with either vehicle or l|iM  L-r/ireo-dihydrosphingosine (DHS) for 30 min. The cells were 
then exposed to either a 10 min treatment of vehicle or IfiM PMA. All treatments were 
carried out at 37°C. The cells were analysed by immunoprécipitation followed by SDS- 
PAGE and phosphorimaging. The data is presented as mean ± SEM of three similar 
experiments. * Denotes a significant difference (p<0.05) versus vehicle-preincubated 
PMA-treated cells. The presence of DHS had no significant effect on PMA-induced EDGl 
phosphorylation.
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Figure 4.22: Effect Of L-r/fz-eo-Dihydrosphingosine On PMA-Induced Stimulation Of
ERK
Samples of ^^P-labelled semm-stai*ved stably transfected CCL-39/mycEDGl cells from the 
experiments described in Figure 20 were solubilised in electrophoresis sample buffer and 
analysed by SDS-PAGE and immunoblotting with an anti-phospho-ERK monoclonal 
antibody. The data is presented as mean ± SEM of three similar experiments. * Denotes a 
significant difference versus vehicle-preincubated PMA-treated cells. DHS had no 
significant effect on PMA-induced ERK activation, suggesting that, at doses of IpM, 
dihydrosphingosine did not inhibit PKC activation by PM A.
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Figure 4.23: Schematic Diagram Of The Regulatory C-Terminal Domain Of The 
Human EDGl Receptor
The C-terminal region of many GPCRs, such as the p2-adrenergic receptor, is critical to the 
processes of receptor phosphorylation and internalisation. In the case of the human EDGl, 
the C-terminal tail contains thirteen potential serine/threonine phosphorylation sites distal 
of the three potential sites of palmitoylation. Truncation of the last 51 amino acids of the 
C-terminal domain (mycEDGlA51) removed all thirteen potential serine/threonine 
phosphorylation sites.
Additionally, there are two distinct clusters of potential serine/threonine phosphorylation 
sites which can be removed by the truncation of the last 12 (EDGlA12) and the last 32 
(EDGlA32) amino acids of the C-tei*minal. Each cluster is preceded by acidic amino acid 
residues, making both clusters potential sites of phosphorylation by the aciditrophic kinase 
GRK2 which was shown in Figure 11 to selectively phosphorylate EDGl in vitro.
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Figure 4.24; Schematic Of The MvcEDGlASl . MvDGlA32 And MvcEDGlA12 
Receptors
The human mycEDGl receptor was truncated using a human pcDNA3.1/human mycEDGl 
template. The sense primer was designed to anneal upstream of the Hindlll site (indicated) 
of the EDGl receptor. The same sense primer was used to for all three truncation mutants 
and was designed to anneal upstream of the HindlH site of the EDGl receptor, as indicated 
in the diagram. The antisense primers for each of the truncation mutant were designed to 
anneal either 12-, 32-, or 51 amino acids upstream of the EDGl C-terminal tail for the 
appropriate tmncation mutant and to add an Xbal site, as shown. Each receptor was then 
ligated into a pcDNA3.1/mycHisA vector at HindQl/Xbal to incorporate a myc tag 
(orange) with 6 histadine residues (blue) at the C-terminus.
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Figure 4.25: Celt Surface Expression Of MvcEDGl and MvcEDGlASl Receptors
CCL-39 cells stably expressing either the mycEDGl or mycEDGlA51 receptor were 
subjected to cell surface biotinylation and receptor immunoprécipitation using the anti-myc 
9E10 antibody as demonstrated in the Materials and Methods. The samples were then 
solubilised in electrophoresis sample buffer, transferred to nitrocellulose following SDS- 
PAGE and visualised by probing with HRP-streptavidin. This represents one of multiple 
experiments.
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Figure 4.26; Comparison Of The Effects SIP And PMA Exposure On The 
Phosphorylation Of The MvcEDGl And MvcEDGlASl
^^P“iabelled serum-stai'ved stably transfected CCL-39/MycEDGl and CCL39/mycEDGl 
truncated cells were exposed to either a 10 min treatment of vehicle, 10p,M SIP or IpM 
PMA at 37“C. The cells were then analysed by immunoprécipitation followed by SDS- 
PAGE and phosphorimaging. These data represent the mean ± SEM[ of three similar 
experiments. * Denotes a significant decrease (p<0.05) versus SIP-induced WT EDGl 
phosphorylation. ~ Denotes a significant decrease (p<0.05) versus PMA-induced WT 
EDGl phosphorylation. Statistical significance was determined using the one-way 
Analysis of Variance (ANOVA) Dunnett multiple comparisons test. The mycEDGl 
receptor is phosphorylated by SIP and PMA as described previously. However, truncation 
of the last 51 amino acids of the C-tenninal of EDGl abolished both SIP- and PMA- 
mediated EDGl phosphorylation.
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Figure 4.27: Immunoblot Analysis Of The MvcEDGl, MvcEDGlA12 And 
MvcEDGl A32 Receptors
I-ÎEK293 cells transiently expressing either the mycEDGl, mycEDGl A12 or 
mycEDGl A3 2 receptor were solubilised and then analysed by SDS-PAGE and 
immunoblotting with the anti-myc 9E10 monoclonal antibody. Tmncation of the C- 
terminal results in the EDGl receptor migrating faster down the SDS-PAGE gel, with the 
truncation of the last 32 amino acids resulting in the furthest migration. This reflects the 
decrease in molecular weight caused by truncation of the C-teraiinal tail.
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Figure 4.28: Comparison Of The Effects Of SSP And PMA Exposure On The 
Phosphorylation Of The MvcEDGl. MvcEDGlA32 And MvcEDGlA12 Receptors
Wild type EDGl, EDG1A32 and the EDG1A12 receptor constructs transiently transfected 
into HEK293 cells. The cells were then serum-starved, incubated with ^^P-orthophosphate 
and then given a 10 min treatment with vehicle, 10|a,M SSP or l|iM  PMA at 37°C. The 
cells were then analysed by immunoprécipitation followed by SDS-PAGE and 
phosphorimaging. Parallel immunoblot analysis of each sample was carried out for each 
phosphorylation study using the 9E10 antibody in order to normalise receptor 
phosphorylation with receptor expression (Figure 28a, panel B). Data is presented as the 
mean ± SEM of three similar experiments. * Denotes a significant decrease (p<0.05) 
versus SSP-induced WT EDGl phosphorylation. ~ Indicates a significant decrease 
(p<0.05) versus PMA-induced WT EDGl phosphorylation Both SSP- and PMA- induced 
phosphorylation were abolished with the 32 amino acid truncated mutant (Figure 29a, 
panel A and Figure 28b). Statistical significance was determined using the one-way 
Analysis of Variance (ANOVA) Dunnett multiple comparisons test
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Figure 4.29: Comparison Of The Effects Of GRK2 And GRK5 On SSP-lnduced 
Phosphorylation Of The MvcEDGl. MvcEDGlA32 And MvcEDGlA12 Receptors In
Vitro
Membranes prepared from serum-starved HEK293 cells transiently expressing either the 
WT, A12 or A32 mutated mycEDGl receptors were incubated with [y-^^P] ATP in the 
absence or presence of lOjuM SSP for 10 min and in the absence or presence of 50nM 
purified recombinant GRK2 or GRK5 at 37°C as indicated. Solubilised extracts were then 
prepared for receptor immunoprécipitation with 9E10 and analysis of receptor 
phosphorylation. Aliquots from each extract (4jig/lane) were also fractionated by SDS- 
PAGE for immunoblotting with 9E10 to normalise to receptor expression in each 
experimental condition. The data represents the mean ± SEM of 3 similar experiments. * 
Denotes a significant decrease (p<0.05) versus the level of phosphorylation observed for 
WT EDGl under the same conditions. Statistical significance was determined using the 
one-way Analysis of Variance (ANOVA) Dunnett multiple comparisons test.
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Chapter 5
Characterisation Of The Internalisation Of 
The Human EDGl Receptor
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Introduction
The process of GPCR internalisation represents an important aspect of receptor 
activity and regulation. For many GPCRs, receptor phosphorylation is a critical precursor 
to receptor internalisation. This has been described for many GPCRs, including the P2AR, 
the A3AR and the thrombin receptor, to name but a few (Ferguson, 2001; Palmer and 
Stiles, 1997; Xiao et aL, 1999). In most cases, receptor phosphorylation increases the 
receptor’s affinity for arrestin molecules, which uncouple the receptors from their 
associated G-proteins and also direct receptor trafficking by functioning as an adapter 
protein and targeting the receptors to clathrin-coated vesicles from where the receptor is 
sequestered into the cell (Giadarov et aL, 1999; Miller and Lefkowitz, 2001; Pierce and 
Lefkowitz; 2001). This process of GPCR internalisation is thought to promote 
dephosphorylation of receptors by bringing them near to an endosome-associated 
phosphatase (Di Fiore and De Camilli, 2001; Ferguson, 2001). Dephosphorylation and 
subsequent recycling of receptors back to the plasma membrane contributes to a reversal of 
the desensitised state (resensitisation), which is required for full recovery of cellular 
signalling potential following agonist withdrawal (Di Fiore and De Camilli, 2001; Krueger 
et aL, 1997; Cao et al; 1998). Alternatively, the internalised receptor can be targeted to 
lysosomes where the receptor is degraded (Di Fiore and De Camilli, 2001; Ferguson, 
2001).
The importance of receptor phosphorylation on receptor internalisation has been 
outlined in Chapter 3 where the loss of cell surface adenosine A% receptor following 
agonist exposure was slow (ti/2=90 min) compared to the A3 receptor (t]/2=19 min). This 
difference was attributed to the lack of phosphorylation observed with the Ai receptor in 
comparison to the rapidly phosphorylated A3 receptor. As described in the previous 
Chapter, EDGl is phosphorylated in the presence of agonist and also in an agonist- 
independent manner, through the activation of PKC. Both regulatory mechanisms of 
EDGl phosphorylation involve phosphorylation of serine and threonine residues within the 
last 32 amino acids of the C-terminal tail. A previous study has also shown that the EDGl 
receptor tagged with GFP is internalised following a 2 hour exposure of SIP (Lee et aL, 
1998).
In this Chapter, the internalisation of the myc-tagged human EDGl receptor stably 
expressed in CCL-39 hamster lung fibroblasts was characterised using cell surface 
biotinylation and confocal microscopic analysis. The relationship between EDGl receptor
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phosphorylation and receptor internalisation was also investigated using the previously 
demonstrated EDGl C-terminal truncation mutants.
Results
CCL-39 cells stably expressing the human mycEDGl receptor, as described in the 
previous Chapter, represents a good model in which to characterise EDGl internalisation. 
Cell surface receptor biotinylation was carried out on CCL-39/mycEDGl cells exposed to 
a range of SIP concentrations. Figure 5.1 shows that there is a concentration-dependent 
loss of mycEDGl receptor from the cell surface (IC5o=0.24|iM, n=3), with a maximal loss 
of 75 ± 16% following a 2 hour 40pM SIP exposure (versus vehicle-treated CCL- 
39/mycEDGl cells (set at 100%), p<0.05, n=3). Cell surface biotinylation assays of CCL- 
39/mycEDGl over a 2 hour time-course of 10|xM SIP treatment demonstrated that loss of 
cell surface mycEDGl is a fairly rapid process (ti/2=15mins, n=3), with a total loss of 70 ± 
3% cell surface EDGl receptors observed after 2 hours (versus vehicle-treated CCL- 
39/mycEDGl cells (set at 100%), p<0.05, n=3) (Figure 5.2). Interestingly, 10p,M SIP- 
induced EDGl internalisation was also shown to be an irreversible process. A 30 minute 
exposure of lOjitM SIP resulted in a loss of 51± 8% of cell surface mycEDGl as compared 
with vehicle-treated EDGl cells (set at 100%, p<0.05, n=3) (Figure 5.3). However, no 
significant difference in mycEDGl cell surface expression was observed following agonist 
removal for 2 hours (68±10% reduction in total cell surface mycEDGl expression (set at 
100%) versus agonist-treated CCL-39/mycEDGl cells, p>0.05, N/S, n=3) (Figure 5.3). 
Interestingly, an immunoblot analysis of total mycEDGl receptor expression on CCL- 
39/mycEDGl cells treated with vehicle or lOjaM SIP for 24 hours showed that there is no 
significant decrease in total mycEDGl receptor expression following a chronic SIP 
exposure (92+5% versus vehicle-treated EDGl cells (set at 100%), p>0.05, N/S, n=3) 
(Figure 5.4).
As described in the previous Chapter, EDGl is phosphorylated in the presence of 
SIP and PMA via distinct mechanisms. It was therefore important to examine whether 
PMA-induced EDGl phosphorylation resulted in EDGl internalisation and if so whether 
this was also via a mechanism distinct from S IP-induced internalisation. Thus, a cell 
surface biotinylation assay was carried out on CCL-39/mycEDGl cells exposed for 2 hours 
with either vehicle, lOjuM SIP or Ip-M PMA in the presence or absence of a 30 min 
pretreatment with 5|LiM  GF109203X, an inhibitor of conventional and novel PKC subtypes
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(Way et al., 2000; Martiny-Baron et a l, 1993). Figure 5.5 shows that, in the absence of 
GF109203X, SIP induced a 46% loss of cell surface EDGl receptors (versus vehicle- 
treated CCL-39/MycEDGl cells (set at 100%), p<0.05, n=3) whereas PMA exposure 
resulted in a significantly smaller reduction in mycEDGl cell surface expression (25 ± 5%, 
significantly less (p<0.05) than SIP-mediated effect, n=3). Preincubation with 
GF109203X abolished the PMA-induced effect (100+14% mycEDGl cell surface 
expression versus vehicle-treated mycEDGl cell surface expression (set at 100%), p<0.05, 
n=3), whereas S IP-induced internalisation was unaffected (45±14% loss of mycEDGl cell 
surface expression versus vehicle-treated CCL-39/mycEDGl cells, p<0.05, n=3), 
suggesting the existence of two distinct pathways of receptor internalisation (Figure 5.5).
In order to visualise SIP- or PMA- induced changes in EDGl receptor trafficking, 
a mycEDGl-GFP construct was generated and stably expressed in CCL-39 hamster lung 
fibroblasts as described in the Methods section (Figure 5.6). Stable expression of the 
mycEDGl-GFP receptor was confirmed by immunoblotting using the anti-myc 
monoclonal antibody 9E10 and a monoclonal anti-GFP antibody (Figure 5.7). Both 
receptors were shown to be expressed at similar levels as visualised by the 9E10 antibody. 
Incubation with the anti-GFP antibody selectively identified the EDGl-GFP protein. The 
observed difference in molecular mass between the wild type EDGl receptor and the 
EDGl-GFP receptor (around 28kDa) was due to the GFP tag. Having confirmed that the 
mycEDGl receptor was GFP-tagged, it was important to determine whether the addition of 
the GFP tag influenced mycEDGl receptor function. Thus, a whole cell phosphorylation 
study was carried out on CCL-39/mycEDGl and CCL-39/mycEDG 1 -GFP cells in the 
presence of a 10 min treatment of vehicle, 10p,M SIP or l^iM PMA. A strong, SIP- 
induced phosphorylation and a weaker, but still significant, PMA-induced phosphorylation 
was observed with both the wild type EDGl and EDGl-GFP receptors (Figure 5.8). This 
indicated that GFP tagging of the EDGl receptor had no discernable effect on its ability to 
be phosphorylated by SIP or PMA. The CCL-39/mycEDG 1 GFP cell line therefore 
represented a relevant model in which to study changes in the trafficking of the EDGl 
receptor following exposure to agonist and PMA.
In order to visualise the changes in agonist-dependent changes in Edgl receptor 
trafficking demonstrated with the cell surface labelling assays, CCL-39/mycEDGlGFP 
cells were then exposed to lOpM SIP over a 2 hour time course. The cells were then 
fixed, mounted on coverslips and examined by confocal microscopy. A 2 hour treatment
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of lOpM SIP results in a significant translocation of mycEDGl-GFP from the cell surface 
into distinct punctate intracellular vesicles within the cytoplasm. The formation of 
intracellular pools of mycEDGl GFP was observed after only 15 min. After 30 min, there 
was a significantly larger movement of mycEDGl GFP from the cell surface into the 
cytoplasm (Figure 5.9). These data correlate with the cell surface biotinylation 
experiments, with cell surface loss observed after 15 mins and the greatest loss of cell 
surface EDGl observed following 30 minutes of 10|iM SIP treatment. Following 2 hours 
of agonist exposure, a large quantity of receptor protein has translocated from the cell 
surface into the cytoplasm.
As shown in Figure 5.5, there is a small, but still significant, loss of mycEDGl 
receptor from the cell surface following a 2 hour treatment of lp.M PMA and that this 
process is distinct from S IP-induced EDGl internalisation. CCL-39/mycEDGlGFP cells 
were therefore given a 2 hour treatment with vehicle, lOfxM SIP or l^iM PMA to visualise 
any differences in EDGl receptor trafficking between SIP- and PMA- induced EDGl 
internalisation. The cells were then fixed, mounted on coverslips and examined by 
confocal microscopy. A 2 hour exposure to 10|iM SIP resulted in a significant 
redistribution of EDGl from the cell surface into punctate vesicles within the cytoplasm. 
In contrast, no significant translocation of EDGl was observed following a 2 hour 
treatment with IjuM PMA. One possibility is that the loss of cell surface EDGl receptor 
observed with the biochemical cell surface assays may be the result of EDGl moving into 
distinct plasma membrane compartments, in which the receptor becomes inaccessible to 
biotin hydrazide used for labelling (Figure 5.10). Therefore, while SIP and PMA exposure 
both result in the loss of EDGl from the cell surface, the extent and nature of each type of 
EDGl re-distribution are distinct.
As described in the previous chapter, truncation of the last 51 amino acids within 
the C-terminal tail of EDGl abolishes both SIP- and PMA- induced receptor 
phosphorylation (Figure 4.26). Since phosphorylation is often a crucial determinant in 
GPCR internalisation (Ferguson, 2001; Palmer and Stiles, 1997; Xiao et al., 1999), it was 
therefore important to investigate the effect of how this truncation might affect EDGl 
internalisation. The mycEDGlA51 receptor was GFP-tagged and stably expressed in 
CCL-39 cells to visualise the effect of a non-phosphorylated EDGl receptor on receptor 
trafficking (Figure 5.11). Figure 5.12 shows an immunoblot analysis of the mycEDGl- 
GFP, mycEDGlA51, and mycEDG 1A51 -GFP receptors each stably expressed in CCL-39
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hamster lung fibroblasts. Truncation of the last 51 amino acids of the C-tail resulted in a 
faster migration of the protein on SDS-PAGE, reflecting the approximately 8kDa reduction 
in molecular mass of the mutated receptor.
CCL-39/mycEDGlcells and CCL-39/mycEDGlA51 -GFP cells were then exposed 
to either vehicle or lOjiiM SIP to visualise any differences in SIP-induced EDGl receptor 
trafficking. The cells were then fixed, mounted on coverslips and examined by confocal 
microscopy. As demonstrated previously in Figure 5.9 and 5.10, a 2 hour treatment with 
10|iM SIP resulted in a significant redistribution of WT mycEDGl-GFP from the cell 
surface into punctate intracellular vesicles within the cytoplasm. In contrast, no changes 
in the subcellular distribution of the mycEDGlA51-GFP receptor were observed 
throughout a 2 hour time-course (Figure 5.13). This suggests that the integrity of the last 
51 amino acids are critical to observe SIP stimulation of EDGl internalisation.
As shown in the last Chapter, truncation of the last 12 and the last 32 amino acids 
from the C-terminal region of EDGl was shown to have distinct effects upon receptor 
phosphorylation. While the EDG1A32 receptor was not phosphorylated in the presence of 
either SIP or PMA, truncation of the last 12 amino acids had no effect on PMA-induced 
EDGl phosphorylation but significantly impaired S IP-induced EDGl phosphorylation 
(Figure 4.28). A study was therefore earned out to examine the effects of each of these 
truncations on EDGl receptor internalisation. Before studying the effect of C-terminal 
EDGl truncations on EDGl receptor internalisation, it was important to observe whether 
truncation of the C-terminal had any effect on the cell surface expression of EDGL 
HEK293 cells transiently expressing the EDGl, EDG1A12 and EDG1A32 cDNA receptors 
were grown on coverslips, washed and then fixed using paraformaldehyde. After 
permeabilisation of the cells, the receptors were immunostained using the 9E10 anti-myc 
antibody followed by incubation with an Alex a 594-conjugated anti-mouse IgG. No 
significant differences in the cell surface expression between each receptor were observed 
(Figure 5.14). Therefore, truncation of the C-terminus had no visible effect on the cell 
surface expression of EDGl under non-stimulated conditions.
In order to quantitate the effect of the removal of 32 amino acids from the EDGl C- 
terminal domain on receptor internalisation, a cell surface biotinylation was carried out on 
HEK293 cells transiently expressing either the mycEDGl or the mycEDGl A3 2 receptor 
exposed to either vehicle or lOjuM SIP over a 2 hour time course. Truncation of 32 amino 
acids from the C-terminal abolished mycEDGl receptor internalisation (111.7±23.3% total
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mycEDGl cell surface expression versus vehicle-treated HEK293 cells expressing the 
mycEDGl A3 2 receptor (set at 100%), p>0.05, N/S, n-3) whereas a 2 hour exposure to 
10|liM s i p  resulted in a 46.61 ± 3.6% loss of the wild type EDGl receptor (versus vehicle- 
treated HEK293 cells expressing the mycEDGl receptor, p<0.05, n=3) (Figure 5.15)
Finally, the effect of the removal of the last 12 amino acids from the EDGl C- 
terminal domain on receptor internalisation was carried out on HEK293 cells transiently 
expressing either the mycEDGl or the mycEDGlA12 receptor exposed to either vehicle or 
10|iM SIP over a 2 hour time course. As with the mycEDGl A3 2 receptor, truncation of 
the last 12 amino acids from the C-terminal abolished mycEDGl receptor internalisation 
(102±16.5% total mycEDGl cell surface expression versus vehicle-treated HEK293 cells 
expressing the mycEDGlA12 receptor (set at 100%), p>0.05, N/S, n=3) whereas a 2 hour 
exposure to lOfiM SIP resulted in a 56.1±11.7% loss of the wild type EDGl receptor 
(versus vehicle-treated HEK293 cells expressing the mycEDGl receptor, p<0.05, n=3) 
(Figure 5.16)
Discussion
As shown in the previous Chapter, the myc-tagged human EDGl receptor is not 
only phosphorylated in the presence of SIP but also via an agonist-independent mechanism 
mediated by PKC activation. In many cases, GPCR phosphorylation is a prerequisite for 
receptor internalisation away from the cell surface (Ferguson, 2001; Palmer and Stiles, 
1997; Xiao et al., 1999). Receptor internalisation represents an important mechanism for 
regulating the signalling of many GPCRs following a sustained agonist exposure. For 
example, GPCR internalisation is involved in the resensitisation of GPCRs. Internalisation 
is also often a prerequisite for receptor degradation. Studies primarily involving the P2AR 
have also shown that internalisation can mediate alternative signalling pathways. Since 
EDGl receptor activation is important in the process of angiogenesis, the regulation of 
EDGl signalling therefore represents a potentially important target for generating 
therapeutics to combat diseases such as cancer and ischaemic heart disease where the 
control of angiogenesis is critical. In this Chapter, the cell surface distribution of the myc- 
tagged human EDGl receptor following either SIP or PMA treatment was characterised 
and compared with the patterns of EDGl phosphorylation established in the previous 
chapter.
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Cell surface biotinylation assays demonstrated that there is a concentration- 
dependent loss of cell surface EDGl receptor (IC5o=0.24|liM) after a 2 hour agonist 
exposure (Figure 5.1). In comparison, the EC50 of SIP-induced EDGl phosphorylation 
was 1.9±0.37|xM (Figure 4.7). This suggests that only relatively low levels of EDGl 
phosphorylation are required for EDGl internalisation. Time-course experiments 
demonstrated that the loss of EDGl receptor from the cell surface was a relatively rapid 
process (ti/2=15 min), with a maximal loss of 70 ± 3% cell surface EDGl receptors 
observed after 2 hours of lOpM SIP exposure (Figure 5.2). As shown in the previous 
Chapter, S IP-induced EDGl phosphorylation is a reversible process (Figure 4.9). 
However, EDGl internalisation was shown to be irreversible over a 2 hour time course 
(Figure 5.3). In addition, total EDGl expression was shown to be unchanged following a 
24 hour agonist exposure (Figure 5.4). Taken together, this would suggest that 
dephosphorylation of EDGl occurs within the cell and that the EDGl receptor remains 
within the cytoplasm following agonist removal, possibly within selected intracellular 
compartments, but that the receptor is not degraded.
Since PMA has been shown to phosphorylate EDGl, there may also be a PKC- 
mediated internalisation of EDGl that was independent of agonist. Figure 5.5 shows that 
whereas a 2 hour exposure to 10|iM SIP decreased cell surface EDGl expression by 
45+8%, a 2 hour exposure to lp,M PMA resulted in a smaller, yet still significant, loss of 
cell surface EDGl receptor (25±5%). The PMA-induced effect was completely abolished 
by preincubation with the PKC inhibitor GF109203X, whereas the same preincubation had 
no effect on S IP-induced EDGl internalisation. This suggests that, as with EDGl 
phosphorylation, there is an agonist-dependent pathway of EDGl internalisation and an 
agonist-independent mechanism mediated through the activation of PKC. As mentioned in 
the previous Chapter, other studies have shown that PKC can phosphorylate and 
subsequently desensitise a number of Gi- and Gq- linked GPCRs, including the aiB- 
adrenoceptor and the type lA  angiotensin II receptor (Diviani et al., 1997; Liang et al., 
1998; Tang et al., 1998). Other studies have also shown a role for PKC in receptor 
internalisation. For example, there is evidence of a PLC-|3- and PKC- dependent 
mechanism of FqyRI internalisation (Norman and Allan, 2000). As discussed for EDGl 
phosphorylation, the existence of an agonist-independent mechanism of EDGl 
internalisation mediated through activation of PKC implies a role for other GPCRs in the 
regulation of EDGl internalisation through a PKC-dependent cross-talk mechanism. For
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example, receptors that play an integral part in the regulation of angiogenesis, such as the 
PDGF receptor, represent potential candidates and future work should be designed to 
examine this further. Future work should also aim to examine the physiological 
significance of the PMA-induced internalisation since the observed effect is relatively 
small.
Confocal analysis of a CCL-39/mycEDG 1-GFP stable cell line demonstrated that 
there is a dramatic re-distribution of mycEDGl-GFP from the cell surface to distinct 
intracellular vesicles following a 2 hour exposure of lOjLiM SIP. A significant 
translocation of receptor into the cytoplasm could be observed as early as a 15 min 
treatment with 10|xM SIP (Figure 5.9). This is in agreement with the cell surface 
biotinylation studies (ti/2=15 min) (Figure 5.2) and also with a previous study where 
HEK293 cells expressing an EDGIGFP construct demonstrated significant receptor 
internalisation from the cell surface following a 2 hour exposure of lOOnM SIP (Lee et al, 
1998). In contrast, a 2 hour treatment with IjiM PMA did not result in a significant 
accumulation of intracellular mycEDGl-GFP (Figure 5.10). Confocal analysis only 
permits the observation of dramatic changes in receptor trafficking whereas cell surface 
labelling will reflect changes in the accessibility of alcohol groups belonging to cell 
surface receptors. Therefore, one explanation for this may be that PMA treatment results 
in the translocation of mycEDGl into selective compartments within the plasma membrane 
where the receptor is inaccessible to the cell surface biotin. Hence, it is possible that the 
differences in cell surface EDGl expression observed following PMA exposure are due to 
the increased sensitivity of cell surface biotinylation over immunocytochemistry. Previous 
studies have shown that the cholecystokinin (CCK) receptor can undergo an agonist- 
dependent translocation to a basolateral plamalemmal compartment similar to caveolin in 
CHO and pancreatic acinar cells where it does not translocate deeper into the cell (Roettger 
et al., 1995; Rosenzweig et al., 1983). Therefore, it is possible that the EDGl receptor may 
translocate into a similar pathway following PMA exposure. Interestingly, the CCK 
receptor exhibits a clathrin-dependent mechanism involved in the lysosomal degradation 
and resensitisation of the receptor and a clathrin-independent mechanism via a vesicular 
compartment in the plasmalemma involved in a more more rapid resensitisation of the 
CCK receptor (Roettger et al., 1995). Therefore, a similar physiological role may exist for 
the PMA-dependent internalisation observed for EDGL
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Like a number of GPCRs, such as the A3 adenosine receptor and the P2-adrenergic 
receptor, the region of the EDGl C-terminal domain distal to the three predicted sites of 
palmitoylation is enriched in potential phosphorylation sites. An EDGl mutant 
(mycEDGlA51-GFP), in which all these potential phosphorylation sites have been 
removed by the truncation of the last 51 amino acids, was GFP-tagged and any agonist- 
induced changes in receptor trafficking observed by confocal microscopy. Whereas the 
wild-type mycEDGl-GFP receptor undergoes significant internalisation following a 2 hour 
exposure of lOpM SIP, there is no significant translocation of the mycEDGlA51-GFP 
receptor from the plasma membrane is observed (Figure 5,13). This is in agreement with a 
similar study where a GFP-tagged EDGl receptor in which all the potential 
phosphorylation sites were removed was not internalised following agonist exposure (Liu 
et al., 1999). This provides strong evidence for a link between EDGl receptor 
phosphorylation within the C-terminal tail and subsequent EDGl receptor internalisation.
As discussed in the previous Chapter, the deletion of the last 12 and the last 32 
amino acids removed two clusters of serine/threonine residues, each of which constituted a 
potential GRK2 phosphorylation site. Cell surface biotinylation studies demonstrated that 
the removal of both the last 12 and the last 32 amino acids from the C-terminal abolished 
EDGl receptor internalisation (Figure 5.15, 5.16). This would suggest that the last 12 
amino acids of the C-terminal tail are crucial for S IP-mediated internalisation to be 
observed. However, the previous Chapter demonstrated that GRK2-mediated EDGl 
phosphorylation was maintained following the truncation of the last 12 amino acids. One 
possibility is that the truncation of the C-terminal hinders the binding of arrestin molecules 
that are essential for receptor internalisation. It should also be noted that the stoichiometry 
of GRK phosphorylation differs, depending upon the GPCR studied such that the primary 
sites of GRK phosphorylation observed in vitro are not necessarily the sites of 
phosphorylation in vivo (Siebold et al., 1998). For example, the mutation of the primary 
GRK phosphorylated residues identified in vitro on the P2AR did not prevent the GRK- 
mediated P2AR desensitisation in cells (Siebold et al., 1998). Alternatively, the 
phosphorylation of secondary GRK phosphorylation sites may compensate for the loss of 
the primary site of GRK-mediated phosphorylation. Additionally, the muscarinic m2 
receptor is phosphorylated by GRK2 and P-arrestins subsequently desensitise the receptor. 
However, the m2 receptor internalises primarily through p-arrestin-independent 
mechanisms (Pais-Rylaarsdam et al., 1997; Pierce and Lefkowitz, 2001). Another
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possibility is that EDGl internalisation may be dependent upon receptor phosphorylation 
in vivo by an acidotrophic kinase distinct from GRK2, as has been shown for the casein 
kinase-la-phosphorylated m3 muscarinic acetylcholine receptor (Budd et al., 2000). As 
mentioned in the previous Chapter, there is also a potential site of casein kinase II 
phosphorylation present within the region of the EDGl C-terminus implicated in the 
process of receptor internalisation (Liu et al., 1999).
This Chapter has established that there is an agonist-mediated internalisation of 
EDGl. In addition, there is also a smaller, but still significant agonist-independent EDGl 
receptor internalisation mediated by PKC. Confocal microscopic analysis of a mutated 
EDGl-GFP chimera in which all the potential phosphorylation sites within the area of the 
EDGl C-terminal domain distal to the three predicted sites of palmitoylation were 
removed completely inhibited agonist-mediated receptor trafficking towards the 
cytoplasm. Further sequential EDGl truncation studies demonstrated that removal of both 
the last 12 and the last 32 amino acids completely inhibited EDGl internalisation.
To establish the amino acids responsible for EDGl internalisation, future work 
should be aimed at site-directed mutagenensis, specifically within the last 1 2  amino acids. 
Identification of the kinase(s) responsible for EDGl internalisation should also be 
examined. The role of GRK2 should be fully examined, in addition to other kinases such 
as casein kinase-la and casein kinase II, The role of the scaffolding proteins, arrestins in 
EDGl internalisation should also be studied.
A previous study has shown that SIP results in the translocation of p-arrestin2 
towards activated EDGl in HEK293 cells (Hobson et al., 2001). However, the role of 
arrestins in EDGl internalisation has yet to be fully characterized. Additionally, little is 
known about the possible effect of arrestins on EDGl signal transduction. Interestingly, a 
recent study has suggested a role for p-arrestin in a cross-talk mechanism between EDGl 
and PDGF (Hobson et al., 2001). Recent evidence has strongly implicated the PDGF- 
dependent activation of EDGl via the intracellular production of SIP. This activation of 
EDGl results in the recruitment of P-arrestin2 and the activation of Rac-dependent 
processes of cell migration. This results in the migration of cells towards PDGF, causing a 
potentiation of PDGF receptor signalling (Hobson, et al., 2001; Rosenfeldt et al., 2001). 
However, it is not known how the internalisation of EDGl affects PDGF signalling. As 
described previously, the recruitment of arrestin molecules towards activated P2AR can 
result in the activation of alternative signalling pathways, such as the activation of INK
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and ERK, Therefore, the effect of the recruitment of arrestin by EDGl on the signalling of 
EDGl and PDGF should be examined.
Additionally, very little is known about the intracellular trafficking of the EDGl 
receptor. As shown previously, the EDGl receptor is dephosphorylated upon agonist 
removal but does not return to the cell surface. Also, the receptor is not down regulated 
following a chronic SIP exposure. Therefore, immunostaining experiments should be 
carried out to determine the fate of the EDGl receptor following internalisation. As 
mentioned earlier, the discovery of an agonist-independent mechanism of receptor 
internalisation via PKC suggests the involvement of other Ca^^-mobilising GPCRs in the 
regulation of the EDGl receptor. Therefore, future work should also be aimed at 
examining the potential role of other GPCRs in regulating EDGl signalling, such as the 
thrombin and PDGF receptors, as well as Tie2, Fit and Flk, all of which are heavily 
involved in the angiogenic process.
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Figure 5.1: Effect Of Increasing Concentrations Of SIP On Cell Surface Expression 
Of EDGl
Serum-starved stably transfected CCL-39/mycEDGl cells were treated with vehicle or 
increasing concentrations of SIP for 2 hours at 37°C. The cells were examined for 
internalisation by cell surface labelling with biotin-LC-hydrazide and solubilised followed 
by immunoprécipitation with the anti-myc 9E10 antibody. Biotin labelling of vehicle- 
treated CCL-39/mycEDGl cells was set at 100% and the results following agonist 
treatment were expressed as a ratio of the control. The data represents the mean ± SEM of 
three similar experiments. The results show a concentration-dependent SIP-induced loss of 
cell surface EDGl receptor (EC5o= 0.24(xM).
163
Mr(xlO-^)
40 0.4 40
mycEDGl
SIP treatment 
(2 hours, 37®C)
nM fiM
140-
U .
120 -
O  1004
8 0 -
6 0 -
4 0 -
20 -
4x10 4 x 1 0 4 x 1 0 ’' 4x10“” 4x10
[S1P]
Figure 5.2: Time-Course Of SSP-Mediated Loss Of Cell Surface EDGl Receptor
Serum-starved stably transfected CCL-39/mycEDGl cells were treated at 37°C with 
vehicle or 10|liM SSP for the times indicated. The cells were examined for internalisation 
by cell surface labelling with biotin-LC-hydrazide and solubilised, followed by 
immunoprécipitation with the anti-myc 9E10 antibody. Biotin labelling of vehicle-treated 
CCL-39/mycEDG 1 cells was set at 100% and the results following agonist treatment 
expressed as a ratio of the control. The data represents the mean ± SEM of three similar 
experiments. The results show a time-dependent SSP-induced EDGl internalisation {\.m= 
15 min).
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Figure 5.3: Effect Of SIP Removal On SIP-Mediated Loss Of EDGl Receptor From 
The Cell Surface
Serum starved stably transfected CCL-39/mycEDGl cells were treated with either vehicle 
or lOpM SIP for 30 minutes at 37°C. Agonist was then removed after 15, 30, 60 or 120 
minutes. The cells were examined for internalisation by cell surface labelling with biotin- 
LC-hydrazide and solubilised followed by immunoprécipitation with the anti-myc 9E10 
antibody. Biotin labelling of vehicle-treated CCL-39/mycEDG1 cells was set at 100% and 
the results following agonist treatment expressed as a ratio of the control. The data 
represents the mean ± SEM of three similai' experiments. * Denotes a significant 
difference (p<0.05) versus vehicle-treated EDGl cells. # Indicates a significant difference 
(p<0.05) versus S IP-treated EDGl cells.
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Figure 5.4: Effect Of Sustained SIP Treatment On Total EDGl Receptor Expression
Serum starved stably transfected CCL-39/mycEDGl cells were treated with either vehicle 
or lOjiM SIP for 24 hours at 37°C. The cells were then solubilised and analysed by SDS- 
PAGE and immunoblotting with anti-myc monoclonal antibody 9E10. The data represents 
the mean ± SEM of three similar experiments. * denotes a significant difference (p<0.05) 
between in treated EDGl-expressing cells. No significant differences in total EDGl 
expression were observed following a chronic SIP exposure.
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Figure 5.5; Comparison Of The Effects Of SSP And PMA Treatment On Cell Surface 
EDGl Receptor Expression
Serum-starved CCL-39/mycEDGl cells were preincubated with vehicle or IpM of the 
PKC inhibitor, GF109203X (GFX) for 30 min. The cells were then incubated for 2 hours 
with vehicle or in the presence of lOpM SSP or IpM PMA. All drug treatments were 
carried out at 37°C. The cells were analysed for receptor internalisation by cell surface 
labelling with biotin-LC-hydrazide, followed by immunoprécipitation with the anti-myc 
9E10 antibody. Biotin labelling of vehicle-treated CCL-39/MycEDGl cells was set at 
100% and the results following agonist treatment normalised accordingly. The data 
represents the mean ± SEM of three similar experiments. * Denotes a significant 
difference (p<0.05) versus vehicle-treated EDGl cells. Whereas a 2 hour lOjuM SSP 
incubation decreased cell surface EDGl levels by 45±8%, a IpM PMA exposure produced 
a significantly smaller reduction of 25±5% in cell surface expression. Preincubation with 
GF109203X abolished PMA-induced EDGl cell surface loss but SSP-induced EDGl cell 
surface loss was completely preserved.
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Figure 5.6: Schematic Of The MvcEDGl-GFP Receptors
The human mycEDGl receptor was tagged with green fluorescent protein using a 
pcDNA/human mycEDGl template. The mycEDGl receptor was ligated into the multiple 
cloning site of pEGFP-Nl at HindQUBainHl. The addition of the GFP tag allowed 
visualisation of any movement of the cell surface EDGl receptor following sustained 
agonist exposure.
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Figure 5.7: Immunoblot Analysis Of MvcEDGl And MvcEDGl-GFP Receptor
Expression
Cell extracts prepared from nontransfected CCL-39 fibroblasts or CCL-39 cells stably 
expressing either mycEDGl or mycEDGl-GFP were solubilised, normalised for protein 
content and analysed by SDS-PAGE and immunoblotting with either an anti-myc 
monoclonal 9E10 antibody or a monoclonal anti-GFP antibody as indicated. mycEDGl 
and mycEDGl-GFP bands are indicated.
169
Mr<x10®) I # mycedgi-GFP
I mycedgi
9E10 anti-GFP 
(anti-myc)
Figure 5.8; Comparison Of The Effects Of SSP And PMA Exposure On MvcEDGl 
And MvcEDGl-GFP Phosphorylation
■^^P-labelled serum-starved stably transfected CCL-39/mycEDGl and CCL-39/mycEDGl- 
GFP cells were incubated at 37°C for 10 min with either vehicle, 10|U-M SSP, or IjiiM 
PMA. Receptor phosphorylation was analysed by immunoprécipitation followed by SDS- 
PAGE and phosphorimaging. The figure shows that both receptors are phosphorylated in 
the presence of either SSP or PMA, with SSP resulting in the strongest phosphorylation. 
Typical data is shown from one of three experiments.
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Figure 5.9: Fixed-Cell Analysis By Confocal Microscopy Of MvcEDGl-GFP Cell 
Surface Expression Following Sustained SIP Treatment
Serum-starved CCL-39/mycEDGl-GFP cells were plated onto coverslips and exposed to 
either vehicle or 10|iM R-PIA for the times indicated. The cells were then washed and 
fixed in paraformaldehyde prior to visualisation of receptor distribution by confocal 
microscopy. Under conditions of no agonist treatment, the mycEDGl-GFP construct was 
expressed on the cell surface. After only 15 min of SIP exposure, small, punctate spots of 
internalised receptor were detected within the cytoplasm. Following two hours of agonist 
exposure, a significant redistribution of cell surface mycEDGl-GFP receptor from the cell 
surface into internalised perinuclear pools within the cytoplasm was observed. This is a 
representative example of three experiments.
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Figure 5.10; Fixed-Cell Analysis By Confocal Microscopy Of MvcEDGl-GFP Cell 
Surface Expression Following SIP And PMA Exposure
Serum-starved CCL-39/mycEDGl-GFP cells were plated onto coverslips and exposed to 
vehicle, lOpM SIP or IpM PMA for 2 hours at 37°C. The cells were then washed and 
fixed in paraformaldehyde prior to visualisation of receptor distribution by confocal 
microscopy. When treated with vehicle alone, the mycEDGl-GFP receptor was expressed 
primarily on the cell surface. A 2 hour exposure to lOpM SIP resulted in a significant 
redistribution of mycEDGl-GFP from the cell surface into punctate intracellular vesicles. 
In contrast, a 2 hour treatment with lp,M PMA produced only a small increase in the 
number of detectable intracellular receptors.
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Figure 5.11: Schematic Of The MvcEDGlA51-GFP Receptor
The human mycEDGlA51 receptor was tagged with green fluorescent protein using a 
pcDNA/human mycEDGlA51 template. The mycEDGlA51 receptor was ligated into the 
multiple cloning site of pEGFP-Nl at HindnUBamHi. The addition of the GFP tag 
allowed visualisation of any movement of the cell surface mycEDG 1A51 -GFP receptor 
following sustained agonist exposure.
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Figure 5.12: Immunoblot Analysis Of The MvcEDGl. MvcEDGlASl And 
MvcEDGlA51-GFP Receptor
CCL-39 cells stably expressing either the mycEDGl-GFP, the mycEDGlA51 or the 
mycEDGlA51GFP receptor were solubilised, noimalised for protein content and analysed 
by SDS-PAGE and immunoblotting with the anti-myc monoclonal 9E10 antibody.
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Figure 5.13: Fixed Cell Analysis By Confocal Microscopy Of MvcEDGlA51-GFP Cell 
Surface Expression Following SIP Exposure
Serum-starved CCL-39/mycEDGl-GFP or CCL-39/mycEDGlA51-GFP cells were plated 
onto coverslips and exposed to either vehicle or 10|iM SIP at 37°C for the times indicated. 
The cells were then washed and fixed in paraformaldehyde prior to visualisation of 
receptor distribution by confocal microscopy. A 2 hour exposure to lOfxM SIP resulted in 
a redistnbution of mycEDGl-GFP from the cell surface into punctate intracellular vesicles. 
In contrast, no significant trafficking of the mycEDG 1A51 -GFP receptor was observed 
throughout a 2 hour time-course in the presence of lOjiM SIP.
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Figure 5.14: Identification Of The MvcEDGl, MvcEDGlA32 And MvcEDGlA12 
Receptors Bv Immunofluorescence
HEK293 cells transiently expressing either the mycEDGl, mycEDGlA32 or the 
inycEDGlA12 receptor were grown on coverslips, washed and then fixed using 
parafonnaidehyde. After permeabilisation, the cells were incubated with the 9E10 anti- 
myc antibody followed by an anti-mouse Alexa-red 594 conjugated IgG. Receptor 
expression was then visualised by confocal microscopy. The figure shows that truncation 
of the last 12 and the last 32 amino acids had no effect on EDGl cell surface expression.
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Figure 5.15: Effect Of SIP Exposure On The Cell Surface Expression Of The 
MvcEDGlA32 Receptor
Serum-starved HEK293 cells transiently expressing either mycEDGl or mycEDGl A3 2 
receptor were treated with vehicle or 10|LiM SIP at 37°C for the times indicated. The cells 
were examined for internalisation by cell surface labelling with biotin-LC-hydrazide, 
solubilised and then immunoprecipitated with the anti-myc 9E10 antibody. Biotin 
labelling of vehicle-treated controls was set at 1 0 0 % and the results for each receptor 
following agonist treatment expressed as a ratio of the control. The data represents the 
mean ± SEM of three similar experiments. Cell surface biotinylation of mycEDGl and 
mycEDGlA32, as shown in panel (B), were normalised for total receptor expression using 
an immunoblot analysis of the immunoprecipitated samples, as shown in Panel (A). * 
Indicates a significant decrease (p<0.05) versus level of internalisation as compared with 
vehicle-treated controls.
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Figure 5.16: Effect Of SIP Exposure On The Cell Surface Expression Of The 
MvcEDGlA12 Receptor
Serum-starved HEK293 cells transiently expressing either the mycEDGl or the 
mycEDGlA12 receptor were treated with vehicle or 10p,M SIP at 37°C for the times 
indicated. The cells were solubilised and examined for internalisation by cell surface 
labelling with biotin-LC-hydrazide, followed by immunoprécipitation with the anti-myc 
9E10 antibody. Biotin labelling of vehicle-treated controls was set at 100% and the results 
for each receptor following agonist treatment normalised accordingly. The data represents 
the mean ± SEM of three similar experiments. Cell surface biotinylation of mycEDGl and 
mycEDGlA12, as shown in panel (B), were normalised for total receptor expression using 
an immunoblot analysis of the immunoprecipitated samples, as shown in Panel (A). * 
Indicates a significant decrease (p<0.05) versus level of internalisation as compared with 
vehicle-treated controls.
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Chapter 6
Final Discussion
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Receptor phosphorylation and receptor internalisation represent two important 
regulatory processes in the signalling of many GPCRs. As described previously, one of the 
most well-characterised models of GPCR phosphorylation and internalisation is the P2AR 
(Jockers et al., 1996; Luttrell et al., 1999; McLean et al., 1999; Menard et a l, 1997; 
Moffett et a l, 1993). Using this model as a starting point, this project has characterised the 
regulation of two GPCRs: the human Ai adenosine receptor and the human SIP receptor 
EDGl. Additionally, the A%AR has been compared with the rat A3AR, an AR subtype 
similar in structure and biological effects containing a number of potential serine and 
threonine phosphorylation sites not present in the AiAR. The AiAR, A3AR and EDGl 
receptor each display distinct differences in terms of their rate and their extent of 
phosphorylation and internalisation. In fact, these receptors highlight the diverse pathways 
of phosphorylation and internalisation that exist between members of the GPCR family and 
demonstrate that all GPCRs are regulated uniquely in a manner that is not identical to the 
P2AR. This study therefore emphasises the need to characterise the regulation of each 
GPCR individually. However, each example also illustrates the importance of receptor 
phosphorylation in the regulation of receptor internalisation
The link between receptor phosphorylation and internalisation has been established 
for a number of receptors and is generally attributed to a synergistic relationship between 
GRK-mediated receptor phosphorylation and the binding of endocytic adaptor proteins 
such as P-arrestin (Ferguson, 2001). For example, GRK2-mediated phosphorylation is 
known to facilitate the internalisation of the m2 muscarinic receptor (Moro et a l, 1993), 
angiotensin ATiaR (Smith et a l, 1998), endothelin A receptor (Bremmes et al, 2000), D2 
dopamine receptor (Itokawa et a l, 1996), and the follitropin receptor (Lazari et a l, 1999). 
Studies using a p2AR-Y326A mutant, which was internalisation-defective and did not 
serve as a substrate for GRK-mediated phosphorylation, also demonstrated that 
overexpression of GRK2 not only promoted internalisation but also re-established GRK- 
mediated phosphorylation of the mutant receptor (Tsuga et a l, 1994). However, this 
model does not apply to all GPCRs. Early studies using P2AR mutants lacking sites for 
both second-messenger-dependent protein kinase- and GRK-mediated phosphorylation 
showed no significant differences in the internalisation of the wild-type and mutant P2ARS 
(Bouvier et a l, 1988; Hausdorff et a l, 1989). Also, m2 muscarinic receptor internalisation 
is GRK-dependent yet appears to be p-arrestin-independent in some cell types (Tsuga et 
a l, 1994; Schlador and Nathanson, 1997; Vogler et a l, 1999; Werbonat et a l, 2000). 
Additionally, in C0S7 cells, which express relatively little GRK and p-arrestin protein, the
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maximal extent of ATiaR internalisation is virtually indistinguishable from that observed 
in HEK293 cells whereas the maximal extent of P2AR internalisation is markedly lower in 
COS7 cells (Zhang et aL, 1996; Menard et al., 1997).
However, the role of phosphorylation in GPCR internalisation is reinforced by the 
differential rates of internalisation of the phosphorylation-deficient AiAR and the rapidly- 
phosphorylated A3AR. In Chapter 3, it was shown that AiARs expressed in CHOs were 
not phosphorylated in response to the agonist, R-PIA. In contrast, the A3AR, which is 
similar in terms of structure, G-protein coupling specificity and biological effects, was 
rapidly phosphorylated following R-PIA exposure. This agreed with a previous study 
which demonstrated that a chimeric A1-A3 adenosine receptor in which the C-terminal 
domain of the AiAR distal to the predicted site of palmitoylation was replaced by the 
corresponding region of the A3AR was able to undergo rapid functional desensitisation and 
agonist-stimulated phosphorylation (Palmer et al., 1996). The differential patterns of 
AiAR and A3AR phosphorylation were reflected in the internalisation rates of both 
receptors. Whereas the A3AR is internalised rapidly following R-PIA exposure (ti/2 = 1 0  
min), the agonist-dependent loss of AiAR from the cell surface was much slower 
(ti/2=90min) and was also smaller in magnitude. Interestingly, the type I GnRH-receptors 
(GnRH-Rs) lack C-terminal tails and do not undergo agonist-induced phosphorylation and 
are resistant to receptor desensitisation and internalise slowly (McArdle et al., 2002a; 
McArdle et al., 2002b). In contrast, the type II GnRH-Rs posses C-terminal tails and show 
rapid desensitisation and internalisation with comcomitant receptor phosphorylation 
(McArdle et al., 2002a; McArdle et al., 2002b).
Palmitoylation of GPCRs has diverse effects on GPCR regulation and signalling. 
For example, as discussed in Chapter 3, mutation of Cys341 within the P2AR C-terminal 
tail increases the accessibility of a PKA phosphorylation site upon agonist stimulation and 
therefore increases receptor phosphorylation (Moffet et al., 1993; Mouillac et al., 1992). 
In contrast, the disruption of a 2A-adrenergic receptor palmitoylation was shown to have no 
effect on receptor phosphorylation but instead abolished receptor down-regulation (Eason 
et al., 1994). Additionally, non-palmitoylated 5 -HT4(a) receptors were indistinguishable 
from the wild type in their ability to interact with Gs, to stimulate adenyly cyclase activity 
and to activate cyclic nucleotide-sensitive cation channels following agonist stimulation 
(Ponimaskin et al., 2002). The mutation of Cys309, a site of palmitoylation within the 
AiAR C-terminal tail, had no visible agonist-dependent effect on the rate of translocation
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of the AiAR from the cell surface during a 1 hour treatment with 10|iM R-PIA. In 
contrast, parallel studies within the lab have demonstrated that mutation of Cys302 and 
Cys305 within the C-terminal of the A3AR resulted in a marked increase in basal receptor 
phosphorylation and an increased rate of internalisation. This difference presumably 
reflects the ability of the WTA3AR to be phosphorylated by GRKs in comparison to the 
phosphorylation-resistant AiAR. However, longer time-course experiments should be 
carried out using the Cys309 mutant of the A%AR to examine the potential effect in relation 
to the ti/2 of wild type receptor internalisation (ti/2= 90 mins).
As discussed in Chapter 3, previous studies have suggested that the AiAR could 
internalise via a unique molecular mechanism involving the clathrin/dynamin endocytic 
machinery or through a clathrin-independent mechanism (Ciruela et al., 1997; Gines et a l, 
2001; Saura et al., 1998; Nie et al., 1997). In LLC-PKi cells, it was suggested that A%AR 
internalisation occurs following their translocation to rafts enriched in caveolin and that the 
putative caveolin binding motif within the C-terminal of the A%AR (YAFRIHKF) is 
involved (Gines et al., 2001). In contrast, a separate study showed that 67±5% of 
adenosine Ai receptors were isolated with caveolae from unstimulated rat cardiac 
ventricular myocytes and, following incubation with the AiAR agonist, CCPA, there was 
rapid translocation of the A% receptors from caveolae into non-caveolar plasma membrane 
compartments (Lasley et al., 2000). Alternatively, the A]AR may move into distinct 
plasma membrane compartments similar to those described for the CCK receptor. The 
CCK receptor has been shown to translocate to a basolateral plasmalemmal compartment 
similar to caveolin in CHO and pancreatic acinar cells yet does not translocate deeper into 
the cell (Roettger et al., 1995; Rosenzweig et al., 1983). As mentioned previously, the 
translocation of the CCK receptor to these membranous compartments is thought to result 
in a rapid desensitisation of the receptor (Roettger et a l, 1995). Therefore, the 
translocation of AiARs to compartments within the membrane may result in a similar 
physiological effect. Interestingly, a radioligand binding assay to measure receptor down- 
regulation demonstrated that time-courses of the loss of cell surface expression and the loss 
of total receptor expression were similar (ti/2=60 mins). Therefore, the loss of cell surface 
AiAR may be attributable to a down-regulation of the receptor. One important further line 
of investigation would be to determine the exact trafficking characteristics of the AiAR 
using a CHO cell line stably expressing the AiAR-GFP construct. This would allow fixed 
cell confocal analysis to be used to determine the precise movements of the AiAR
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following a long-term agonist treatment and permit visualisation of the changes in AiAR 
expression determined here biochemically by biotin-labelling and radioligand binding 
assays.
It remains unclear why it is physiologically beneficial to have two subtypes of 
receptor that are so similar in terms of structure, ligand and biological effects but which 
exhibit markedly different regulatory mechanisms of phosphorylation and internalisation. 
As described in the Introduction, both the AiAR and the A3AR are involved in the process 
of ischaemic preconditioning (Carr et a l, 1997; Feminandy et a l, 1998; Heurteaux, 1995; 
Liang and Jacobson, 1998; Rubino and Yellon, 2000; Sumeray and Yellon, 1997; Thourani 
et a l, 1999). Ischaemic preconditioning is defined as a cardio- and neuroprotective, acute 
adaptation to brief periods of ischaemia. This is where a brief period of sublethal 
ischaemia, consisting of either a single five minute period or a cycle of two or more 5 
minute periods, is then followed by reflow, rendering the heart resistant to infarction from 
a subsequent, more sustained period of ischaemia (Rubino and Yellon, 2000; Sumeray and 
Yellon, 1997). As a result, there is a reduction in arrythmias and cardiac cell death from 
the prolonged, potentially injurious period of ischaemia. The process is bi-phasic. The first 
phase is termed classical preconditioning and occurs within a few minutes of the initial 
preconditioning ischaemia. If the period of time between preconditioning ischaemia is 
extended beyond 120 minutes, no protection is observed. Delayed preconditioning, also 
referred to as the second window of protection, is where the preconditioning effect is 
observed 24 hours after the initial period of ischaemia and is thought to be associated with 
the induction of cytoprotective proteins, such as heat shock protein and endogenous anti­
oxidants (Rubino and Yellon, 2000; Sumeray and Yellon, 1997). However, it is not known 
how the regulation of the AiAR and the A3AR is reflected in their mediation of ischaemic 
preconditioning. For example, how does the slow, incomplete loss of AiAR from the cell 
surface influence the sustained protection observed with ischaemic preconditioning? 
Therefore, future research could involve cardiac myocytes infected with an adenoviral 
construct of either the AiAR, A3AR or the chimeric A1/A3AR described above in order to 
ensure efficient receptor overexpression since primary cells are difficult to transfect. This 
could then be used to study how the different regulatory patterns observed between the 
AiAR and the A3AR influence the process of ischaemic preconditioning. For example, 
how does the regulation of each receptor affect the activation of K'^a t p  channels? 
Additionally, previous studies have demonstrated that a significant proportion of the 
cardioprotective effect elicited by the A^AR is due to the inhibition of the pzAR-dependent
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increase in cAMP activity (Auchampach and Bolli, 1999; McIntyre Jr. et al., 1994; Perlini 
et al., 1998; Song and Belardinelli, 1996). Hence, it would be beneficial to examine 
potential cross-talk mechanisms between the AiAR and the P2AR and also to determine 
whether the regulation of each receptor has any bearing on the signalling and the regulation 
of the other.
EDGl is activated by the bioactive phospholipid SIP and is heavily involved in the 
process of angiogenesis (HIa et al., 2001, Pyne and Pyne, 2000a, Pyne and Pyne, 2000b, 
Spiegel and Milstien, 2000). Chapter 4 demonstrated that EDGl is phosphorylated in 
response to agonist (S IP) and also in response to PMA, a phorbol ester that activates PKC 
subtypes and that these processes are mechanistically distinct. Additionally, incubation of 
PMA and SIP together did not result in a significant increase in EDGl phosphorylation 
when compared to that achieved by SIP treatment alone. This suggested that although 
PMA- and SIP- mediated EDGl phosphorylation were distinct, each pathway utilised 
overlapping phosphorylation sites within EDGl. Interestingly, the removal of 12 amino 
acids from the C-terminal tail of EDGl significantly reduced SIP- but not PMA-stimulated 
phosphorylation. Hence, SIP treatment induces the phosphorylation of sites within the last 
12 amino acids of the EDGl C-terminal tail that are not phosphorylated following PMA 
exposure. This implies that each mechanism of phosphorylation is distinct. Future work 
might employ the use of 2D gels to examine the patterns of EDGl phosphorylation 
following SIP and PMA exposure. If the patterns observed with each activator are 
different, then this further suggests that each mechanism of EDGl phosphorylation is 
distinct. Site-directed mutagenesis studies within the last 32 amino acids of the C-terminal 
tail should also determine the exact the sites of EDGl phosphorylation following SIP and 
PMA treatment. In addition, the removal of 12 amino acids from C-terminal tail of EDGl 
significantly reduced SIP- but not PMA-stimulated phosphorylation. In vitro assays 
implicated a role for GRK2 in SIP-induced EDGl phosphorylation observed in intact 
cells. Also, the region between the last 12 and the last 32 amino acids was shown to be 
responsible for the in vitro S IP-dependent phosphorylation of EDGl in the presence of 
GRK2. Again, the precise sites of GRK2 phosphorylation in vitro could be examined 
using site-directed mutagenesis of the EDGl C-terminus.
The patterns of EDGl phosphorylation established in Chapter 4 were related to 
loss of EDGl cell surface receptor studies presented in Chapter 5. Two separate 
mechanisms of EDGl internalisation were observed: an S IP-dependent loss of cell surface 
EDGl receptor and a less complete but still significant agonist -independent loss of cell
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surface EDGl mediated by PMA. Confocal analysis demonstrated that, whereas SIP 
induces the trafficking of EDGl from the cell surface into perinuclear pits, PMA exposure 
did not visibly affect receptor trafficking. As discussed in Chapter 5, PMA-induced EDGl 
internalisation may involve the trafficking of EDGl into membranous compartments, 
similar to those described for the CCK receptor (Roettger et al., 1995; Rosenzweig et a l, 
1983). Whether the PMA-induced internalisation of EDGl is physiologically significant, 
given the relatively small effect observed in Chapter 5, should be addressed in future 
studies.
The removal of the 12 residues from the carboxyl terminal of EDGl completely 
inhibited S IP-induced EDGl internalisation, implicating this domain in the control of 
EDGl internalisation while retaining sensitivity to SIP phosphorylation. Interestingly, this 
region is not required for the in vitro phosphorylation of EDGl by GRK2 in the presence 
of SIP. Hence, this suggests that another kinase may be responsible for EDGl 
internalisation. Interestingly, the muscarinic m2 receptor is phosphorylated by GRK2 and 
p-arrestins subsequently desensitise the receptor. However, the m2 receptor internalises 
primarily through p-arrestin-independent mechanisms (Pais-Rylaarsdam et al., 1997; 
Pierce and Lefkowitz, (2001). Future work should therefore be aimed at examining the 
role of other aciditrophic kinases, such as casein kinase-la. Alternatively, the sites of 
GRK2-dependent phosphorylation of EDGl in vitro may not be the sites phosphorylated in 
vivo. For example, the mutation of the primary GRK phosphorylated residues on the P2AR 
did not prevent the GRK-mediated P2AR desensitisation in cells (Siebold et al., 1998). 
Therefore, a role for GRK2 in the internalisation of EDGl in vivo cannot be completely 
ruled out. However, the possibility that EDGl may internalise via a mechanism that is 
independent of GRK phosphorylation again highlights the need to examine the regulation 
of a given GPCR independently. Additionally, if GRK2 is found to phosphorylate EDGl 
in vivo then the physiological role of GRK2-dependent EDGl phosphorylation must be 
addressed. Elucidation of the exact sites of EDGl phosphorylation stimulated by SIP and 
PMA through site-directed mutations and phosphopeptide mapping of EDGl should 
address these issues.
Chapter 5 also demonstrated that a 30 min agonist-dependent internalisation of the 
EDGl receptor was irreversible following 2 hours of agonist removal. Additionally, no 
significant decrease in total EDGl receptor expression was observed following a 24 hour 
agonist exposure, suggesting that the receptor is not down-regulated. Chapter 4 also
185
demonstrated that EDGl phosphorylation was reversible following a 2 hour agonist 
removal. Together, this would suggest that the EDGl receptor is phosphorylated following 
agonist exposure. The receptor is then internalised where it is then dephosphorylated but 
not degraded. Alternatively, EDGl may be slowly recycled back to the cell surface, 
requiring a period of agonist removal longer than 2 hours. Although GPCRs are generally 
rapidly recycled back to the cell surface or targeted for degradation following 
internalisation, some GPCRs are retained within the cell. For example, both the 
angiotensin ATia and vasopressin V2  receptor are retained within endocytic vesicles, 
resulting in a prolonged state of functional desensitisation (Zhang et ah, 1999; Anborough 
et al., 2000; Innamorati et al., 1998; Oakley et a l, 1999). Future studies using confocal 
microscopy should therefore determine the exact trafficking pathway of the internalised 
EDGl receptor. Future work should also investigate why the EDGl receptor is 
dephosphorylated and then remains within the cell. As mentioned previously, SIP has 
been shown to be an intracellular messenger yet the precise targets for EDGl within the 
cell remain unknown (Spiegel and Milstien, 2000). Therefore, does the EDGl receptor 
elicit S IP-dependent biological responses within the cell? The elicitation of signalling 
responses by internalised receptors has been shown previously. For example, it has been 
proposed that internalised PzARs activate MAP kinase signalling via a Src-associated 
endocytic signalling complex containing the activated receptor (Luttrell et al., 1999). 
Additionally, the protease-activated receptor, PAR2 and the neurokinin NKi receptor have 
also been shown to activate MAPK following their translocation into endocytic vesicles 
(DeFea et al., 2000a; DeFea et al., 2000b; Luttrell et al., 2001).
The demonstration of agonist-independent processes of phosphorylation and 
internalisation, mediated by PKC activation, suggest the existence of potentially important 
physiological cross-talk mechanisms between the EDGl receptor and other receptors. For 
example, recent studies have revealed an important role for EDGl in a cross-talk 
mechanism with the PDGF receptor (Hobson et al., 2001; Rosenfeldt et al., 2001). It has 
been shown that activation of the PDGF receptor can, in turn, increase SIP production 
through the activation of sphingosine kinase. This results in the activation of EDGl and 
the subsequent activation of Rac-dependent cell migration pathways. Consequently, cells 
migrate towards PDGF, thus enhancing PDGF receptor signalling in cell maturation 
(Hobson et al., 2001; Rosenfeldt et al., 2001). Therefore, the discovery of agonist- 
independent pathways of EDGl phosphorylation and internalisation has important 
implications in the role of the EDGl receptor in cross-talk mechanisms with other
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receptors, such as the PDGF receptor. For example, can PDGF receptor activation directly 
phosphorylate EDGl by the activation of PKC to enhance EDGl signalling as well as 
indirectly via an increase in SIP production? Also, the effect on PDGF receptor signalling 
of a phosphorylation and/or internalisation-deficient mutant of EDGl should be examined. 
Additionally, future research should be aimed at examining the potential effects of EDGl 
signalling in terms of other angiogenic receptors such as the angiopoietin receptors, Tiel 
and Tie2, and other receptor tyrosine kinase receptors, such as the VEGF receptors, Fit and 
Flk. Future experiments should also relate the phosphorylation and internalisation patterns 
of EDGl established in Chapters 4 and 5 to a more physiologically relevant environment. 
This could be achieved by generation of adenoviral constructs of the WT EDGl, 
EDG1A12 and EDG1A32 receptors. These could be used to infect human umbilical vein 
endothelial cells as a means of overexpressing these receptors in endothelial cells. A viral 
construct of the EDG1A32 receptor represents both a phosphorylation- and an 
internalisation-deficient mutant of the EDGl receptor whereas an EDG1A12 viral 
construct would represent an internalisation-deficient mutant that can still be significantly 
phosphorylated by agonist. The effect of overexpressing these receptors on angiogenesis 
could then be examined using a matrigel system. Additionally, the possible generation 
through site-directed mutagenesis of an EDGl mutant that differentiates between PMA, 
but not SIP induced EDGl phosphorylation could be used to elucidate any potential 
physiological consequences of each phosphorylation pathway.
The regulation of small G-proteins, such as Rac and Rho, represents an integral part 
of EDGl signalling (Lee et al., 2001; Paik et al., 2001; Hobson et al., 2001). For instance, 
the activation of Rac has been shown to mediate EDGl-dependent cell migration pathways 
(Lee et a l, 2001; Hobson et a l, 2001). In addition, EDGl, along with EDG3, has been 
shown to stimulate Rac- and Rho-coupled pathways that regulate morphogenesis, such as 
adherens junction assembly and translocation of P- and E-cadherin (Lee et a l, 1998, Lee et 
a l, 1999; Liu et a l, 2000). The activation of Rac by EDGl has also recently been shown 
to be dependent upon EDGl phosphorylation by Akt (Lee et a l, 2001). Future studies 
should examine the consequences of EDGl phosphorylation and internalisation for small 
G-protein activation. Conversely, the effect of small G-proteins on the regulation of 
GPCRs should be examined. A number of reports have indicated that Rho family GTPases 
are involved in regulating endocytic traffic. For example, the microinjection of 
constitutively activated forms of RhoA and Racl have been shown to block clathrin- 
mediated endocytosis of the transferrin receptor in fibroblasts (Lamaze et a l, 1996).
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Additionally, a constitutively active form of Racl has been shown to induce the formation 
of large intracellular vesicles around which Racl and E-cadherin tightly colocalise 
(Nakagawa et al., 2001).
The physiological significance of EDGl regulation can be related primarily to the 
process of angiogenesis (Hla et a i, 2001, Pyne and Pyne, 2000a, Pyne and Pyne, 2000b, 
Spiegel and Milstien, 2000). The regulation of angiogenesis represents an important 
process in a number of disease states where blood vessel formation is critical such as 
ischaemic heart disease, solid tumour growth and diabetic retinopathy (Carmeliet and Jain, 
2000; Fan et al., 1995; Griffioen and Molema, 2000; Isner, 2002; Yancopoulos et al., 
2000). This is reflected in the current interest in designing clinical treatments aimed at 
controlling angiogenesis (Carmeliet and Jain, 2000). For example, gene transfer of 
plasmid DNA encoding VEGF in patients with peripheral artery disease resulted in a 
variety of clinical benefits such as the abolition of rest pain, limb salvage and the healing 
of ischaemic ulcers (Isner, 2002). Recently, phase I clinical trials have began using similar 
gene transfer strategies in the treatment of myocardial ischaemia (Carmeliet and Jain, 
2000; Isner, 2002; Yancopoulos et al., 2000). Interestingly, out of 30 individuals 
receiving plasmid DNA encoding VEGF, 29 experienced reduced angina (Isner, 2002). 
Similar trials are underway using gene transfer strategies with plasmid DNA encoding FGF 
and a constitutively active form of HIT-la (Carmeliet and Jain, 2000; Isner, 2002; 
Yancopoulos et al., 2000).
Alternatively, the inhibition of angiogenesis represents a potential target against 
solid tumour growth and diabetic retinopathy (Carmeliet and Jain, 2000; Fan et al., 1995). 
Tumours cannot grow beyond a critical size or metastasize to another organ without blood 
vessels (Cameliet and Jain, 2000). In 1971, Folkman proposed that tumour growth and 
metastasis are angiogenesis-dependent and hence, blocking angiogenesis could be a 
strategy to arrest tumour growth (Cameliet and Jain, 2000). It is widely accepted that a 
change in the balance of anti- and pro-angiogenic factors in favour of the latter through, for 
example, metabolic stress or genetic mutations, regulates tumour formation (Bouck et al., 
1996; Carmeliet and Jain, 2000; Fan et al., 1995; Hanahan and Weinberg; 2000). A 
number of anti angiogenic agents are now being investigated clinically. These include 
treatments aimed at specific angiogenic ligands, their receptors and downstream signalling 
and also at the upregulation or deliverance of endogenous inhibitors (Carmeliet and Jain, 
2000; Fan et al., 1995). However, a major side-effect of antiangiogenic treatments may be 
the inhibition of bone fracture healing (Hausman et al., 2001). This is particularly
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important in the treatment of skeletal tumours, where bone fractures are a frequent 
complication (Hausman et aL, 2001).
As discussed in the Introduction, regulation of blood vessel formation can be 
attributed to the action of a number of growth factors being carefully orchestrated in terms 
of space, time and dose. Hence, future treatments controlling angiogenesis will most likely 
involve some form of combination therapy involving more than one growth factor. This is 
highlighted by studies showing that vessels formed in ischaemic tissue following the 
delivery of VEGF are leaky and tortuous (Carmeliet and Jain, 2000). The orchestration of 
growth factors is also demonstrated by the cross-talk mechanism discussed elsewhere 
between the PDGF receptor and EDGl which mediates cell maturation (Hobson et al., 
2001; Rosenfeldt et al., 2001). At present, no selective EDGl agonists or antagonists are 
available. However, studies using anti sense EDGl and knockout mice have demonstrated 
that EDGl plays a crucial role in angiogenesis, particularly at the stage of cell maturation 
(Lee et al., 1999; Liu et al., 2000). Hence, the regulation of EDGl-dependent angiogenic 
changes in blood vessel formation represents a potentially important clinical target. Future 
treatments involving EDGl control of angiogenesis will most likely be used in 
combination with treatments affecting other growth factors, such as VEGF and PDGF.
Understanding how both the adenosine AiAR and the SIP receptor EDGl are 
regulated represents an area of research with potentially important clinical implications. In 
terms of AiAR signalling, understanding how the receptor is regulated will help to fully 
establish the role of the AiAR in physiologically important processes such as ischaemic 
preconditioning, an important cardio- and neuroprotective process. The EDGl receptor 
plays an important role in the process of angiogenesis. Enhanced angiogenesis has been 
implicated in solid tumour growth, diabetic retinopathy and endometriosis (Carmeliet and 
Jain, 2000; Fan et al., 1995; Griffioen and Molema, 2000; Isner, 2002; Yancopoulos et a l, 
2000). Hence, future antagonists of EDGl could prove useful in the treatment of these 
disease states. On the other hand, EDGl agonists could be clinically useful in the 
treatment of diseases where the promotion of angiogenesis would be beneficial, such as 
ischaemic heart disease. A more complete understanding about the regulation of both 
AiAR and EDGl signalling will aid the future production of more selective and more 
effective treatments involving these receptors. For example, the identification of novel 
drug targets based on an understanding of how the AiAR and EDGl respond to agonist 
treatment in terms of receptor desensitisation, changes in total receptor expression and 
receptor resensitisation.
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